---
document_datetime: 2023-09-21 17:52:57
document_pages: 105
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/darzalex-h-c-4077-ii-0002-epar-assessment-report-variation_en.pdf
document_name: darzalex-h-c-4077-ii-0002-epar-assessment-report-variation_en.pdf
version: success
processing_time: 151.2336978
conversion_datetime: 2025-12-21 22:34:05.086733
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

23 February 2017 EMA/193295/2017 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Darzalex

International non-proprietary name: daratumumab

Procedure No. EMEA/H/C/004077/II/0002

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

+44 (0)20 3660 6000

Facsimile

+44 (0)20 3660 5520

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                   | 6                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................6 |                                                                                                           |
| 1.2. Steps taken for the assessment of the product                                                                         | ........................................................7                                                 |
| 2. Scientific discussion................................................................................                   | 8                                                                                                         |
| 2.1. Introduction                                                                                                          | ........................................................................................................8 |
| 2.2. Non-clinical aspects..............................................................................................9   |                                                                                                           |
| 2.2.1. Ecotoxicity/environmental risk assessment...........................................................9               |                                                                                                           |
| 2.2.2. Discussion and Conclusion on non-clinical aspects                                                                   | .................................................9                                                        |
| 2.3. Clinical aspects                                                                                                      | ....................................................................................................9     |
| 2.3.1. Introduction......................................................................................................9 |                                                                                                           |
| 2.3.2. Pharmacokinetics                                                                                                    | ............................................................................................ 10           |
| 2.3.3. Pharmacodynamics..........................................................................................          | 14                                                                                                        |
| 2.3.4. PK/PD modelling .............................................................................................       | 14                                                                                                        |
| 2.3.5. Discussion on clinical pharmacology...................................................................              | 18                                                                                                        |
| 2.3.6. Conclusions on clinical pharmacology.................................................................               | 19                                                                                                        |
| 2.4. Clinical efficacy                                                                                                     | .................................................................................................. 20     |
| 2.4.1. Dose response study........................................................................................         | 20                                                                                                        |
| 2.4.2. Main studies                                                                                                        | ................................................................................................... 20    |
| 2.4.3. Discussion on clinical efficacy............................................................................         | 59                                                                                                        |
| 2.4.4. Conclusions on the clinical efficacy ....................................................................           | 60                                                                                                        |
| 2.5. Clinical safety                                                                                                       | .................................................................................................... 60   |
| 2.5.1. Discussion on clinical safety..............................................................................         | 81                                                                                                        |
| 2.5.2. Conclusions on clinical safety ............................................................................         | 84                                                                                                        |
| 2.5.3. PSUR cycle                                                                                                          | ..................................................................................................... 84  |
| 2.6. Risk management plan                                                                                                  | ....................................................................................... 84                |
| 2.7. Update of the Product information........................................................................             | 88                                                                                                        |
| 2.7.1. User consultation ............................................................................................      | 88                                                                                                        |
| 3. Benefit-Risk Balance                                                                                                    | ............................................................................. 88                          |
| 3.1. Therapeutic Context ...........................................................................................       | 88                                                                                                        |
| 3.1.1. Disease or condition                                                                                                | ........................................................................................ 88               |
| 3.1.2. Available therapies and unmet medical need.......................................................                   | 88                                                                                                        |
| 3.1.3. Main clinical studies.........................................................................................      | 88                                                                                                        |
| 3.2. Favourable effects..............................................................................................      | 89                                                                                                        |
| 3.3. Uncertainties and limitations about favourable effects.............................................                   | 89                                                                                                        |
| 3.4. Unfavourable effects...........................................................................................       | 90                                                                                                        |
| 3.5. Uncertainties and limitations about unfavourable effects                                                              | ......................................... 90                                                              |
| 3.6. Effects Table......................................................................................................   | 90                                                                                                        |
| 3.7. Benefit-risk assessment and discussion.................................................................               | 91                                                                                                        |
| 3.7.1. Importance of favourable and unfavourable effects..............................................                     | 91                                                                                                        |
| 3.7.2. Balance of benefits and risks                                                                                       | ............................................................................ 91                           |
| 3.8. Conclusions.......................................................................................................    | 92                                                                                                        |

<div style=\"page-break-after: always\"></div>

4. Recommendations  ................................................................................. 92

5. EPAR changes ....................................................................................... 95

Appendix  ................................................................................................... 96

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADCC

antibody dependent cell-mediated cytotoxicity

ADCP

antibody dependent cell phagocytosis

ADME

absorption, distribution, metabolism and excretion

ADR

adverse drug reaction

ALT

alanine aminotransferase

ASCT

autologous stem cell transplant

AST

aspartate aminotransferase

CDC

complement-dependent toxicity

CHMP

Committee for Medicinal Products for Human Use

CI

confidence interval

CL

non-specific linear clearance

Cmax

end of infusion concentration

CR

complete response

DOR

duration of response

DPd

daratumumab + pomalidomide + dexamethasone

DRd

daratumumab + lenalidomide + dexamethasone

DVd

daratumumab + VELCADE + dexamethasone

ECG

electrocardiogram

ECOG

Eastern Cooperative Oncology Group

ERd

elotuzumab+lenalidomide+dexamethasone

EU

European Union

FDA

Food and Drug Administration

GCP

Good Clinical Practice

HR

hazard ratio

IMiD

immunomodulatory agent

IMWG

International Myeloma Working Group

IRD

ixazomib+lenalidomide+dexamethasone

IRR

infusion related reaction

ISS

International Staging System

IV

intravenous

Kd

carfilzomib+dexamethasone

kg

kilogram

KRd

carfilzomib+lenalidomide+dexamethasone

LEN

lenalidomide

mAb

monoclonal antibody

MDSCs

myeloid-derived suppressor cells

mg

milligram

min

minute

mL

milliliter

MoA

mechanism of action

MRD

minimal residual disease

NGS

next-generation sequencing

NK

natural killer

ORR

overall response rate

OS

overall survival

PFS

progression-free survival

PI

proteasome inhibitor

Pd

pomalidomide + dexamethasone

Rd

Lenalidomide + dexamethasone

RD

Lenalidomide + high dose dexamethasone

sCR

stringent complete response

SD

standard deviation

SOC

System Organ Class

SPM

secondary primary malignancy

TB

total bilirubin

TEAE

treatment emergent adverse event

TTP

time-to-progression

US

United States

V1

volume of distribution in the central compartment

<div style=\"page-break-after: always\"></div>

| V2   | volume of distribution in the peripheral compartment           |
|------|----------------------------------------------------------------|
| Vd   | VELCADE-dexamethasone                                          |
| VGPR | very good partial response                                     |
| Vmax | saturable target-mediated drug disposition elimination process |
| VMP  | bortezomib-melphalan-prednisone                                |
| VTD  | bortezomib-thalidomide-dexamethasone                           |
| w    | weeks                                                          |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Janssen-Cilag International NV submitted to the European Medicines Agency on 23 August 2016 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of Indication for Darzalex in the treatment of adult patients with multiple myeloma who have received at least 1 prior therapy.

As a consequence, sections 4.2, 4.4, 4.5, 5.1 and 5.2 of the SmPC are updated in order to update the information on posology, warnings, interactions, efficacy and pharmacokinetics. A new warning is introduced in section 4.4 regarding neutropenia/thrombocytopenia induced by background therapy. Annex II is updated to remove all the specific obligations following submissions of the final results of studies MMY3003 and MMY3004.

The Package Leaflet and Risk Management Plan (RMP version 2) are updated in accordance.

In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.

The requested variation proposed amendments to the Summary of Product Characteristics, Annex II and Package Leaflet and to the Risk Management Plan (RMP).

Darzalex was designated as an orphan medicinal product EU/3/13/1153 on 17 July 2013. Darzalex was designated as an orphan medicinal product in the following indication:

- -treatment of plasma cell myeloma.

The new indication, which is the subject of this application, falls within the above mentioned orphan designation.

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision CW/1/2011 on the granting of a class waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products.

## MAH request for additional market protection

The MAH requested consideration of its application in accordance with Article 14(11) of Regulation (EC) 726/2004 - one year of market protection for a new indication.

<div style=\"page-break-after: always\"></div>

## Protocol assistance

The MAH received Protocol Assistance from the CHMP on 20 February 2014 (EMEA/H/SA/2456/1/FU/1/2014/PA/II). The Protocol Assistance pertained to clinical aspects of the dossier.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were:

Rapporteur:

Sinan B. Sarac

Co-Rapporteur:

N/A

|                                                                                                                                                       | Actual dates      |
|-------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| Submission date                                                                                                                                       | 23 August 2016    |
| Start of procedure:                                                                                                                                   | 17 September 2016 |
| CHMP Rapporteur Assessment Report                                                                                                                     | 14 November 2016  |
| PRAC Rapporteur Assessment Report                                                                                                                     | 18 November 2016  |
| PRAC members comments                                                                                                                                 | 23 November 2016  |
| PRAC Outcome                                                                                                                                          | 1 December 2016   |
| CHMP members comments                                                                                                                                 | 5 December 2016   |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report                                                                                                  | 9 December 2016   |
| Request for supplementary information (RSI)                                                                                                           | 15 December 2016  |
| CHMP Rapporteur Assessment Report                                                                                                                     | 24 January 2017   |
| PRAC Rapporteur Assessment Report                                                                                                                     | 27 January 2017   |
| PRAC members comments                                                                                                                                 | 1 February 2017   |
| Updated PRAC Rapporteur Assessment Report                                                                                                             | 2 February 2017   |
| PRAC Outcome                                                                                                                                          | 9 February 2017   |
| CHMP members comments                                                                                                                                 | 13 February 2017  |
| Updated CHMP Rapporteur Assessment Report                                                                                                             | n.a.              |
| Opinion                                                                                                                                               | 23 February 2017  |
| The CHMP adopted a report on similarity of Dazalex with Thalidomide Celgene, Revlimid, Imnovid, Farydak, Kyprolis and Ninlaro                         | 23 February 2017  |
| The CHMP adopted a report on the novelty of the indication/significant clinical benefit for Darzalex in comparison with existing therapies (Appendix) | 23 February 2017  |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

Multiple myeloma is an incurable malignant disorder of the plasma cells, characterized by uncontrolled and progressive proliferation of a plasma cell clone. The median age of patients at diagnosis is 65 years. The abnormal plasma cell proliferation accumulate in the bone marrow, displacing the normal hematopoietic tissue. The plasma cells produce a monoclonal antibody, paraprotein (M-protein and free-light chain), which is an immunoglobulin (Ig) or a fragment of one that has lost its function (Kyle 2009, Palumbo 2011). The normal  immunoglobulins  (Ig)  are  compromised  leading  to  increased  susceptibility  to  infections. Other important characteristics include dysfunction in normal hematopoietic tissue and destruction of the normal bone marrow architecture due to proliferation of multiple myeloma cells. This is reflected by clinical findings such as anemia, thrombocytopenia, myelosuppression, paraprotein in serum or urine, and bone resorption seen as diffuse osteoporosis or lytic lesions shown in radiographs (Kyle 2003). Furthermore, hypercalcemia, renal  insufficiency  or  failure,  and  neurological  complications  are  frequently  seen  (Palumbo  2011). At diagnosis,  frequent  and  pronounced  symptoms  impacting  health-related  quality  of  life  typically  include anemia (approximately 73%), renal insufficiency (approximately 30%)  and skeletal destruction (approximately 80%) (Sonneveld 2013).

For relapsed or refractory multiple myeloma, the treatment is determined on an individual basis where the patient's age, prior therapy, bone marrow function, co-morbidities, patient preference and time to relapse are taken into account. Current treatment options for patients with relapsed or refractory multiple myeloma include combination chemotherapy, proteasome inhibitors (PIs; eg, bortezomib, carfilzomib, ixazomib), immunomodulatory agents (IMiDs; eg, thalidomide, lenalidomide, and pomalidomide), histone deacetylase inhibitors (eg, panobinostat); monoclonal antibodies (mAb) (eg, daratumumab and elotuzumab), high-dose chemotherapy, and autologous stem cell transplantation (ASCT).

Daratumumab is an IgG1κ human monoclonal antibody (mAb) that binds to the CD38 protein expressed at a high level on the surface of multiple myeloma tumour cells, as well as other cell types and tissues at various levels. CD38 protein has multiple functions such as receptor mediated adhesion, signalling and enzymatic activity (SmPC, section 5.1).

The initial marketing authorisation application for Darzalex was based on data from 2 single agent studies (MMY2002 and GEN501) and the European Commission issued a conditional marketing for Darzalex on 20 May 2016 for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy  included  a  Proteasome  Inhibitor  (PI)  and  an  immunomodulatory  agent  (IMiD)  and  who demonstrated disease progression on the last therapy with the following conditions:

· In order to address the uncertainties related to the single arm design of the pivotal study supporting the approval of Darzalex, the MAH should submit the results of study MMY3003, a phase III randomised study  investigating  lenalidomide  and  dexamethasone  with  or  without  daratumumab  in  patients  with previously treated multiple myeloma.

· In order to address the uncertainties related to the single arm design of the pivotal study supporting the approval of Darzalex, the MAH should submit the results of study MMY3004, a phase III randomised study  investigating  bortezomib  and  dexamethasone  with  or  without  daratumumab  in  patients  with previously treated multiple myeloma.

The MAH submitted the clinical study reports for MMY3003 and MMY3004 as part of this application.

The current indication for Darzalex is as follows:

<div style=\"page-break-after: always\"></div>

Darzalex as monotherapy is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy (SmPC, section 4.1).

The MAH applied for the following extension of indication: Darzalex is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

The recommended indication for approval by CHMP after considering all data submitted is: Darzalex is indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (SmPC, section 4.1).

The recommended dose is Darzalex 16 mg/kg body weight administered as an intravenous infusion ( SmPC, section 4.2).

## 2.2. Non-clinical aspects

No new non clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

No ERA studies were submitted (see discussion on non-clinical aspects).

## 2.2.2. Discussion and Conclusion on non-clinical aspects

The justification provided by the MAH for not performing environmental risk assessment studies was considered acceptable since daratumumab is a protein therefore, unlikely to result in significant risk to the environment. This is in accordance with the 'Guideline on Environmental Risk Assessment of Medicinal Products for Human Use (EMEA/CHMP/SWP/4447/00 corr 21*).

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

A Tabular overview of Daratumumab Clinical Studies Included in the Safety and Efficacy Analyses is provided in Figure 1.

<div style=\"page-break-after: always\"></div>

Figure 1. Daratumumab Clinical Studies Included in the Safety and Efficacy Analyses (N=Number of Subjects Enrolled or Randomized)

<!-- image -->

DPd=daratumumab, pomalidomide and dexamethasone; DRd=daratumumab, lenalidomide and dexamethasone; DVd=daratumumab, bortezomib and dexamethasone; Rd=lenalidomide and dexamethasone; Vd=bortezomib and dexamethasone

## 2.3.2. Pharmacokinetics

The clinical pharmacology properties of daratumumab in combination treatment were studied in 680 subjects in two Phase 1/2 and two Phase 3 combination studies (Table 1). These four studies as well as a population PK (Pop-PK) analysis support the PK data of the present application.

Table 1. Combination Studies Used to Support Pharmacokinetic Results

| Study Number   |     | PhaseSubject Population                              | Doses (Number of Subjects Dosed)                                                              | Number of Subjects Evaluable for Pharmacokinetic Analysis/Number of Subjects Treated   |
|----------------|-----|------------------------------------------------------|-----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| GEN503         | 1/2 | relapsed or relapsed and refractory multiple myeloma | Phase 1: 2 mg/kg (3 subjects) 4 mg/kg (3 subjects) 8 mg/kg (4 subjects) 16 mg/kg (3 subjects) | 45/45 Phase 1=13;                                                                      |
| GEN503         | 1/2 | relapsed or relapsed and refractory multiple myeloma | Phase 2: 16 mg/kg (32 subjects)                                                               | Phase 2=32                                                                             |
| MMY1001        | 1/2 | multiple myeloma                                     | 16 mg/kg (133 subjects)                                                                       | 128/133                                                                                |
| MMY3003        | 3   | relapsed or refractory multiple myeloma              | 16 mg/kg (283 subjects)                                                                       | 282/283                                                                                |

<div style=\"page-break-after: always\"></div>

| MMY3004   | 3   | relapsed or refractory multiple myeloma   | 16 mg/kg (243 subjects)   | 225/243   |
|-----------|-----|-------------------------------------------|---------------------------|-----------|

Total Subjects Evaluable for Pharmacokinetic Analysis/Total Subjects Treated: 680/704.

All daratumumab PK parameters were calculated using conventional non-compartmental methods using actual times of blood sampling. Background therapy PK parameters, including bortezomib, thalidomide, and pomalidomide were calculated using conventional non-compartmental methods using nominal times of blood sampling.

Values presented in the tables represent arithmetic mean, standard deviation (SD) and coefficient of variation (%CV); tmax values are presented as median (range).

## Absorption

Absorption data are not required since all studies administered daratumumab as an IV infusion.

## Distribution

In Study GEN503 (combination therapy), mean volume of distribution (Vd) for the 2 mg/kg and 4 mg/kg cohorts was estimated as 100.83 mL/kg and 88.35 mL/kg, respectively compared to 90.19±43.40 mL/kg after the first dose and 59.51±54.68 mL/kg following repeat dosing of 16 mg/kg in Study GEN501 (monotherapy). There was no data for the 16 mg/kg dose group. Overall, results showed that daratumumab is primarily localised to the vascular system with limited extravascular tissue distribution.

## Elimination

By the initial  assessment for the monotherapy indication, the elimination halftime (T½) increased with multiple doses: from 25.62±5.61 hours for 2 mg/kg to 154.65±36.48 hours for 24 mg/kg. In the 16 mg/kg group, mean T½ increased from 109.9±42.05 hours after the first full infusion to 586.56±486.89 hours after the seventh (last) full infusion (Study GEN501, Part 1).

Regarding the elimination in the combination treatment, PK data from Study GEN503 showed that after the first full infusion mean T½ was estimated to be 37.92 hours for the 2 mg/kg cohort and 46.80 hours for the 4  mg/kg  group.  Daratumumab  elimination  showed  nonlinear  characteristics;  Cmax  after  the  first  full infusion increased with dose while AUClast increased in a greater than dose-proportional manner.

## Dose proportionality and time dependencies

## Dose proportionality

Only in Study GEN503, other doses than the recommended 16 mg/kg dosing regimen was used. Data for doses 2 mg/kg - 8 mg/kg is available for a total of 10 patients. In Phase 1 of Study GEN503, Cmax increased in approximate proportion to the daratumumab dose in the range of 2-16 mg/kg after the first full infusion. The observed mean Cmax after the first full dose rose in a ratio of 1: 2: 6: 11 as the dose increased in a ratio of 1: 2: 4: 8. Mean daratumumab serum concentrations (μg/mL) for the first full infusion for the different doses are presented in Figure 2.

<div style=\"page-break-after: always\"></div>

Figure 2. Mean Daratumumab Serum Concentration (μg/mL) for the First Full Infusion; Subjects Evaluable for Daratumumab PK (Study GEN503 Phase 1)

<!-- image -->

Keys: C=cycle; D=day; H=hour; W=week; EOI=end ofinfusion; PK=pharmacokinetics. The error bars are mean +/- standard error.

## Time dependencies

Data is available from Study GEN503 (combination therapy). Accumulation appeared to continue throughout the first 2 cycles of weekly dosing in both Phase 1 and 2, after which concentrations began to decrease slightly with the less frequent daratumumab administration (Table 3). In the 16 mg/kg cohort (Phase 2), the mean±SD trough concentration at the end of weekly dosing (Cycle 3 Day 1 pre-dose) was 546.65±226.34 μg/mL. The mean±SD concentration at the end of the ninth planned full infusion (Cycle 3 Day 1 pre-dose; 898.53±242.27 μg/mL) was approximately 3-fold higher than the mean concentration following the first full infusion (Cycle 1 Day 1 post-dose; 289.11±90.39 μg/mL).

<div style=\"page-break-after: always\"></div>

Table 2: Summary of daratumumab select serum predose and end of infusion concentrations; evaluable for daratumumab PK (Study GEN503 Phase 2)

<!-- image -->

|                                                      | 16 mgkg Dara + Len/Dex   |
|------------------------------------------------------|--------------------------|
| Analysis set: Subjects evaluable for daratumumab PK\" | 32                       |
| Cycle 1 day 1 pre-dose                               |                          |
| N                                                    | 31                       |
| Mean (SD)                                            | 0.06 (0.238)             |
| Cycle 1 day I post-dose                              |                          |
| N                                                    | 24                       |
| Mean (SD)                                            | 289.11 (90.386)          |
| Cycle 2 day 1 pre-dose                               |                          |
| N                                                    | 14                       |
| Mean (SD)                                            | 343.05 (111.492)         |
| Cycle 2 day 1 post-dose                              |                          |
|                                                      | 16                       |
| N Mean (SD)                                          | 689.12 (207.219)         |
| Cycle 3 day 1 pre-dose                               |                          |
| N                                                    | 24                       |
| Mean (SD)                                            | 545.65 (226.336)         |
| Cycle 3 day 1 post-dose                              |                          |
| N Mean (SD)                                          | 25                       |
|                                                      | 898.53 (242.271)         |
| Cycle 6 day 1 pre-dose                               |                          |
| N                                                    | 20                       |
| Mean (SD)                                            | 432.20 (218.918)         |
| Cycle 6 day 1 post-dose                              |                          |
| N                                                    | 19                       |
| Mean (SD)                                            | 799.33 (246.240)         |
| Cycle 12 day 1 pre-dose                              |                          |
| N                                                    | 12                       |
| Mean (SD)                                            | 224.44 (168.530)         |
| Cycle 12 day l post-dose                             |                          |
| N                                                    | 12                       |
| Mean (SD)                                            | 616.68 (181.298)         |

a  Subjects who treated with daratumumab and had at least one post-treatment PK assessment. Only 19 of these subjects are evaluable for PK parameter estimates.

Note: Samples outside of allowed sampling windows are not included. In addition, samples collected after an incomplete dose

(less than 80% intended dose was administered) and prior to the next complete dose are not included. Keys: Dara=daratumumab, Len/Dex=lenalidomide/dexamethasone.

In general, the area under the curve to the last quantifiable time point (AUClast) increased in a greater than dose-proportional manner after the first doses. Observed mean AUClast after the first full dose rose in a ratio of 1 : 3 : 7 : 43 as the dose increased in a ratio of 1 : 2 : 4 : 8. The results obtained in Study GEN503 were supported by the results obtained in Study MMY1001.

Similar results were observed in the two Phase 3 studies MMY3003 and MMY3004. In Study MMY3003, the mean±SD Cmax concentration after the 1st dose (Cycle 1 Day 1 post-infusion) was 329.07±95.89 μg/mL. Accumulation  of  daratumumab  through  the  first  9  doses  resulted  in  a  2.9-fold  increase  in  Cmax  to 972.12±272.35  μg/mL  at  Cycle  3  Day  1  post-dose.  The  mean±SD  Cycle  3  Day  1  pre-dose  trough concentration after 8 weekly doses was 607.73±231.98 μg/mL. In Study MMY3004, the mean±SD Cmax concentration after the 1st dose (Cycle 1 Day 1 post-infusion) was 317.68±98.87 μg/mL. Accumulation of daratumumab continued through at least the first 7 weekly doses (the last PK sampling time point in weekly dosing), resulting in a 2.7-fold increase in daratumumab Cmax concentration to 860.19±262.60 μg/mL at Cycle 3 Day 1 post-dose. The mean±SD Cycle 3 Day 1 pre-dose trough concentration after 6 weekly doses was 502.43±196.46μg/mL.

<div style=\"page-break-after: always\"></div>

## Special populations

See 2.3.4 PK/PD modelling section.

## Pharmacokinetic interaction studies

No drug-drug interaction studies have been performed.

## 2.3.3. Pharmacodynamics

## Mechanism of action

## Primary and secondary pharmacology

In subjects treated with combination therapy, 2 (0.7%) of the 298 evaluable subjects were positive for anti-daratumumab antibodies (ADAs) (1 subject each in Studies MMY1001 and MMY3003). Both positive subjects demonstrated low titer (1:20) responses which were near the lower limit of the assay method sensitivity.

In Study MMY3003, the positive status was assigned to 1 subject due to the detection of ADAs following an IRR at Cycle 1 Day 1. The ADA positive sample inhibited daratumumab binding in the validated neutralising antibody assay; thus, the response was classified as neutralising. The pre-dose Cycle 1 Day 1 and the end of treatment (follow up Week 4) samples were both negative for ADAs, demonstrating that the immune response was transient. Despite the single positive ADA response, this subject demonstrated a stringent complete response (sCR) on Day 139, suggesting no impact of observed ADAs on efficacy, but the patient discontinued treatment on Day 302 due to disease progression.

In Study MMY1001, 1 subject in the DVTd cohort was positive for ADAs at the Week 9 Follow-Up visit; the antibodies were non-neutralising. This subject was negative for ADAs on 2 other visits (pre-dose on Cycle 1 Day 1 and Week 3 Follow-up) and was on treatment for 4 cycles. This subject was not evaluable for drug response per protocol and discontinued due to autologous stem cell transplantation. There was no notable safety signals observed in this subject.

The evaluation of QTc intervals versus serum concentration of daratumumab has been provided in the monotherapy submission. There are no new data to be summarised.

## 2.3.4. PK/PD modelling

## Population Pharmacokinetic Analysis

The population pharmacokinetic (pop-PK) analysis was based on 4,426 PK samples from 694 subjects (684 subjects  received  daratumumab  at  16  mg/kg).  Nine  subjects  were  excluded  because  they  had  no measurable post-dose concentrations of daratumumab. One subject was excluded because the actual dosing time of the first dose was missing.

As expected, the PK of daratumumab was similar following the monotherapy and combination therapies. The observed concentration-time data of daratumumab were adequately described by a 2-compartment Pop-PK model with parallel linear and nonlinear Michaelis-Menten eliminations. The model was parameterised in terms  of  total  systemic  clearance  (CL),  volume  of  distribution  in  the  central  compartment  (V1), inter-compartmental clearance (Q), volume of distribution in the peripheral compartment (V2), maximum rate  of  the  saturable  target-mediated  drug  disposition  (TMDD)  elimination  process  (Vmax),  and daratumumab concentration (Km) associated with half of Vmax.

<div style=\"page-break-after: always\"></div>

The  estimated  CL  value  was  similar  to  the  clearance  of  non-specific  endogenous  IgG  reported  in  the literature and the estimated V1 value approached plasma volume. The model-derived half-life associated with linear elimination was approximately 23.3±11.8 days (mean±standard deviation), comparable to the half-life (18±9 days) derived from the monotherapy data. Similar to what was observed in monotherapy studies, apparent steady state seems to be reached approximately 5 months into the Q4W dosing period. The ratio of the steady-state peak concentration after Q4W dosing and the peak concentration after the first dose was 1.85±0.67 (mean±standard deviation).

## Effects of Covariates

A  forest  plot  was  constructed  to  compare  the  exposure  (maximal  pre-infusion  concentration)  of daratumumab in subgroups defined by specific covariates (Figure 3).

Figure 3: Forest Plot of Subgroup Analyses on Change Relative to Reference Value of Predicted Maximal Pre-infusion (Trough) Concentration for MMY3003 Dosing Schedule

<!-- image -->

<div style=\"page-break-after: always\"></div>

Key:  Solid  blue  circle  represents  mean  and  error  bar  represents  95%  confidence  interval.  Dashed  line  represents reference value of 1. Numbers represent ratio, confidence interval, and number of subjects in the comparison groups. Gray shaded region represents ±25% from reference value.

Note: Analyses assumed that all subjects in Studies GEN503, MMY1001, MMY3003 andMMY3004 received 16 mg/kg QW for  8  weeks  (8  doses),  Q2W  for  16  weeks  (8  doses),  and  then  Q4W  thereafter.  Maximal  pre-infusion  (trough) concentration was derived as the pre-infusion concentration of the 1st dose of the every 2 week dosing period.

The number of subjects in the reference group for each covariate: normal renal function (N=251); normal hepatic  function  (N=598);  age  &lt;65  yr  (N=352);  age  &lt;75  yr  (N=630);  female  (N=291);  non-white (N=136);  western  European  N.  America  (N=590);  body  weight  &gt;88  kg  (N=164);  normal  albumin concentration (N=513); Phase 2 product (N=44); 1 prior line of therapy (N=282); not refractory (N=42); ECOG = 0 (N=309); RD (N=326); non-IgG myeloma (N=293).Body Weight: When daratumumab was administered  on  a  mg/kg  basis,  no  clinically  important  differences  (ie,  &lt;20%)  in  the  exposure  to daratumumab were observed in subjects with different weight despite a numeric trend. The CL and V1 of daratumumab significantly increased with increasing body weight. The difference in exposure had minimum impact on target saturation.

Age: Similar to monotherapy, no clinically important influence of age on the exposure to daratumumab was observed  in  the  population  PK  analyses  in  patients  receiving  combination  therapies.  The  difference  in exposure was within 6% between younger (age &lt; 65 years, n = 352; or age &lt; 75 years, n = 630) and older subjects (age ≥ 65 years, n = 342; or age ≥ 75 years, n = 64) (SmPC, section 5.2).

Sex: No clinically important influence of sex on the exposure to daratumumab was observed. The difference in  exposure  was  approximately  4%  between  males  (n=403)  and  females  (n=291)  although  V1  of daratumumab in female subjects was 15% lower than that of male subjects.

Race: In the population PK analysis in multiple myeloma patients that received daratumumab with various combination therapies, the exposure to daratumumab was also similar between white (n = 558) and non white (n = 136) subjects (SmPC, section 5.2).

Region: The majority (85%) of subjects were Western European (EU), United States (US), or Canadian (CA) subjects  (EU+US+CA).  The  effect  of  region  was  evaluated  in  western  EU+US+CA  (n=590)  and  Other (n=104). The exposures were virtually identical in western EU+US+CA subjects and subjects from other regions as the difference was approximately 3%.

Renal Impairment: Additional population PK analyses in patients receiving combination treatments also showed  no  clinically  important  differences  in  exposure  to  daratumumab  between  patients  with  renal impairment (mild, n = 264; moderate, n = 166; severe, n = 12) and those with normal renal function (n = 251) (SmPC, section 5.2).

Hepatic Impairment: The PK analysis of patients with multiple myeloma that received daratumumab in various combination therapies included 598 patients with normal hepatic function, 83 patients with mild hepatic impairment and 5 patients with moderate (TB &gt; 1.5 x to 3.0 x ULN), or severe (TB &gt; 3.0 x ULN) hepatic impairment. No clinically important differences in the exposure to daratumumab were observed between patients with hepatic impairment and those with normal hepatic function (SmPC, section 5.2).

Baseline  Albumin: No  clinically  important  differences  in  the  exposure  to  daratumumab  were  observed between  subjects  with  abnormal  albumin  and  those  with  normal  albumin  level.  The  exposure  to daratumumab was 21% lower in subjects with abnormal albumin level (&lt;35 g/L; n=181) compared with subjects who had normal albumin level (≥35 g/L; n=513). The difference in exposure had minimum impact on target saturation

Type of  Myeloma: No clinically  important  differences  in  the  exposure  to  daratumumab  were  observed between subjects with baseline IgG myeloma and non-IgG myeloma. The exposure to daratumumab was

<div style=\"page-break-after: always\"></div>

approximately 23% lower in the IgG multiple myeloma subjects (n=401) compared to the non-IgG subjects (n=293). The difference in exposure had minimum impact on target saturation and the treatment effect on efficacy endpoints was similar for subjects with IgG and non-IgG myeloma.

Immunogenicity: Across all included studies, 2 out of 298 immunogenicity evaluable subjects (1 each in Study MMY1001 and Study MMY3003) in the pop-PK analysis were positive for ADA to daratumumab. No discernible differences in the PK between subjects with and without ADAs could be identified.

ECOG Score: No clinically important differences in the exposure to daratumumab (≤5%) were observed between subjects with ECOG scores of 1 (N=345) or 2 (N=39) and those with ECOG scores of 0 (N=309).

Refractory  Status : No  clinically  important  differences  in  the  exposure  to  daratumumab  ( ˂ 10%)  were observed between subjects refractory to IMiD only (N=103), PI only (N=73), or both (N=89) and those who were not refractory (N=42).

Other Baseline Variables: The effects of baseline disease status such as number of prior lines of therapy and various  therapies  in  combination  with  daratumumab  treatment  were  evaluated  on  the  exposures  to daratumumab. The daratumumab exposures were similar across the subgroups of these variables.

## Exploratory Exposure-Response Relationships

The relative hazard for disease progression and death decreased rapidly with increasing daratumumab exposure based on the data from Studies MMY3003, MMY3004, and MMY1001 (DPd patients) ( Figure 4 ).

Figure 4: Relative Hazard of Progression-free Survival at Different Predicted Maximal Trough Concentration

<!-- image -->

Key: the solid red line is the point estimate; the grey shaded areas represent the 95% confidence interval. The blue vertical dotted lines separate the quartiles of maximal pre-infusion concentration. Minimum Cpre-infusion,max for each study  was  used  as  the  reference  level.  Cpre-infusion,max  up  to  the  8th  weekly  dose  for  Studies  MMY1001  (DPd), MMY3003, and MMY3004.

When maximal trough concentration was greater than ~250 μg/mL, the decreasing trend of relative hazards appears to slow down, suggesting limited additional benefit at higher concentrations. As the majority of the patients (&gt;90% in Studies MMY3003 and MMY3004, and &gt;80% in Study MMY1001) had maximal trough concentration greater than 250 μg/mL, it indicated that maximum clinical benefit on PFS has been attained for most subjects treated with 16 mg/kg. This observation was consistent with the (274 μg/mL) that was identified from the analyses based on the monotherapy studies.

The concentration-Duration of Response (DOR) relationship was similar to the observed concentration-PFS relationship. Furthermore, in all 3 studies (MMY3003, MMY3004, and MMY1001), when the maximal trough concentration  was  above  the (274  μg/mL)  identified  from  the  monotherapy  studies,  the  Overall Response Rate (ORR) was markedly higher compared to the those with maximal trough concentrations below 274 μg/mL (Figure 5).

<div style=\"page-break-after: always\"></div>

Figure 5 Relative Hazard based on Duration of Response at Different Predicted Maximal Trough Concentration

<!-- image -->

Key: The solid blue dots at concentration 0 μg/mL represent the proportion of responders in control groups (ie, Rd in MMY3003 and Vd in MMY3004). The solid blue dots at concentrations greater than 0 represent the proportion of responders grouped by quantiles of maximal pre-infusion concentration and plotted at the geometric mean for each group. The bar represents the 95% confidence interval for the proportion in each group. The red vertical dotted lines represent the (274 μg/mL) that was identified from the analyses based on the monotherapy studies. Cpre-infusion,max up to the 8th weekly dose for Studies MMY1001 (DPd), MMY3003, and MMY3004.

There was no apparent exposure-response relationship within the studied concentration range between Cmax,1st and IRR, and Cpost-infusion,max and thrombocytopenia, anaemia, neutropenia, and lymphopenia based on the data from different combination therapies, ie, DRd subjects (Studies GEN503 and MMY3003), DVd subjects (Study MMY3004), and DPd (Study MMY1001). Although the event rate of infections (any grade)  appeared  to  increase  with  drug  exposure,  this  trend  was  not  observed  for  Grade  3  or  higher infections.

## 2.3.5. Discussion on clinical pharmacology

The clinical pharmacology of daratumumab used as monotherapy is well established. Clinical pharmacology data for the combination treatment derive from four clinical studies with a total of 680 patients evaluable for PK analyses. Additional, a pop-PK analysis contributed with data. The applied analytical methods for both the PK data analysis and the statistical analysis are appropriate.

The PK findings (bioavailability, volume of distribution and T½) from Study GEN503 are in line with the findings from the PK results from the mono-therapy studies (Study GEN501). The results support the expectations that as a mAb, the distribution of daratumumab is primarily localised to the vascular system, and the elimination is expected to occur via degradation of the daratumumab molecule into small peptides and amino acids. Overall, there were no unexpected findings with regards to absorption, distribution or elimination. The dose-dependent elimination (nonlinear characteristics) is consistent with target-mediated elimination (where clearance decreases as a function of dose).

No pharmacokinetic interactions are expected and it is acceptable that no formal drug-drug interaction studies have been performed. Serum concentrations of daratumumab as well as bortezomib, pomalidomide and thalidomide in various combination therapies show that there are no PK interactions for any of the products.

There is only very sparse PK data (from 10 patients) with regards to other doses than the 16 mg/kg daratumumab used in combination therapy. As treatment with 16 mg/kg is the recommended dose for monotherapy and is also proposed to be used in the combination treatment, more data with lower (or higher) dosing regimen is not considered necessary and thus, it is acceptable that there is only very limited experience with other doses and limited data regarding dose proportionality. Dose proportionality as observed in monotherapy is also expected to apply for combination therapy.

<div style=\"page-break-after: always\"></div>

Results over time showed consistent results across the four studies and furthermore, in study MMY1001 where different combination treatments were used, consistent results were observed across the different combination therapies. As expected, the AUC last increased in a greater than dose-proportional manner after the first doses. Accumulation continued throughout the first 2 cycles due to the frequent dosing, thereafter concentrations began to decrease slightly with the less frequent daratumumab administration.

An additional population PK analysis was conducted in patients with multiple myeloma that received daratumumab in various combination therapies from four clinical trials (694 patients of which 684 received daratumumab at 16 mg/kg). Daratumumab concentration-time profiles were similar following the monotherapy and combination therapies. The mean (SD) estimated terminal half-life associated with linear clearance in combination therapy was approximately 23 (12) days (SmPC, section 5.2).

Several covariates were investigated in the pop-PK analysis. Consistent with the results from the initial (monotherapy) pop-PK analysis, results from the present pop-PK analysis showed that albumin level, type of myeloma and body weight were the covariates with the highest impact on the PK values. However, when further evaluated, it is concluded that though a few numeric and statistically significant differences were observed for a few covariates, these observation were in line with the observations from the monotherapy pop-PK analysis and more importantly, the differences are not expected to be of clinical relevance. No dose-adjustments are necessary.

A logistic regression analysis of overall response rate and predicted maximal pre-infusion (trough) daratumumab concentration showed that a lower dose than 16 mg/kg is not expected to be able to obtain a sufficient response in the majority of patients even when daratumumab is given as combination-therapy. From a clinical pharmacological point of view, it is acknowledged that the proposed dose of 16 mg/kg is a suitable daratumumab dose also when used in combination-therapy.

With regards to the pharmacodynamics, no new data related to mechanism of action or QTc evaluation is presented. This is overall acceptable. There is no formal experience regarding potential worsening of cardiac adverse when daratumumab is given in combination treatment (PD interaction), but as described in the clinical safety part of the assessment report, no increase in cardiac adverse events were observed, and the issue will not be pursued from a clinical pharmacological point of view.

Across the studies, two patients developed anti-daratumumab antibodies; in one of the patients, the antibodies were neutralising but transient. The MAH has provided sufficient information regarding the two patients. It is agreed that the immunogenicity profile of daratumumab still appears to be low. Immunogenicity is already included as an important potential risk in the RMP.

## 2.3.6. Conclusions on clinical pharmacology

The  clinical  pharmacology  is  sufficiently  covered  with  PK  data  from  four  clinical  studies  and  a  pop-PK analysis.  All  results  from  the  combination  therapy  are  in  line  with  the  results  obtained  by  the  initial application  for  daratumumab  used  as  monotherapy.  From  a  clinical  pharmacology  point  of  view,  no unexpected findings have been revealed and no concerns were identified.

<div style=\"page-break-after: always\"></div>

## 2.4. Clinical efficacy

## 2.4.1. Dose response study

No dose-response studies were submitted. In the study GEN503, 16 mg/kg daratumumab was established as the optimal dose for administration of daratumumab as monotherapy (see 2.3.5 section discussion on clinical pharmacology).

## 2.4.2. Main studies

· Study MMY3003 was a phase 3 open-label, multicentre study comparing the efficacy of daratumumab when combined with lenalidomide and low-dose dexamethasone (DRd) with lenalidomide and low-dose dexamethasone (Rd) in patients with relapsed or refractory multiple myeloma.

· Study MMY3004 was a phase 3, open-label, multicentre study comparing the efficacy of daratumumab when combined with bortezomib and low-dose dexamethasone (DVd) with bortezomib and low-dose dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma.

The MMY3003 and the MMY3004 studies are very similar in the study design. The methods part as well as the design is applied for both studies, unless otherwise specified.

## Study MMY3003 and Study MMY3004

## Methods

## Study participants

The study population consisted of subjects with documented relapsed or refractory multiple myeloma (e.g., have documented multiple myeloma; have received at least 1 prior line of therapy for multiple myeloma; have achieved a response (partial response [PR] or better) to at least one prior regimen; have documented evidence of progressive disease as defined by the International Myeloma Working Group (IMWG) criteria on or after their last regimen) and an Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1 or 2.

Refractory status is defined according to IMWG consensus criteria and documented by the treating physician. Refractory is defined as being nonresponsive while on therapy or progressed within 60 days of stopping therapy in subjects who have achieved minimal response (MR) or better.

The key inclusion criteria were the following:

- The patient's age had to be at least 18 years.
- Documented multiple myeloma as defined by the criteria below:
- Monoclonal plasma cells in the bone marrow ≥ 10% or presence of a biopsy-proven plasmacytoma.
- Measurable disease at screening as defined by any of the following:
- o IgG multiple myeloma: Serum M-protein level ≥ 1.0 g/dL or urine M-protein level ≥ 200 mg/24h; or
- o IgA, IgD, IgR, IgM multiple myeloma: serum M-protein level ≥ 1.0 g/dL (in the MMY3004 study it is ≥ 0.5 g/dL) or urine M-protein level M-protein level ≥ 200 mg/24h; or
- o Light chain multiple myeloma without measurable disease in the serum or the urine: serum immunoglobulin free light chain ≥ 10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio.
-  Evidence of a response (PR or better based on the investigator's determination of response by the IMWG criteria) to at least 1 prior regimen.
-  ECOG performance status score of 0, 1, or 2.

<div style=\"page-break-after: always\"></div>

The key exclusion criteria were the following:

- Previously received daratumumab or other anti-CD38 therapies.
- Received anti-myeloma treatment within 2 weeks or 5 pharmacokinetic half-lives of the treatment, whichever was longer, before the date of randomization or had received ASCT within 12 weeks before the randomization.
- Previously received an allogeneic stem cell transplant or ASCT.
- Subject had a history of malignancy (other than multiple myeloma) within 5 years before the date of randomization (exceptions were squamous and basal cell carcinomas of the skin, carcinoma in situ of the cervix or breast, or other non-invasive lesion that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, was considered cured with minimal risk of recurrence within 5 years).
-  Subject had known meningeal involvement of multiple myeloma.
-  Subject had known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) &lt;50% of predicted normal.
-  Subject had known moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification.
-  Subject was seropositive for human immunodeficiency virus, had hepatitis B surface antigen positivity, or had a history of hepatitis C.
-  Subject had any concurrent medical condition or disease (eg, active systemic infection) that was likely to interfere with study procedures or results, or that in the opinion of the investigator could constitute a hazard for participating in this study.
-  Subject had clinically significant cardiac disease.

MMY3003 only: Refractoriness or intolerance to lenalidomide.

MMY3004 only: Refractoriness to bortezomib, or another PI, like ixazomib and carfilzomib,  i.e.subject had progression of disease while receiving bortezomib therapy or within 60 days of ending bortezomib therapy, or another PI therapy, like ixazomib and carfilzomib. This was added in Amendment 1 when 40 subjects were randomized. Intolerance to bortezomib.

## Treatments

In both studies, daratumumab was administered as an IV infusion at a dose of 16 mg/kg until disease progression, unacceptable toxicity, or other reasons.

## MMY3003

Daratumumab was administered weekly for 8 weeks, then every 2 weeks for 16 weeks, and then every 4 weeks thereafter.

Oral lenalidomide was administered as shown in figure 3 for patients with creatinine clearance &gt; 60 mL/min. Patients with creatinine clearance between 30 and 60 mL/min received 10 mg every 24 h.

Oral dexamethasone was administered at a total dose of 40 mg weekly. Patients older than 75 years or underweight (body mass (BMI) &lt;18.5) received a dose of 20 mg weekly. An overview of the MMY3003 is showed in Figure 6.

<div style=\"page-break-after: always\"></div>

Figure 6: Schematic Overview Study MMY3003

<!-- image -->

DRd=daratumumab, lenalidomide and dexamethasone; Rd=lenalidomide and dexamethasone Note: Long-term follow up includes a visit 8 weeks after the end of treatment

## MMY3004

Daratumumab was to be administered weekly for the first 3 cycles, on Day 1 of Cycles 4-8, and then every 4 weeks thereafter. Bortezomib was to be administered subcutaneously (SC) on Days 1, 4, 8, and 11 of each 21-day cycle. Eight bortezomib treatment cycles were to be administered.  Oral dexamethasone was administered orally at a dose of 20 mg on days 1, 2, 4, 5, 8, 9, 11, and 12 of the first 8 bortezomib treatment cycles. For subjects who were older than 75 years, underweight (body mass index (BMI) &lt;18.5), had poorly controlled diabetes mellitus or prior intolerance/ adverse event (AE) to steroid therapy, the dexamethasone dose could be administered at a dose of 20 mg weekly. An overview of the MMY3004 is showed in Figure 6.

<div style=\"page-break-after: always\"></div>

Figure 7:  Schematic Overview Study MMY3004

Note: Cyeles 1 thmongh 8 were 21-doy cydles, Cycle9 md onwird were 28-dy cyeles

<!-- image -->

The median number of treatment cycles, the duration of study treatment and the median relative dose intensity are showed in

<div style=\"page-break-after: always\"></div>

Table 34.

## Objectives (MMY3003/MMY3004)

The primary objective of the MMY3003 study was to compare the efficacy of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival ( PFS) in patients with relapsed or refractory multiple myeloma.

The primary objective of the MMY3004 study was to compare the efficacy of daratumumab when combined with bortezomib (velcade) and dexamethasone (DVd) to that of bortezomib and dexamethasone (Vd), in terms of PFS in patients with relapsed or refractory multiple myeloma.

The major secondary objectives were to compare the 2 treatment groups with respect to:

-  Time to progression (TTP), overall ORR, and OS.
-  Proportion of patients with a response of very good partial response (VGPR) or better.
-  Duration of and time to response (DOR and TTR).
-  Time to subsequent antimyeloma treatment (MMY3003 only).
-  Minimal residual disease (MRD) negativity rate.
-  Safety and tolerability of daratumumab when administered in combination with Rd/Vd respectively.

Other secondary endpoints were as follows:

-  To assess the pharmacokinetics of daratumumab in combination with Rd/Vd respectively
-  To assess the immunogenicity of daratumumab
-  To determine ORR (MMY3003) and to evaluate clinical efficacy (MMY3004) in high risk molecular subgroups.
-  To evaluate treatment effects on patient-reported outcome (PROs) including the EuroQol-2 Dimensrions (EQ-5D-5L) and European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30.

The exploratory objective of both trials was to explore biomarkers predictive of response to daratumumab and potential mechanisms of treatment resistance.

<div style=\"page-break-after: always\"></div>

## Outcomes/endpoints (MMY3003/MMY3004)

The primary efficacy endpoint, PFS, was defined as the duration from the date of randomization to either progressive disease, according to the International Myeloma Working Group (IMWG) criteria, or death, whichever occurred first.

The secondary efficacy endpoints included:

- Time to disease progression (TTP), defined as the time between the date of randomization and the date of first documented evidence of confirmed progressive disease (PD), as defined in the IMWG criteria, or death due to PD, whichever occurred first.
- Response rate of VGPR or better, defined as the proportion of subjects with a response of VGPR or better (ie, VGPR, CR, or sCR) according to the IMWG criteria during or after the study treatment.
- Minimal residual disease (MRD) negative rate, defined as the proportion of subjects with negative MRD at any timepoint after the first dose by bone marrow aspirate or whole blood.
- Overall response rate (ORR), defined as the proportion of subjects who achieved a partial response (PR) or better (ie, PR, very good partial response (VGPR), complete response (CR), or stringent complete response (sCR)), according to the IMWG criteria, during or after the study treatment.
- Overall survival (OS), measured from the date of randomization to the date of death due to any cause.
- Time to response (TTR), defined as the time between the date of randomization and the first efficacy evaluation that the subject met all criteria for PR or better.
- Duration of response (DOR), defined for subjects with a confirmed response (PR or better) as the time between first documentation of response and disease progression, according to IMWG response criteria, or death due to PD, whichever occurs first.

Table 3 Comparison of Key Elements of Study MMY3003 and Study MMY3004

|                                  | Study MMY3003                                                                                                                                                                                                                                  | Study MMY3004                                                                                                                                                                                                                                  |
|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Patient population               | Subjects with relapsed or refractory multiple myeloma who received at least 1 prior therapy for multiple myeloma and had PD based on investigator's determination of response by the IMWGcriteria on or after their last regimen were included | Subjects with relapsed or refractory multiple myeloma who received at least 1 prior therapy for multiple myeloma and had PD based on investigator's determination of response by the IMWGcriteria on or after their last regimen were included |
| Patient population               |  Subjects excluded for refractoriness or intolerance to lenalidomide                                                                                                                                                                          |  Subjects excluded for refractoriness to bortezomib or another PI                                                                                                                                                                             |
| Primary efficacy endpoint        | PFS                                                                                                                                                                                                                                            | PFS                                                                                                                                                                                                                                            |
| Key Secondary efficacy endpoints | TTP, ORR, VGPR or better rate, TTR, DOR, MRDnegativity, OS, time to subsequent antimyeloma therapy, PFS2                                                                                                                                       | TTP, ORR, VGPR or better rate, TTR, DOR, MRDnegativity, OS, time to subsequent antimyeloma therapy, PFS2                                                                                                                                       |
| Stratification                   | ISS (I, II, or III) at screening No. of prior lines (1 vs. 2 or 3 vs. >3)                                                                                                                                                                      | ISS (I, II, or III) at screening No. of prior lines (1 vs. 2 or 3 vs. >3)                                                                                                                                                                      |
| Stratification                   | Prior lenalidomide (no vs. yes)                                                                                                                                                                                                                | Prior bortezomib (no vs. yes)                                                                                                                                                                                                                  |
| Duration of treatment            | Rd: Until disease progression or unacceptable toxicity Daratumumab: Until disease progression or unacceptable toxicity                                                                                                                         | Vd 8 cycles in both treatment groups Daratumumab: Until disease progression or unacceptable toxicity                                                                                                                                           |

DOR=duration of response: ISS=International Staging System; MRD=minimum residual disease; ORR=overall response rate; OS=overall survival; PFS2=progression-free survival on next line of therapy; TTP=time to progression; TTR=time to response; VGPR=very good partial response

## Sample size

## Study MMY3003

<div style=\"page-break-after: always\"></div>

The total sample size needed for the study was approximately 560 subjects (280 per treatment group). It was assumed, that DRd could reduce the risk of disease progression or death by 30%, ie, assuming the HR (DRd  vs.  Rd)  of  0.70.  Analysis  of  the  primary  endpoint  PFS  was  planned  to  be  performed  when approximately 295 PFS events had occurred to achieve a power of 85% to detect a HR of 0.70 with a log-rank test (two-sided alpha being 0.05).  Long-term survival follow-up was to continue until 330 deaths had been observed.

## Study MMY3004

Approximately 480 subjects (240 per group) were to be randomized in the study. The sample size was based on the hypothesis of a 30% reduction in the risk of either progression or death. A total of 295 PFS events would provide a power of 85% to detect a reduction of 30% in the risk of either progression or death (HR [DVd vs Vd] of 0.70) with a log-rank test, assuming a two-sided significance level of 5%. A 16-month accrual period and an additional 10-month follow-up were assumed. Long-term survival follow-up was to continue until 320 deaths (ie. 2/3 of the randomized subjects) had been observed.

For both the MMY3003 and the MMY3004 studies, the sample size calculation took into consideration an annual dropout rate of 5%.

## Randomisation

In both studies, subjects were randomly assigned by an interactive web response system (IWRS) to 1 of 2 treatment groups based on a computer-generated randomization schedule. The randomization was stratified by ISS at screening (I, II, or III), number of prior lines of therapy (1 vs. 2 or 3 vs. &gt;3) and prior lenalidomide/bortezomib treatment (no vs. yes).

## Blinding (masking)

Both studies were open-label.

## Statistical methods

The statistical methods for key efficacy endpoints is provided in below Table:

<div style=\"page-break-after: always\"></div>

Table 4 Statistical method for key efficacy endpoints (study MMY3003)

| Endpoint                               | StatistiealAfethods                                                                                             |
|----------------------------------------|-----------------------------------------------------------------------------------------------------------------|
| PrinaryEndpoint                        | PrinaryEndpoint                                                                                                 |
| PFS                                    | Kaplan-Meiermethod,stratified log-rank test,stratified Cox'sregressionmodel                                     |
| Statification for primary analysis     | ISS staging(,I1,I1),number of prior lines therapy (l vs.2or 3vs.>3),and prior lenalidomide treatment(no vs.yes) |
| SecondaryEndpoints                     | SecondaryEndpoints                                                                                              |
| TTP                                    | Kaplan-Meiermethod,stratifiedlog-ranktest,stratifiedCoxregressionmodel                                          |
| ORR                                    | CMHy2testcontrolledfor3statificationfactors                                                                     |
| Responserate of VGPRor better          | CMHy2testcontrolled for3stralificationfactors                                                                   |
| TTR                                    | Kaplan-Meiermethod,stratifiedlog-rank test                                                                      |
| DOR                                    | Kaplan-Meiermethod                                                                                              |
| MRD negativity rate                    | Fisher'sexact test(Mantel-Haenszel oddsratio)and Likelihood-ratio(Chi-squared odds ratio)                       |
| OS                                     | Kaplan-Meier method,unstratified Cox'sregression model                                                          |
| Time to subsequent antimyeloma therapy | Kaplan-Meiermethod,stratified Cox'sregressionmodel                                                              |
| PFS2                                   | Kaplan-Meiermethod                                                                                              |

x2=chi-squaie;CMH=Coclran-Mantel-Haenszel;DOR=duration ofresponse;ISS=Intermational Staging System;

MRD=minimalresidual disease;ORR=overallresponse rate;OS=overall suvival;PFS=progression-free survival;

TTP=time-to-progression;TTR=time to response.

For both the MMY3003 and the MMY3004 studies, the analyses of efficacy endpoints were conducted on the ITT population, defined as subjects who have been randomised: PFS, TTP, MRD, OS, time to subsequent therapy, demographics and baseline characteristic.

Response-evaluable patients were defined as subjects who had a confirmed diagnosis of multiple myeloma and measurable disease at baseline or screening visit. In addition, subjects must have received at least 1 administration of study treatment and have at least 1 post baseline disease assessment. Analyses of major secondary endpoints of ORR, rate of VGPR or better, and duration of and time to response are based on this population.

The per-protocol population was defined as subjects who are randomized and have no major protocol deviations due to not meeting all inclusion/exclusion criteria.

The safety population was defined as subjects who have received at least 1 administration of any study treatment (partial or complete). This population is used for all safety analyses. The safety analysis grouping is according to the treatment actually received.

The immune response-evaluable population was defined as subjects assigned to the DRd group who have at least 1 immunogenicity sample obtained after their first daratumumab administration.

Two interim analyses were planned for the MMY3003 and the MMY3004 studies by an Independent Data Monitoring Committee (IDMC). The first interim analysis was to provide a comprehensive evaluation of safety after 80 subjects had been treated for at least 8 weeks or discontinued the study treatment.

The second interim analysis was to evaluate cumulative interim safety and efficacy data, and was to be performed when approximately 60% of the total planned events had been accumulated. The significance level at this interim analysis to establish the superiority of DRd over Rd and DVd over Vd respectively, with regard to PFS was determined based on the observed number of PFS events at the interim analysis, using

<div style=\"page-break-after: always\"></div>

the  O'Brien-Fleming  boundaries  as  implemented  by  the  Lan-DeMets  alpha  spending  method.  IDMC continues to review safety data at regular intervals during the study.

Response to study treatment and progressive disease was based on IMWG response criteria (by a validated computer algorithm) with minimal response (MR) defined according to European Society for Blood and Marrow Transplantation criteria.

## Results

## MMY3003

## Participant flow

The disposition of Subjects randomized into Study MMY3003 is shown in Figure 8.

Figure 8 Disposition of Subjects randomized into Study MMY3003

<!-- image -->

## Recruitment

The study was conducted in 18 countries, 12 of the countries were in the EU region (68% of subjects), 4 in the Asia-Pacific region (20%) and 12% of subjects were from Canada and the United States.

The first subject was randomized on 16 June 2014 and the last subject started treatment on 15 July 2015. The clinical cut-off was 7 March 2016.

## Conduct of the study

The original protocol was dated 10 February 2014. There were 2 global amendments and 4 country-specific amendments.

Amendment FRA-1 (8 May 2014): Exclusion Criteria #6 was modified to exclude subjects with a history of malignancy within 5 years, instead of 3 years.

Amendment INT-1 (16 June 2014): The sample size was changed to reflect the median PFS assumption for the  comparator  arm.  Lenalidomide  Global  Pregnancy  Prevention  Plan  was  added.  Feedback  from investigators and Health Authorities was incorporated.

Amendment JPN-1 (26 August 2014): In response to PMDA comments, a section and attachment were added  to  describe  the  enhanced  reporting,  monitoring,  and  review  of  pre-specified  safety  events  for Japanese subjects in the DRd group (minimum of 3 subjects).

<div style=\"page-break-after: always\"></div>

Amendment  INT-2  (20  November  2014):  The  requirements  for  bone  marrow  sample  collection  were modified to allow for differences across countries in local clinical practice. Other protocol procedures were clarified based on feedback from investigative sites. Changes from FRA-1 and JPN-1 amendments were rolled into the global INT-2 amendment.

Amendment DEU-1 (15 December 2014), INT-2/DEU-1 (7 April 2015): The exclusion criterion #9 text that was incorporated into Protocol Amendment INT-1 and INT-2 was replaced with the original protocol text. A summary of protocol deviations occurred is shown in Table 5.

Table 5 Major protocol deviations, Intention-to-Treat Analysis Set (Study MMY3004)

| Analysis set: intent-to-treat                          | Rd n (%) 283   | DRd n (%) 286   | Total n (%) 569   |
|--------------------------------------------------------|----------------|-----------------|-------------------|
| Total mumber of subjects with major protocol deviation | 16 (5.7%)      | 26 (9.1%)       | 42 (7.4%)         |
| Iype of major protocol deviation                       |                |                 |                   |
| Entered but did not satisfy criteria                   | 9 (3.2%)       | 9 (3.1%)        | 18 (3.2%)         |
| Received wrong treatment or incoirect dose             | 2 (0.7%)       | 12 (4.2%)       | 14 (2.5%)         |
| Efficacy assessment deviation                          | 2 (0.7%)       | 5 (1.7%)        | 7 (1.2%)          |
| Other                                                  | 2 (0.7%)       | 0               | 2 (0.4%)          |
| Developed withdrawal criteria but not withdrawm        | 0              | 1 (0.3%)        | 1 (0.2%)          |
| Received a disallowed concomitant treahment            | 1 (0.4%)       | 0               | 1 (0.2%)          |

Keys: Rd = lenalidomide-dexamethasone; DRd = daratumumab-lenalidomide-dexamethasone.

Note: Percentages calculated with the mumber of subjects in each treatment group as denominator.

[TSIDEM07.RTF] [UNI-54767414MMY3003DBR\\_CSRIRE\\_CSRIPR0DITSIDEM07.SAS] 13MAY2016,14:59

<div style=\"page-break-after: always\"></div>

## Baseline data

The demographic and baseline disease characteristics are presented in the following tables:

## Table 6 Demographic and Baseline characteristics, ITT Analysis set (Study MMY3003)

|                                      | Rd            | DRd            | Total          |
|--------------------------------------|---------------|----------------|----------------|
| Analysis set: intent-to-treat        | 283           | 286            | 569            |
| Age, years                           |               |                |                |
| N                                    | 283           | 286            | 569            |
| Category, n (%)                      |               |                |                |
| ≤65                                  | 140 (49.5%)   | 133 (46.5%)    | 273 (48.0%)    |
| 65-74                                | 108 (38.2%)   | 124 (43.4%)    | 232 (40.8%)    |
| ≥75                                  | 35 (12.4%)    | 29 (10.1%)     | 64 (11.2%)     |
| Mean (SD)                            | 64.3 (8.84)   | 64.4 (9.03)    | 64.4 (8.93)    |
| Median                               | 65.0          | 65.0           | 65.0           |
| Range                                | (42; 87)      | (34; 89)       | (34; 89)       |
| Sex, n (%)                           |               |                |                |
| N                                    | 283           | 286            | 569            |
| Male                                 | 164 (58.0%)   | 173 (60.5%)    | 337 (59.2%)    |
| Female                               | 119 (42.0%)   | 113 (39.5%)    | 232 (40.8%)    |
| Ethnicity, n (%)                     |               |                |                |
| N                                    | 283           | 286            | 569            |
| Hispamic or Latino                   | 3 (1.1%)      | 1 (0.3%)       | 4 (0.7%)       |
| Not Hispanic or Latino               | 238 (84.1%)   | 258 (90.2%)    | 496 (87.2%)    |
| Unknown                              | 1 (0.4%)      | 2 (0.7%)       | 3 (0.5%)       |
| Not Reported                         | 41 (14.5%)    | 25 (8.7%)      | 66 (11.6%)     |
| Race, n (%)                          |               |                |                |
| N                                    | 283           | 286            | 569            |
| White                                | 186 (65.7%)   | 207 (72.4%)    | 393 (69.1%)    |
| Black or Afican American             | 11 (3.9%)     | 5 (1.7%)       | 16 (2.8%)      |
| Asian                                | 46 (16.3%)    | 54 (18.9%)     | 100 (17.6%)    |
| American Indian or Alaska Native     | 0             | 0              | 0              |
| NativeHawaiianorotherPacificIslander | 0             | 0              | 0              |
| Other                                | 2 (0.7%)      | 1 (0.3%)       | 3 (0.5%)       |
| Unknowm                              | 2 (0.7%)      | 1 (0.3%)       | 3 (0.5%)       |
| Not Reported                         | 36 (12.7%)    | 18 (6.3%)      | 54 (9.5%)      |
| Weight (kg)                          |               |                |                |
| N                                    | 2             | 280            | 282            |
| Mean (SD)                            | 64.00 (5.657) | 73.69 (16.268) | 73.62 (16.234) |
| Median                               | 64.00         | 73.00          | 73.00          |
| Range                                | (60.0; 68.0)  | (37.0; 132.0)  | (37.0; 132.0)  |
| Height (cm)                          |               |                |                |
| N                                    | 279           | 282            | 561            |
| Mean (SD)                            | 166.0 (10.59) | 165.8 (10.54)  | 165.9 (10.56)  |
| Median                               | 166.0         | 165.8          | 166.0          |
| Range                                | (137; 201)    | (132; 195)     | (132; 201)     |
| Baseline ECOG score, n (%)           |               |                |                |
| N                                    | 283           | 286            | 569            |
| 0                                    | 150 (53.0%)   | 139 (48.6%)    | 289 (50.8%)    |
| 1                                    | 118 (41.7%)   | 136 (47.6%)    | 254 (44.6%)    |
| 2                                    | 15 (5.3%)     | 11 (3.8%)      | 26 (4.6%)      |
| >2                                   | 0             | 0              | 0              |

Keys:Rd=lenalidomide-dexamethasone;DRd=daratumumab-lenalidomide-dexamethasone.

[TSIDEM02.RTF][UNJ-54767414MIMY3003DBR\\_CSRIRE\\_CSRIPRODITSIDEM02.SAS]13MAY2016,14:58

<div style=\"page-break-after: always\"></div>

Table 7 Baseline disease characteristics, ITT Analysis set (Study MMY3003)

|                                           | Rd           | DRd          | Total      |
|-------------------------------------------|--------------|--------------|------------|
| Analysis set:intent-to-reat               | 283          | 286          | 569        |
| Type of myeloma by immmofixation,n(%)     |              |              |            |
| N                                         | 283          | 286          | 569        |
| IgG                                       | 167 (59.0%)  | 164 (57.3%)  | 331 (58.2! |
| IgA                                       | 56 (19.8%)   | 55 (19.2%)   | 111 (19.5  |
| IgM                                       | 0            | 2 (0.7%)     | 2 (0.4%    |
| IgD                                       | 6 (2.1%)     | 5 (1.7%)     | 11 (1.9%   |
| IgE                                       | 0            | 0            | 0          |
| Light chain                               | 46 (16.3%)   | 55(19.2%)    | 101(17.81  |
| Kappa                                     | 32 (11.3%)   | 34 (11.9%)   | 66 (11.6%  |
| Lambda                                    | 14 (4.9%)    | 21 (7.3%)    | 35 (6.2%   |
| Biclonal                                  | 0            | 1 (0.3%)     | 1 (0.2%    |
| Negativeimmmofixation                     | 8 (2.8%)     | 4 (1.4%)     | 122.1%     |
| Type ofmeasurable disease,n(%)            |              |              |            |
| N                                         | 283          | 286          | 569        |
| IgG                                       | 158 (55.8%)  | 151 (52.8%)  | 309 (54.31 |
| IgA                                       | 51 (18.0%)   | 49 (17.1%)   | 100(17.6)  |
| Otherb                                    | 2 (0.7%)     | 5 (1.7%)     | 7(1.2%/    |
| Urine only                                | 37 (13.1%)   | 41 (14.3%)   | 78(13.7%   |
| SenumFLConly                              | 33 (11.7%)   | 39(13.6%)    | 72 (12.70  |
| NE                                        | 0            | 1 (0.3%)     | 1 (0.2%    |
| ISS staging, n (%)                        |              |              |            |
| N                                         | 283          | 286          | 569        |
| I                                         | 140 (49.5%)  | 137 (47.9%)  | 277(48.7*1 |
| II                                        | 86 (30.4%)   | 93 (32.5%)   | 179 (31.5  |
|                                           | 57 (20.1%)   | 56 (19.6%)   | 113 (19.9  |
| TimefromMMdiagnosistorandomization(years) |              |              |            |
| N                                         | 283          | 286          | 569        |
| Mean (SD)                                 | 4.82 (3.607) | 4.56 (3.607) | 4.69(3.60  |
| Median                                    | 3.95         | 3.48         | 3.64       |
| Range                                     | (0.4;21.7)   | (0.4; 27.0)  | (0.4;27.0. |

## Table 8 Risk stratification in Multiple Myeloma, ITT analysis set (Study MMY3003)

|                             | Rd n (%)    | DRd (%) u   | Total n(%)   |
|-----------------------------|-------------|-------------|--------------|
| Analysisset:intent-to-treat | 283         | 286         | 569          |
| Risk stratification         |             |             |              |
| N                           | 283         | 286         | 569          |
| High-nisk                   | 18 (6.4%)   | 21(7.3%)    | 39 (6.9%)    |
| Standard-risk               | 167 (59.0%) | 182 (63.6%) | 349 (61.3%)  |
| Low-risk                    | 26 (9.2%)   | 25 (8.7%)   | 51 (9.0%)    |
| Notdone                     | 72 (25.4%)  | 58(20.3%)   | 130 (22.8%)  |

Keys:Rd=lenalidomide-dexamethasone;DRd=daratumumab-lenalidomide-dexamethasone.

Deteminationofa subjectsriskstratificationisbasedon three factors:Intemational StagingSystem(ISS);presence of

chromosomal abnormaliiesof t（4;14),del17or del17p byFISH orKaryotype testing and age Note:Percentages arecalculated with themumber of subjectsin each groupwith availabledata as denominator.

[TSICYT002RTF][NJ-54767414MMY3003DBR\\_CSRIRECSRPRODTSICYTO02SAS]13MAY2016,14:58

<div style=\"page-break-after: always\"></div>

Table 9 Prior Therapies for Multiple Myeloma, ITT analysis set (Study MMY3003)

|                                                               | Rd n (%)     | DRd (%)u     | Total n(%)   |
|---------------------------------------------------------------|--------------|--------------|--------------|
| Analysisset:intent-to-treat                                   | 283          | 286          | 569          |
| Totalmumberofsubjectswithanypriortherapiesformultiple myeloma | 283 (100.0%) | 286 (100.0%) | 569 (100.0%) |
| Priorsystemictherapy                                          | 283 (100.0%) | 286 (100.0%) | 569 (100.0%) |
| Priorautologous stem cell transplant(ASCT)                    | 180 (63.6%)  | 180 (62.9%)  | 360 (63.3%)  |
| Priorradiotherapy                                             | 57 (20.1%)   | 65 (22.7%)   | 122 (21.4%)  |
| Priorcancer-related surgery                                   | 42 (14.8%)   | 43 (15.0%)   | 85 (14.9%)   |
| Number of prior lines of therapy                              |              |              |              |
| N                                                             | 283          | 286          | 569          |
| Category, n (%)                                               |              |              |              |
| 1                                                             | 146 (51.6%)  | 149 (52.1%)  | 295 (51.8%)  |
| 乙                                                             | 80 (28.3%)   | 85 (29.7%)   | 165 (29.0%)  |
| 3                                                             | 38(13.4%)    | 38 (13.3%)   | 76 (13.4%)   |
| 3                                                             | 19 (6.7%)    | 14 (4.9%)    | 33 (5.8%)    |
| Mean (SD)                                                     | 1.8(1.14)    | 1.8 (1.17)   | 1.8(1.15)    |
| Median                                                        | 1.0          | 1.0          | 1.0          |
| Range                                                         | (1: 8)       | (1:11)       | (1:11)       |
|                                                               | 242 (85.5%)  | 245 (85.7%)  | 487 (85.6%)  |
| Bortezomib                                                    | 238 (84.1%)  | 241 (84.3%)  | 479 (84.2%)  |
| Carfilzomib                                                   | 6(2.1%)      | 6 (2.1%)     | 12 (2.1%)    |
| Ixazomib                                                      | 2(0.7%)      | 2 (0.7%)     | 4(0.7%)      |
| PriorIMiD                                                     | 156 (55.1%)  | 158 (55.2%)  | 314 (55.2%)  |
| Lenalidomide                                                  | 50 (17.7%)   | 50 (17.5%)   | 100 (17.6%)  |
| Pomalidomide                                                  | 0            | 2 (0.7%)     | 2 (0.4%)     |
| Thalidomide                                                   | 125(44.2%)   | 122 (42.7%)  | 247 (43.4%)  |
| Prior corticosteroids                                         | 281 (99.3%)  | 280 (97.9%)  | 561 (98.6%)  |
| Dexamethasone                                                 | 240 (84.8%)  | 249 (87.1%)  | 489 (85.9%)  |
| Prednisone                                                    | 83 (29.3%)   | 81 (28.3%)   | 164 (28.8%)  |
| Prior allkylating agents                                      | 270 (95.4%)  | 268 (93.7%)  | 538 (94.6%)  |
| Prior anturacyclines                                          | 79 (27.9%)   | 77 (26.9%)   | 156 (27.4%)  |
| PriorPI+IMiD                                                  | 125 (44.2%)  | 125 (43.7%)  | 250 (43.9%)  |
| PniorPI+IMiD+ALKY                                             | 121 (42.8%)  | 118 (41.3%)  | 239 (42.0%)  |
| PriorBORT+LEN                                                 | 43 (15.2%)   | 44 (15.4%)   | 87 (15.3%)   |
| PriorCARF+POM                                                 | 0            | 2 (0.7%)     | 2 (0.4%)     |

Keys:Rd=lenalidomide-dexamethasone:DRd=daratumumab-lenalidomide-dexamethasone

Keys:PI=proteasome inhibitor,MiD=Immumomodulatoryagent.ALKY=allkylatingagents;BORT=bortezomib;

LEN=lenalidomide;CARF=carfilzomib;POM=pomalidomide

Based ondata recorded onprior systemictherapyeCRFpage.

Note:Percentagescalculated with themumber of subjectsimeach treatmentgroup asdenominator.

<div style=\"page-break-after: always\"></div>

Table 10: Refractory status to prior Multiple Myeloma Therapy ,ITT analysis set (MMY3003 and MMY3004  Study)

|                                      | MMY3003    | MMY3003    | MY3004      | MY3004      |
|--------------------------------------|------------|------------|-------------|-------------|
|                                      | Rd         | DRd        | PA          | DVd         |
| Analysis set:intent-to-treat         | 283        | 286        | 247         | 251         |
| Refiactoryatanypoint topriortherapy  | 96(33.996) | 97(33.9%)  | 113 (45.7%) | 104(41.49)  |
| Refractory Status                    |            |            |             |             |
| PIonly                               | 46(16.396) | 57(19.9%)  | 4(1.69)     | 3(1296)     |
| DiDouly                              | 11 (3.9%)  | 10 (3.5%)  | 90(36.496)  | 74(29.596)  |
| Bo山PIand LD                          | 14(4.9%6)  | 7(2.49)    | 7(2.8%)     | 9(3.6%6)    |
| Reffactory tolastline ofpniortherapy | 76(26.996) | 80 (28.09) | 85(34.4%)   | 76(30.396)  |
| Refractory to                        |            |            |             |             |
| Bortezomib                           | 58(20.596) | 59 (20.6%) | 2(0.89)     | 1(0.496)    |
| Carfilzomb                           | 3(1.196)   | (060'1)E   | 4(1.6%)     | 5(2.096)    |
| Lxazomib                             | 0          | 2(0.796)   | 5(2.0%)     | 6(2496)     |
| Lenalidomide                         | 0          | 0          | 81(32.8%)   | 60 (23.996) |
| Pomalidomide                         | 0          | 2(0.796)   | 6(2.49)     | 7(2.896)    |
| Thalidomide                          | 26(9.296)  | 17(5.9%)   | 27(10.9%)   | 29(11.69)   |

Key.D=Daratuummab,Vd=bortezomib-dexamethasone,Rd=lenalidomide-dexamethasone

Keys:PI=proteasome inhibitor,IMiD=Inmmomodulatory agent.

Note:Perceutagescalculated with themunberof subjects ineach treatment group as denominator.

Note:Refractory to eachmedicationrefers to refractory to theirmostrecentmedication-containing line.

## Numbers analysed

Five hundred sixty-nine (569) subjects were randomized in the MMY3003 study, 286 received the study drug arm DRd and 283 received Rd (ITT population). Numbers treated were 564 patients, 283 in the DRd arm and 281 in the Rd arm (safety population).

## Outcomes and estimation

## Primary endpoint - PFS

As of 7 March 2016 clinical cut-off, the median duration of follow-up, based on Kaplan-Meier estimate was 13.54 months (range:0.0;20.7) for the ITT population. In the DRd arm 13.60 months (range: 0.0; 20.7) and 13.54 months (range: 0.1;20.3) in the Rd arm.

Results in terms of Progressive-Free Survival are reported in Table 11 and Figure 9.

<div style=\"page-break-after: always\"></div>

Table 11 Progression Free survival, ITT analysis set (study MMY03003)

|                                | Rd               | DRd              |
|--------------------------------|------------------|------------------|
| Analysisset:intent-to-treat    | 283              | 286              |
| Progression-free survival(PFS) |                  |                  |
| Numberofevents (%)             | 116 (41.0%)      | 53(18.5%)        |
| Numberofcensored(%)            | 167 (59.0%)      | 233 (81.5%)      |
| Kaplan-Meierestimate(months)   |                  |                  |
| 25%quantile(95%CI)             | 6.70(5.55,8.34)  | NE (13.17, NE)   |
| Median (95%CI)                 | 18.43(13.86,NE)  | NE (NE,NE)       |
| 75%quantile (95%C1)            | NE(18.43,NE)     | NE (NE, NE)      |
| P-valuea                       |                  | <0.0001          |
| Hazard ratio (95%C1)b          |                  | 0.37(0.27,0.52)  |
| 6-monthPFSrate%(95%CI)         | 77.1 (71.6,81.6) | 89.6(85.4,92.7)  |
| 12-monthPFSrate%(95%CI)        | 60.1 (54.0,65.7) | 83.2（78.3,87.2)  |
| 18-monthPFSrate%(95%CI)        | 52.2（44.3.59.5)  | 77.9 (71.3,83.2) |

Keys:Rd=lenalidomide-dexamethasone;DRd=daratumumab-lenalidomide-dexamethasone.

Key:CI=confidence interval.

p-valueisbasedon thelog-rank teststratifiedwithISS(I,II,orIIl),numberofpriorlinesof therapy（1vs.2or3vs.&gt;3), andpriorlenalidomidetreatment(novs.yes).

Hazardratioand95%CI fromaCoxproportional hazardsmodel with treatment as the sole explanatory variable and yes).A hazardratio&lt;1 indicatesanadvantageforDRd.

[TEFPFS01.RTF][JNJ-54767414MMY3003\\DBR\\_CSRRE\\_CSRPRODTEFPFS01.SAS]13MAY2016,14:37

Figure 9 Kaplan-Meier Plot for PFS, ITT population (Study MMY3003)

<!-- image -->

[GEFPFS01.RTF][NJ-54767414MMY3003\\DBR\\_CSRIRE\\_CSRIPRODIGEFPFS01.SAS]13MAY2016,14:41

<div style=\"page-break-after: always\"></div>

Figure 10 Subgroup Analyses of PFS, ITT population (Study MMY3003)

<!-- image -->

Note:Typeof MMsubgroupanalysisisbasedonsubjectswithmeasurablediseaseinserum.

Note:Refractory toPI subgroupanalysis isbasedon subjectswhoreceivedpriorPI therapy.

[GEFPFSFP01RTF][JNJ-54767414MMY3003DBRCSRRECSRPRODGEFPFSFP01.SAS]13MAY2016,14:42

<div style=\"page-break-after: always\"></div>

Table 12 Time to disease progression , ITT population (study MMY3003)

|                                | Rd                 | DRd              |
|--------------------------------|--------------------|------------------|
| Analysis set: intent-to-treat  | 283                | 286              |
| Time to disease progression    |                    |                  |
| Number of events (%)           | 104 (36.7%)        | 44 (15.4%)       |
| Number of censored (%)         | 179 (63.3%)        | 242 (84.6%)      |
| Kaplan-Meier estimate (months) |                    |                  |
| 25% quantile (95% CI)          | 7.66 (5.82, 10.12) | NE (NE, NE)      |
| Median (95% CI)                | 18.43 (14.78, NE)  | NE (NE, NE)      |
| 75% quantile (95% CI)          | NE (18.43, NE)     | NE (NE, NE)      |
| P-valuea                       |                    | <0.0001          |
| Hazard ratio (95% CI)b         |                    | 0.34 (0.23,0.48) |

Keys: Rd = lenalidomide-dexamethasone; DRd = daratumumab-lenalidomide-dexamethasone.

Key: CI = confidence interval.

p-value is based on the log-rank test stratified with ISS (I, II, or Ill), mumber of prior lines of therapy (1 vs. 2 or 3 vs. &gt;3), and prior lenalidomide treatment (no vs. yes).

b Hazard ratio and 95% CI from a Cox proportional hazards model with treatment as the sole explanatory variable and stratified with ISS (I, II, or I), number of prior lines of therapy (1 vs. 2 or 3 vs. &gt;3), and prior lenalidomide treatment (no vs. yes). A hazard ratio &lt; 1 indicates an advantage for DRd.

[TEFTTP01.RTF] [JNJ-54767414MMY3003DBR\\_CSRIRE\\_CSRIPR0DITEFTTP01.SAS] 13MAY2016,14:39

Figure 11 Kaplan-Meier plot for Time to Disease Progression, ITT population (study MMY3003)

<!-- image -->

[GEFTTP01.RTF] [NJ-54767414MMY3003\\DBR\\_CSRIRE\\_CSRIPRODIGEFTTP01.SAS]13MAY2016,14:42

## Secondary endpoint: Overall response rate

<div style=\"page-break-after: always\"></div>

Table 13 Overall best confirmed response, Response-evaluable set (study MMY3003)

|                                        | Rd          | Rd               | DRd          | DRd              | Odds Ratio (95% CT)   | P-valueb   |
|----------------------------------------|-------------|------------------|--------------|------------------|-----------------------|------------|
|                                        | n(%)        | 95% CI for %     | n(%)         | 95% CI for %     |                       |            |
| Analysis set: response-evaluable       | 276         |                  | 281          |                  |                       |            |
| Response category                      |             |                  |              |                  |                       |            |
| Stingent complete response (sCR)       | 20 (7.2%6)  | (4.59%, 11.0%6)  | 51 (18.1%)   | (13.8%6, 23.296) |                       |            |
| Complete response (CR)                 | 33 (12.0%)  | (8.4%6, 16.4%6)  | 70 (24.9%)   | (20.0%6, 30.496) |                       |            |
| Very good partial response (VGPR)      | 69 (25.0%)  | (20.0%6, 30.5%6) | 92 (32.7%6)  | (27.3%6, 38.696) |                       |            |
| Partial response (PR)                  | 89 (32.2%6) | (26.896, 38.196) | 48 (17.1%)   | (12.996, 22.096) |                       |            |
| Minimal response (MR)                  | 26 (9.4%)   | (6.2%6, 13.596)  | 5 (1.8%)     | (0.6%6, 4.196)   |                       |            |
| Stable disease (SD)                    |             | (8.4%6, 16.4%)   | 13 (4.6%)    | (2.5%6, 7.896)   |                       |            |
| Progressive disease (PD)               | 4 (1.4%)    | (0.4%, 3.7%)     | 0            | (NE, NE)         |                       |            |
| Not evaluable (NE)                     | 2 (0.7%)    | (0.1%, 2.6%)     | 2 (0.7%6)    | (0.196, 2.596)   |                       |            |
| Overallresponse(sCR+CR+VGPR+PR)        | 211 (76.4%) | (71.0%, 81.396)  | 261 (92.9%6) | (89.296,95.696)  | 4.62 (2.62, 8.15)     | <0.0001    |
| Climical benefit (Overallresponse +MR) | 237 (85.9%) | (81.2%6, 89.896) | 266 (94.7%)  | (91.396,97.096)  |                       |            |
| VGPR or better (sCR + CR + VGPR)       | 122 (44.2%) | (38.396, 50.396) | 213 (75.89%) | (70.4%6, 80.796) | 3.90 (2.72, 5.59)     | 0.0001     |
| CR or better (sCR+CR)                  | 53 (19.2%)  | (14.796, 24.496) | 121 (43.1%)  | (37.296, 49.196) | 3.17 (2.16, 4.66)     | <0.0001    |

Keys: Rd = lenalidomide-dexamethasone: DRd = daratmmmab-lenalidomide-dexamethasone.

Key. CI = exact confidence interval.

Mantel-Haenszel estimate of the common odds ratio for stratified tables is used The stratification factors are: ISS (1, II, or M), mumber of prior lines of therapy (1 vs. 2 or 3

P-value fom the Cochran Mantel-Haenszel Chi-Squared test.

Note: Response was assessed by computerized algorithm, based on Intermational Unifonm Response Criteria Consensus Recomumendatious.

Note: Response-evaluable is defined as subjects who have a confimed diaguosis of multiple myeloma and measuable disease at baseline or screening visit In addition, subjects must have received at least 1 administration of study treatment and have at least I post baseline disease assessment.

Note: Percentages are calculated with the number of subjects in each group as denominator.

## Secondary endpoint: Time to response/duration of response

The median time to response was 1.0 months (95% CI: 1.0, 1.1) in the DRd group compared with 1.3 months (95% CI: 1.1, 1.9) for the Rd group (p&lt;0.0001). The duration of response (DOR) was not reached in the DRd group, and was 17.4 months (95% CI: 17.4, NE) in the RD group.

Table 14 Duration of Response, responders in the Response evaluable set (study MMY3003)

|                                                                       | Rd               | DRd         |
|-----------------------------------------------------------------------|------------------|-------------|
| Amalysis set: responders (PR.or better) in the response-evaluable set | 211              | 261         |
| Dhuation of response\"                                                 |                  |             |
| Number of events (96)                                                 | 58 (27.596)      | 34 (13.096) |
| Number of censored (96)                                               | 153 (72.596)     | 227 (87.0%) |
| Kaplan-Meier estimate (months)                                        |                  |             |
| 25% quantile (95%6 CT)                                                | 10.8 (9.0, 12.9) | NE (NE, NE) |
| Median (95%6 CI)                                                      | 17.4 (17.4, NE)  | NE (NE, NE) |
| 75% quantile (95% CI)                                                 | NE (17.4, NE)    | NE (NE, NE) |

Keys:Rd=lenalidomide-dexamethasone;DRd=daratummmab-lenalidomide-dexamethasone.

Key: CI=confidence interval; PR=Partial response; NE =Not estimable.

First response PR or better.

Note: Nummber of events refers to number of responders (PR. or better) who developed disease progression or died dhne to disease progression.

Secondary endpoint: Minimal residual disease (MRD)

<div style=\"page-break-after: always\"></div>

## Table 15 MRD Negative Rate at 10 -4  in Bone Marrow, ITT analysis set (study MMY3003)

| TBMKMRD02D: Summary of MRDNegative Rate at 10 -4 in Bone Marrow; Analysis Set (Study 54767414MMY3003)   | Intent-to-Treat   | Intent-to-Treat      |
|---------------------------------------------------------------------------------------------------------|-------------------|----------------------|
|                                                                                                         | Rd                | DRd                  |
| Analysis set: intent-to-treat                                                                           | 283               | 286                  |
| MRDnegative rate (10 -4 )                                                                               | 22 (7.8%)         | 83 (29.0%)           |
| 95% CI a of MRDnegative rate                                                                            | (4.9%, 11.5%)     | (23.8%, 34.7%)       |
| Odds ratio with 95% CI b                                                                                |                   | 4.851 (2.929, 8.034) |
| P-value c                                                                                               |                   | <0.000001            |

Keys: Rd = lenalidomide-dexamethasone; DRd = daratumumab-lenalidomide-dexamethasone; CI = exact confidence interval.

a  Exact 95% confidence interval.

b  Chi-squared estimate of the common odds ratio is used. An odds ratio &gt; 1 indicates an advantage for DRd.

c  P-value from likelihood-ratio chi-squared test.

[TBMKMRD02D.RTF] [JNJ-54767414\\MMY3003\\DBR\\_CSR\\RE\\_CSR\\PROD\\TBMKMRD02D.SAS] 09JUN2016, 13:07

## Secondary endpoint: Overall survival

## Table 16 Overall survival , unstratified analysis,  ITT population (study MMY3003)

|                                   | Rd                | DRd               |
|-----------------------------------|-------------------|-------------------|
| Analysis set: intent-to-treat     | 283               | 286               |
| Overall survival                  |                   |                   |
| Number of events (%)              | 45 (15.9%)        | 30 (10.5%)        |
| Number of censored (%)            | 238 (84.1%)       | 256 (89.5%)       |
| Kaplan-Meier estimate (months)    |                   |                   |
| 25% quantile (95% CI)             | 20.27 (17.74, NE) | NE (NE, NE)       |
| Median (95% CI)                   | 20.27 (20.27, NE) | NE (NE, NE)       |
| 75% quantile (95% CI)             | NE (20.27, NE)    | NE (NE, NE)       |
| P-value?                          |                   | 0.0534            |
| Hazard ratio (95% CI)             |                   | 0.64 (0.40, 1.01) |
| 12-month survival rate % (95% CI) | 86.8 (82.2, 90.3) | 92.1 (88.2, 94.7) |
| 18-month survival rate % (95% CI) | 75.6 (59.8, 85.9) | 86.1 (79.9, 90.5) |

Keys: Rd = lenalidomide-dexamethasone; DRd = daratumumab-lenalidomide-dexamethasone.

Key: CI = confidence interval.

p-value is based on the log-rank test.

b Hazard ratio and 95% CI from a Cox proportional hazards model with treatment as the sole explanatory variable.

<div style=\"page-break-after: always\"></div>

Figure 12. Kaplan-Meier Plot for Overall Survival; Intent-to-Treat Population (Study MMY3003)

<!-- image -->

## Ancillary analyses

The time to subsequent antimyeloma treatment was significantly delayed for patients in the DRd group compared with patients in the Rd group (HR=0.38, 95% CI: 0.26, 0.55; p&lt; 0.0001). Forty (14%) and 89 (31%) of the patients in the DRd and Rd group, respectively, started subsequent anti-myeloma therapy. The median time to subsequent therapy or death due to progressive disease was not reached for either group (data not shown).

Patient-reported outcome were assessed using 2 PRO measures, the EORTC-QLQ-C30 and the EQ-5D-5L. No statistically significant difference was observed between DRd and Rd in change from baseline or median time to  improvement or worsening in the Global Healts Status/QOL subscale of the EORTC-QLQ-C30 or the EQ-5D-5L Utility score or EQ-5D-5L Visual Analog Scale (VAS) (data not shown).

## Study MMY3004

## Results

## Participant flow

The disposition of Subjects randomized into Study MMY3003 is shown in

<div style=\"page-break-after: always\"></div>

## Figure 13 .

Figure 13 Disposition of Subjects randomized into Study 5476741MMY3004

<!-- image -->

## Recruitment

The study was conducted in 16 countries, most of the subjects (75%) were enrolled in countries in the European Region (11 countries), 12% of the subjects were from the Asia-Pacific region (Australia and Korea), 7% of the subjects were from the United States, and 5% from Brazil and Mexico.

The first subject was randomized on 24 September 2014, and the last subject started treatment on 5 October 2015. The clinical cutoff was 11 January 2016.

## Conduct of the study

The original protocol was dated 2 April 2014; there was 1 global and 1 country-specific amendment to the protocol.

<div style=\"page-break-after: always\"></div>

Amendment INT-1 (23 December 2014): Clarification was made to the inclusion/exclusion criteria to align with other daratumumab protocols, and investigator feedback was incorporated into the protocol.

Amendment SWE-1 (10 July 2014): Specific concerns from the Health Authority in Sweden were addressed. Text was revised to indicate that study status updates were to be submitted to the Independent Ethics Committee/Institutional Review Board annually, or more frequently, if requested.

## Protocol deviations

Major protocol deviations were reported for 49 subjects (19%) across both treatment groups, as listed in Table 17.

Table 17 Major Protocol Deviations, Intent-to-Treat analysis set (study MMY3004)

|                                                        | Vd n (%)   | DVd n (%)   | Total n (%)   |
|--------------------------------------------------------|------------|-------------|---------------|
| Analysis set: intent-to-treat                          | 247        | 251         | 498           |
| Total number of subjects with major protocol deviation | 21 (8.5%)  | 28 (11.2%)  | 49 (9.8%)     |
| Type of major protocol deviation                       |            |             |               |
| Entered but did not satisfy criteria                   | 15 (6.1%)  | 14 (5.6%)   | 29 (5.8%)     |
| Received wrong treatment or incorrect dose             | 1 (0.4%)   | 10 (4.0%)   | 11 (2.2%)     |
| Received a disallowed concomitant treatment            | 2 (0.8%)   | 2 (0.8%)    | 4 (0.8%)      |
| Developed withdrawal criteria but not withdrawn        | 1 (0.4%)   | 1 (0.4%)    | 2 (0.4%)      |
| Other                                                  | 1 (0.4%)   | 1 (0.4%)    | 2 (0.4%)      |
| Safety assessment deviation                            | 1 (0.4%)   | 1 (0.4%)    | 2 (0.4%)      |

Keys: Vd = bortezomib-dexamethasone; DVd = daratumumab-bortezomib-dexamethasone.

Note: Percentages calculated with the number of subjects in each treatment group as denominator.

[TSIDEM07.RTF] [NJ-54767414MMY3004DBR\\_CSRIRE\\_CSRPR0DIISIDEM07.SAS] 05APR2016,15:51

<div style=\"page-break-after: always\"></div>

## Baseline data

The demographic and baseline disease characteristics are presented in the following tables:

Table 18 Demographic and Baseline characteristics, Intent-to-Treat analysis set (study MMY3004)

|                                       | Vd             | DVd            | Total          |
|---------------------------------------|----------------|----------------|----------------|
| Analysis set: intent-to-treat         | 247            | 251            | 498            |
| Age, years                            |                |                |                |
| N                                     | 247            | 251            | 498            |
| Category, n (%6)                      |                |                |                |
| c 65                                  | 125 (50.696)   | 132 (52.6%)    | 257 (51.6%6)   |
| 65 - 74                               | 87 (35.296)    | 96 (38.296)    | 183 (36.7%6)   |
| ≥75                                   | 35 (14.296)    | 23 (9.2%)      | 58 (11.6%6)    |
| Mean (SD)                             | 63.9 (9.81)    | 62.8 (9.66)    | 63.3 (9.74)    |
| Median                                | 64.0           | 64.0           | 64.0           |
| Range                                 | (33; 85)       | (30; 88)       | (30; 88)       |
| Sex, n (96)                           |                |                |                |
| N                                     | 247            | 251            | 498            |
| Male                                  | 147 (59.596)   | 137 (54.6%6)   | 284 (57.0%6)   |
| Female                                | 100 (40.596)   | 114 (45.496)   | 214 (43.0%)    |
| Ethmicity, n (96)                     |                |                |                |
| N                                     | 247            | 251            | 498            |
| Hispanic or Latino                    | 24 (9.796)     | 17 (6.8%6)     | 41 (8.296)     |
| Not Hispanic or Latino                | 212 (85.896)   | 227 (90.496)   | 439 (88.296)   |
| Unknown                               | 3 (1.2%6)      | 1 (0.4%6)      | 4 (0.8%)       |
| Not Reported                          | 8 (3.2%6)      | 6 (2.4%)       | 14 (2.8%)      |
| Race, n (%6)                          |                |                |                |
| N                                     | 247            | 251            | 498            |
| White                                 | 219 (88.796)   | 216 (86.1%)    | 435 (87.396)   |
| Black or Afican American              | 6 (2.49)       | 14 (5.6%)      | 20 (4.0%)      |
| Asian                                 | 11 (4.5%)      | 12 (4.8%)      | 23 (4.696)     |
| American Indian or Alaska Native      | 1 (0.4%)       | 1 (0.4%)       | 2 (0.4%%)      |
| NativeHawaiian orotherPacificIslander | 0              | 1 (0.4%)       | 1 (0.2%)       |
| Other                                 | 1 (0.4%)       | 5 (2.0%6)      | 6 (1.2%)       |
| Unknown                               | 2 (0.8%)       | 0              | 2 (0.4%)       |
| Not Reported                          | 7 (2.8%)       | 2 (0.8%)       | 9 (1.8%)       |
| Weight (kg)                           |                |                |                |
| N                                     | 235            | 243            | 478            |
| Mean (SD)                             | 77.17 (16.256) | 78.19 (17.010) | 77.69 (16.634) |
| Median                                | 76.00          | 77.00          | 76.00          |
| Range                                 | (37.5; 131.6)  | (45.0; 134.8)  | (37.5; 134.8)  |
| Height (cm)                           |                |                |                |
| N                                     | 247            | 251            | 498            |
| Mean (SD)                             | 166.8 (9.95)   | 166.8 (9.95)   | 166.8 (9.94)   |
| Median                                | 167.0          | 167.0          | 167.0          |
| Rauge                                 | (139; 192)     | (141; 194)     | (139; 194)     |
| Baseline ECOG score, n (96)           |                |                |                |
| N                                     | 247            | 250            | 497            |
| 0                                     | 116 (47.096)   | 106 (42.4%)    | 222 (44.796)   |
| 1                                     | 112 (45.396)   | 131 (52.4%)    | 243 (48.9%)    |
| 2                                     | 19 (7.7%)      | 13 (5.2%)      | 32 (6.4%)      |
| >2                                    | 0              | 0              | 0              |

Keys:Vd=bortezomib-dexamethasone;DVd =daratumumab-bortezomib-dexamethasone.

Note: Percentages calculated with the number of subjects in each teatment group with available data as denominator.

<div style=\"page-break-after: always\"></div>

Table 19 Baseline disease characteristics, Intent-to-Treat analysis set (study MMY3004)

<!-- image -->

|                                                | PA           | DVd          | Total        |
|------------------------------------------------|--------------|--------------|--------------|
| Analysis set: intent-to-treat                  | 247          | 251          | 498          |
| Type of myeloma by immumofixation, n (96)      |              |              |              |
| N                                              | 247          | 251          | 498          |
| IgG                                            | 148 (59.9%)  | 136 (54.296) | 284 (57.096) |
| IgA                                            | 54 (21.9%6)  | 59 (23.5%)   | 113 (22.7%)  |
| IgM                                            | 1 (0.4%)     | 1 (0.4%)     | 2 (0.496)    |
| IgD                                            | 3 (1.2%6)    | 6 (2.4%6)    | 9 (1.8%)     |
| IgE                                            | 0            | 0            | 0            |
| Light chain                                    | 36 (14.6%6)  | 43 (17.196)  | 79 (15.996)  |
| Kappa                                          | 17 (6.9%6)   | 30 (12.0%)   | 47 (9.496)   |
| Lambda                                         | 19 (7.7%)    | 13 (5.296)   | 32 (6.496)   |
| Biclonal                                       | 3 (1.296)    | 2 (0.8%)     | 5 (1.0%6)    |
| Negative immunofixation                        | 2 (0.8%)     | 4 (1.6%)     | 6 (1.2%)     |
| Type of measurable disease', n (9%6)           |              |              |              |
| N                                              | 247          | 251          | 498          |
| IgG                                            | 138 (55.9%)  | 125 (49.8%)  | 263 (52.8%)  |
| IgA.                                           | 54 (21.996)  | 56 (22.3%)   | 110 (22.1%)  |
| Otherb                                         | 4 (1.6%)     | 5 (2.0%)     | 9 (1.896)    |
| Urine only                                     | 36 (14.6%6)  | 40 (15.9%)   | 76 (15.3%6)  |
| Senum FLC only                                 | 14 (5.7%)    | 25 (10.0%)   | 39 (7.8%)    |
| NE                                             | 1 (0.4%)     | 0            | 1 (0.2%6)    |
| ISS staging', n (%)                            |              |              |              |
| N                                              |              | 251          | 498          |
| I                                              | 96 (38.9%)   | 98 (39.0%)   | 194 (39.0%6) |
| n                                              | 100 (40.5%)  | 94 (37.5%6)  | 194 (39.0%)  |
|                                                | 51 (20.6%6)  | 59 (23.596)  | 110 (22.1%6) |
| Time from MM diagnosis to randomization(years) |              |              |              |
| N                                              | 247          | 251          | 498          |
| Mean (SD)                                      | 4.77 (3.284) | 4.71 (3.228) | 4.74 (3.253) |
| Median.                                        | 3.72         | 3.87         | 3.77         |

<div style=\"page-break-after: always\"></div>

|                                                         | Vd           | DVd          | Total        |
|---------------------------------------------------------|--------------|--------------|--------------|
| Range                                                   | (0.6; 18.6)  | (0.7; 20.7)  | (0.6; 20.7)  |
| Number of lytic bone lesions, n (%6)                    |              |              |              |
| N                                                       | 246          | 249          | 495          |
| Noue                                                    | 50 (20.396)  | 56 (22.596)  | 106 (21.4%)  |
| 1-3                                                     | 43 (17.596)  | 50 (20.1%6)  | 93 (18.8%6)  |
| 4-10                                                    | 55 (22.4%)   | 53 (21.3%)   | 108 (21.8%)  |
| More than 10                                            | 98 (39.8%6)  | 90 (36.1%6)  | 188 (38.0%)  |
| Presence of diffuse myeloma-related osteopemia, n (9%6) |              |              |              |
| N                                                       | 247          | 249          | 496          |
|                                                         | 111 (44.9%)  | 88 (35.396)  | 199 (40.1%)  |
| No                                                      | 136 (55.1%6) | 161 (64.796) | 297 (59.996) |
| Number of extramedullary plasmacytomas, n (%6)          |              |              |              |
| N                                                       | 247          | 251          | 498          |
| 0                                                       | 233 (94.3%)  | 242 (96.496) | 475 (95.4%6) |
| 21                                                      | 14 (5.7%)    | 9 (3.6%)     | 23 (4.696)   |
| Presence of evaluable bone marrow assessment            |              |              |              |
| N                                                       | 247          | 251          | 498          |
|                                                         | 245 (99.2%)  | 249 (99.296) | 494 (99.2%)  |
| No                                                      | 2 (0.8%)     | 2 (0.8%)     | 4 (0.8%)     |
| % Plasma cells, bone marrow biopsy                      |              |              |              |
| N                                                       | 96           | 102          | 198          |
| ≤10                                                     | 14 (14.6%)   | 12 (11.8%)   | 26 (13.1%)   |
| 10-30                                                   | 37 (38.596)  | 40 (39.296)  | 77 (38.9%6)  |
| 30                                                      | 45 (46.996)  | 50 (49.0%6)  | 95 (48.0%6)  |
| % Plasma cells, bone mairow aspirate                    |              |              |              |
| N                                                       | 232          | 240          | 472          |
| ≤10                                                     | 44 (19.0%)   | 65 (27.1%6)  | 109 (23.1%)  |
| 10-30                                                   | 111 (47.8%6) | 97 (40.4%6)  | 208 (44.1%)  |
| OEc                                                     | 77 (33.2%)   | 78 (32.5%6)  | 155 (32.8%6) |
| % Plasma cells, bone mairow biopsy/aspirate             |              |              |              |
| N                                                       | 245          | 249          | 494          |
| ≤10                                                     | 42 (17.196)  | 42 (16.996)  | 84 (17.0%6)  |
| 10-30                                                   | 108 (44.1%)  | 106 (42.6%)  | 214 (43.3%)  |
| OE4                                                     | 95 (38.8%6)  | 101 (40.6%)  | 196 (39.7%)  |
| Any cytogenetic abnormality                             |              |              |              |
| N                                                       | 174          | 181          | 355          |
| Standard risk                                           | 137 (78.7%6) | 140 (77.3%6) | 277 (78.0%)  |
| High risk                                               | 37 (21.3%)   | 41 (22.7%)   | 78 (22.0%6)  |
| Dell7p                                                  | 21 (12.1%)   | 28 (15.5%)   | 49 (13.8%)   |
| T(4;14)                                                 | 15 (8.6%6)   | 14 (7.796)   | 29 (8.296)   |
| T(14:10)                                                | 5 (2.996)    | 4 (2.296)    | 9 (2.5%6)    |

Keys: Vd=bortezomib-dexamethasone; DVd = daratumumab-bortezomib-dexamethasone.

Key: FLC = senum fee light chain; ISS = International staging system.

'Includes subjects without measurable disease in senum and urine.

b Includes IgD, IgM, IgE and biclonal.

* ISS staging is derived based on the combination of senum β2-microglobulin and albumin.

sugsal adiofeq 1o Hsia mo paseq aie saeuonqe sganaaof p

[TSIDEM03.RTF] [UNJ-54767414IMMY3004IDBR\\_CSRIRE\\_CSRIPR0DATSIDEM03.SAS] 05APR2016.15:50

<div style=\"page-break-after: always\"></div>

Table 20 Risk stratification in Intent-to-Treat analysis set (study MMY3004)

|                               | PA n (96)   | DVd (%6)    | Total n (96)   |
|-------------------------------|-------------|-------------|----------------|
| Analysis set: intent-to-treat | 247         | 251         | 498            |
| Risk Stratification\"          |             |             |                |
| N                             | 247         | 251         | 498            |
| High-risk                     | 22 (8.9%6)  | 19 (7.6%)   | 41 (8.2%6)     |
| Standard-risk                 | 134 (54.3%) | 137 (54.6%) | 271 (54.4%)    |
| Low-risk                      | 18 (7.3%6)  | 25 (10.0%)  | 43 (8.6%6)     |
| Not done                      | 73 (29.696) | 70 (27.9%6) | 143 (28.7%)    |

Keys:Vd=bortezomib-dexamethasone;DVd=daratumumab-bortezomib-dexamethasone

* Determination of a subjecis risk stratification is based on three factors: Intemational Staging System (ISS); presence of chromosomal abnormalities of t(4; 14), dell7 or dell7p by FISH or Karyotype testing and age.

Note: Percentages are calculated with the number of subjects in each group with available data as denominator.

ITCTVTOMRTE1IINT54767414IMMV3ON4INRRCCRIRECCRIDRODITSIVTOMSAS1N5ADR01615

Table 21 Prior therapies for Multiple Myeloma, Intent-to-Treat analysis set (study MMY3004)

|                                                                        | PL (%6)      | DVd (%6)     | Total (%6)   |
|------------------------------------------------------------------------|--------------|--------------|--------------|
| Analysis set: intent-to-treat                                          | 247          | 251          | 498          |
| Total mumber of subjects with any prior therapies for multiple myeloma | 247 (100.0%) | 251 (100.0%) | 498 (100.0%) |
| Prior systemic therapy                                                 | 247 (100.0%) | 251 (100.0%) | 498 (100.0%) |
| Prior autologous stem cell transplant(ASCT)                            | 149 (60.3%)  | 156 (62.2%)  | 305 (61.296) |
| Prior radiotherapy                                                     | 59 (23.9%)   | 63 (25.1%6)  | 122 (24.596) |
| Prior cancer-related surgery                                           | 35 (14.2%)   | 33 (13.1%)   | 68 (13.7%6)  |
| Number of prior lines of therapy                                       |              |              |              |
| N                                                                      | 247          | 251          | 498          |
| Category, n (%)                                                        |              |              |              |
| 1                                                                      | 113 (45.7%)  | 122 (48.6%)  | 235 (47.296) |
| 2                                                                      | 74 (30.0%)   | 70 (27.9%)   | 144 (28.996) |
| 3                                                                      | 32 (13.0%)   | 37 (14.7%)   | 69 (13.9%)   |
|                                                                        | 28 (11.3%)   | 22 (8.8%)    | 50 (10.0%)   |
| Mean (SD)                                                              | 2.0 (1.38)   | 1.9 (1.21)   | 2.0 (1.29)   |
| Median                                                                 | 2.0          | 2.0          | 2.0          |
| Range                                                                  | (1; 10)      | (6 :D)       | (1; 10)      |
| Prior PI                                                               | 172 (69.6%6) | 169 (67.3%)  | 341 (68.5%)  |
| Bortezomib                                                             | 164 (66.4%)  | 162 (64.5%)  | 326 (65.596) |
| Carfilzomib                                                            | 10 (4.0%)    | 12 (4.8%)    | 22 (4.4%)    |
| Ixazomib                                                               | 7 (2.8%)     | 12 (4.8%)    | 19 (3.896)   |
| Prior IMiD                                                             | 198 (80.2%)  | 179 (71.3%%) | 377 (75.7%6) |
| Lenalidomide                                                           | 120 (48.6%)  | 89 (35.5%6)  | 209 (42.0%)  |
| Pomalidomide                                                           | 7 (2.8%)     | 7 (2.896)    | 14 (2.8%6)   |
| Thalidomide                                                            | 121 (49.0%)  | 125 (49.896) | 246 (49.496) |
| Prior corticosteroids                                                  | 245 (99.2%)  | 244 (97.2%)  | 489 (98.2%)  |
| Dexamethasone                                                          | 233 (94.3%)  | 218 (86.9%)  | 451 (90.6%)  |
| Prednisone                                                             | 77 (31.2%)   | 83 (33.1%)   | 160 (32.1%)  |
| Prior alkylating agents                                                | 224 (90.7%)  | 240 (95.6%)  | 464 (93.2%6) |
| Prior anthracyclines                                                   | 80 (32.4%)   | 72 (28.7%6)  | 152 (30.5%6) |
| Prior PI+IMiD                                                          | 129 (52.296) | 112 (44.6%%) | 241 (48.4%)  |
| Prior PI+IMiD+ALKY                                                     | 121 (49.0%)  | 112 (44.6%)  | 233 (46.896) |
| Prior BORT+LEN                                                         | 89 (36.0%)   | 75 (29.9%6)  | 164 (32.9%)  |
| Prior CARF+POM                                                         | 0            | 4 (1.6%)     | 4 (0.8%)     |

Keys:Vd=bortezomib-dexamethasone;DVd =daratumumab-bortezomib-dexamethasone.

Keys: PI = proteasome inhibitor; IMiD = Immumomodulatory agent; ALKY=alkylating agents; BORT= bortezomib;

LEN=lenalidomide: CARF=carfilzomib; POM=pomalidomide.

Based on data recorded on prior systemic therapy eCRF page.

Note: Percentages calculated with the nuumber of subjects in each treatment group as denominator.

<div style=\"page-break-after: always\"></div>

## Numbers analysed

Four hundred ninety-eight (498) subjects were randomized in the MMY3004 study, 251 in the study drug arm DVd and 247 In the Vd arm (ITT population). Numbers treated were 480 patients, 243 received DVd and 237 received the Vd arm (safety population).

## Outcomes and estimation

As of the data cutoff, the median duration of follow-up was 7.5 months (range: 0.1;14.9) for the DVd group and 7.4 months (0.0;14.5) for the Vd group, 67 subjects (27%) in the DVd group and 122 subjects (49%) in the Vd group had progressive disease or died.

## Primary endpoint - PFS

Table 22 Progression-free survival based on Computerized Algorithm; Intent-to-Treat analysis set (study MMY3004)

|                                | Vd                | DVd               |
|--------------------------------|-------------------|-------------------|
| Analysis set: intent-to-treat  | 247               | 251               |
| Progression-ffee suvival (PFS) |                   |                   |
| Nuumber of events (%)          | 122 (49.4%)       | 67 (26.7%)        |
| Nuumber of censored (%)        | 125 (50.6%)       | 184 (73.3%)       |
| Kaplan-Meier estimate (months) |                   |                   |
| 25% quantile (95% CI)          | 4.21 (3.19, 4.90) | 7.20 (6.47, 8.84) |
| Mediam (95% CI)                | 7.16 (6.21, 7.85) | NE (12.25, NE)    |
| 75% quantile (95% CI)          | 12.02 (9.10, NE)  | NE (NE, NE)       |
| P-valuea                       |                   | -0.0001           |
| Hazard ratio (95% CI)b         |                   | 0.39 (0.28,0.53)  |
| 6-month PFS rate % (95% CI)    | 60.6 (53.8, 66.8) | 81.9 (76.3, 86.2) |
| 12-month PFS rate % (95% CI)   | 26.9 (17.1,37.5)  | 60.7 (51.2, 69.0) |
| 18-month PFS rate % (95% CI)   | NE (NE, NE)       | NE (NE, NE)       |

Keys: Vd = bortezomib-dexamethasone; DVd = daratumumab-bortezomib-dexamethasone.

Key: CI = confidence interval.

p-value is based on the log-rank test stratified with ISS (I, II, or Ill), nuumber of prior lines of therapy (1 vs. 2 or 3 vs. &gt;3). and prior bortezomib treatment (no vs. yes).

b Hazard ratio and 95% CI from a Cox proportional hazards model with treatment as the sole explanatory variable and stratified with ISS (I, II, or IIl), mumber of prior lines of therapy (1 vs. 2 or 3 vs. &gt;3), and prior bortezomib treatment (no vs. yes). A hazard ratio &lt; 1 indicates an advantage for DVd.

[TEFPFS01.RTF][INU-54767414MMY3004DBR\\_CSRIRE\\_CSRIPRODITEFPFS01.SAS] 05APR2016, 14:55

Figure 14 Kaplan-Meier Plot for Progression-free Survival based on Computerized Algorithm; Intent-to-Treat analysis set (study MMY3004)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 15 Forest Plot of Subgroup Analyses of PFS based on Computerized Algorithm; Intent-to-Treat analysis set (study MMY3004)

<!-- image -->

Note: Type of MM subgroup analysis is based on subjects with measurable disease in serum. Note: Refractory to IMiD subgroup analysis is based on subjects who received prior IMiD therapy.

[GEFPFSFP01RTF] [JNI-54767414MMY3004DBR\\_CSRIRE\\_CSRIPRODIGEFPFSFP01.SAS] 20MAY2016, 08:50

<div style=\"page-break-after: always\"></div>

## Secondary endpoints: Time to disease progression

The TTP results and Kaplan-Meier curves for the ITT population are provided in Table 23 and Figure 16

Table 23 Time to Disease Progression, Intent-to-Treat analysis set (study MMY3004)

|                                | Vd               | DVd                |
|--------------------------------|------------------|--------------------|
| Amalysis set: intent-to-treat  | 247              | 251                |
| Time to disease progression    |                  |                    |
| Number of events (%6)          | 112 (45.3%)      | 51 (20.3%6)        |
| Number of censored (%6)        | 135 (54.7%)      | 200 (79.7%)        |
| Kaplan-Meier estimate (months) |                  |                    |
| 25% quantle (95% C))           | 4.40 (3.78.4.99) | 8.64 (7.03, 10.25) |
| Median (95% C1)                | 7.29 (6.41.8.08) | NE (12.25, NE)     |
| 75% quantile (95%6 C)          | 12.02 (9.33, NE) | NE (NE, NE)        |
| P-value\"                       |                  | ~0.0001            |
| Hazard ratio (95%. CI)         |                  | 0.30 (0.21,0.43)   |

Keys:Vd=bortezouib-dewamethasone:DVd=daratwmumab-bortezomib-dexamethnsone

Key: CI =confidence interval p-nhue is based on the log-rank test statified with ISS (1. I, or M). mumber of prior lines of theapy (l vs. 2 or 3 vs. &gt;3). and prior bortezomib treatment (no Ws. yes)

Hazard ratio and 95%, CI from a Cox proportional hazards model with treatment as the sole explamatory variable and sharified with ISS (1. I, or m),. mumber of prior lines of therapy (1 vs. 2 or 3 vs. &gt;3). and prior bortezouib treatment (no Vs. yes). A hazard ratio &lt; 1 indicates an adwantage for DVd

[TEFTIP01RTF] (NI-54767414MMY3004IDBR\\_CSRIRE\\_CSRIPRODTEFTTP01.SAS]05APR2016, 14:5S

Figure 16 Kaplan-Meier plot for Time to Disease Progression, based on Computerized Algorithm; Intent-to-Treat analysis set (study MMY3004)

<!-- image -->

## Secondary endpoint: Overall response rate

<div style=\"page-break-after: always\"></div>

Table 24 Overall best confirmed response based on Computerized Algorithm; Response-evaluable analysis set (Study MMY3004)

|                                        | Vd          | Vd              | DVd         | DVd            | Odds Ratio (95% CI)   | P-valueb   |
|----------------------------------------|-------------|-----------------|-------------|----------------|-----------------------|------------|
|                                        | n(%)        | 95% CI for %    | n(%)        | 95% CI for %   |                       |            |
| Analysis set: response-ewaluable       | 234         |                 | 240         |                |                       |            |
| Response category                      |             |                 |             |                |                       |            |
| Stingent complete response (sCR)       | 5 (2.1%)    | (0.7%, 4.9%)    | 11 (4.6%)   | (2.3%, 8.1%)   |                       |            |
| Complete response (CR)                 | 16 (6.8%)   | (4.0%, 10.9%)   | 35 (14.6%)  | (10.4%, 19.7%) |                       |            |
| Very good pauntial response(VGPR)      | 47 (20.1%)  | (15.1%, 25.8%%) | 96 (40.0%)  | (33.8%,46.5%)  |                       |            |
| Partial response (PR)                  | 80 (34.2%)  | (28.1%, 40.7%6) | 57 (23.8%)  | (18.5%,29.6%)  |                       |            |
| Minimal response (MR)                  | 20 (8.5%)   | (5.3%, 12.9%)   | 10 (4.2%)   | (2.0%, 7.5%)   |                       |            |
| Stable disease                         | 47 (20.1%)  | (15.1%, 25.8%)  | 24 (10.0%)  | (6.5%, 14.5%)  |                       |            |
| Progressive disense (PD)               | 16 (6.8%)   | (4.0%,10.9%)    | 5 (2.1%)    | (0.7%, 4.8%)   |                       |            |
| Not ewluable (NE)                      | 3 (1.3%)    | (0.3%, 3.7%)    | 2 (0.8%)    | (0.1%, 3.0%)   |                       |            |
| Overallresponse(sCR+CR+VGPR+PR)        | 148 (63.2%) | (56.7%6, 69.4%) | 199 (82.9%) | (77.5%, 87.5%) | 3.13 (1.97.4.97)      | c0.0001    |
| Clinical benefit (Ovenllresponse + MR) | 168 (71.8%) | (65.6%, 77.5%)  | 209 (87.1%) | (82.2%, 91.1%) |                       |            |
| VGPR or better (sCR + CR. +VGPR)       | 68 (29.1%)  | (23.3%, 35.3%%) | 142 (59.2%) | (52.7%, 65.4%) | 3.99 (2.64,6.02)      | ≤0.0001    |
| CR or better (sCR + CR)                | 21(9.0%)    | (5.6%, 13.4%)   | 46 (19.2%)  | (14.4%, 24.7%) | 2.53 (1.42.4.51)      | 0.0012     |

Keys: Vd = bortezomib-dexamethasone; DVd = darahmumab-bortezomib-dexamethasone

Key: CI = exact confidence interwal.

P-value fom the Cochran Mantel-Haenszel Chi-Squared test.

Mantel-Haenszel estimate of the common odds ratio for stratified tables is used. The stratification factors are: ISS (I. I, or ). number of prior ines of therapy (1 vs. 2 or 3 Vs. &gt;3), and prior bortezomib treatment (no vs. yes). An odds ratio &gt; I indicates an advantage for DVd.

Note: Response was assessed by computerized algorithm, based on Intemational Uniform Response Criteria Consensus Recommendations.

Note: Percentages are calculated with the number of subjects in each goup as denominator.

Note: Response-evaluable set includes subjects who have a confimed dingnosis of multiple myeloma and measurable disease at baseline or screening. In addifion, subjects must have received at least I administration of study treatment and have at least 1 post baseline disease assessment.

[TEFRESP01RTF][INJ-54767414WIMY3004DBR\\_CSRIRE\\_CSRIPRODITEFRESP01.SAS]06APR2016,10:28

<div style=\"page-break-after: always\"></div>

Figure 17 Subgroup analysis on Overall Response rate based on Computerized Algorithm; Response-evaluable analysis set (Study MMY3004)

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

Secondary endpoint: Time to response/duration of response

The median time to response was 0.9 months (95% CI: 0.8, 1.4) in the DVd group compared with 1.6 months (95% CI: 1.5, 2.1) for the Vd group (p&lt;0.0001).

Table 25 Kaplan-Meier Plot for Time to response based on Computerized Algorithm; Response evaluable analysis set (Study MMY3004)

<!-- image -->

[GEFTTR01.RTF][NI-54767414IMMY3004IDBR\\_CSRIRE\\_CSRUPRODIGEFTTR01.SAS]05APR2016,15:00

Table 26 Summary of Duration of Response based on computerized Algorithm, Response-evaluable analysis set (Study MMY3004)

|                                                                        | P              | DVd           |
|------------------------------------------------------------------------|----------------|---------------|
| Anmalysis set: responders (PR. or better) in the response-evalable set | 148            | 199           |
| Duation of response\"                                                   |                |               |
| Number of events (%)                                                   | 52 (35.1%)     | 30 (15.1%%)   |
| Number of censored (%6)                                                | 96 (64.9%%)    | 169 (84.9%)   |
| Kaplan-Meier estimate (months)                                         |                |               |
| 25% quantile (95% C)                                                   | 4.9 (4.3.5.7)  | 9.5 (7.9.NE)  |
| Median (95% CI)                                                        | 7.9 (6.7. 113) | NE (11.5. NE) |
| 75% quantile (95% C)                                                   | NE (10.7, NE)  | NE (NE, NE)   |

Keys: Vd = bortezomib-dexamethasone; DVd= darahmumab-bortezomib-dexamethasone.

Key: CI = confidence interval; PR =patinl response: NE =not evalnble.

'First response PR or better.

Note: Number of events refers to number of responders (PR or better) who developed disease progression or died dhe to disease progression.

[TEFD0R01RTF] [INI-54767414MMY30041DBR\\_CSRIRE\\_CSRPRODITEFD0R01.SAS]05APR2016, 15:01

Seconday endpoint: Minimal residual disease (MRD)

<div style=\"page-break-after: always\"></div>

Table 27 MRD Negative rate at 10 -4  in Bone marrow, Intent-to-Treat analysis set (study MMY3004)

| TBMKMRD02D: Summary of MRDNegative Rate at 10 -4 in Bone Marrow; Intent-to-Treat Analysis Set (Study 54767414MMY3004)   | TBMKMRD02D: Summary of MRDNegative Rate at 10 -4 in Bone Marrow; Intent-to-Treat Analysis Set (Study 54767414MMY3004)   | TBMKMRD02D: Summary of MRDNegative Rate at 10 -4 in Bone Marrow; Intent-to-Treat Analysis Set (Study 54767414MMY3004)   |
|-------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                         | Vd                                                                                                                      | DVd                                                                                                                     |
| Analysis set: intent-to-treat                                                                                           | 247                                                                                                                     | 251                                                                                                                     |
| MRDnegative rate (10 -4 )                                                                                               | 7 (2.8%)                                                                                                                | 34 (13.5%)                                                                                                              |
| 95% CI a of MRDnegative rate                                                                                            | (1.1%, 5.8%)                                                                                                            | (9.6%, 18.4%)                                                                                                           |
| Odds ratio with 95% CI b                                                                                                |                                                                                                                         | 5.372 (2.333, 12.368)                                                                                                   |
| P-value c                                                                                                               |                                                                                                                         | 0.000006                                                                                                                |

Keys: Vd = bortezomib-dexamethasone; DVd = daratumumab-bortezomib-dexamethasone; CI = exact confidence interval.

a  Exact 95% confidence interval.

b  Chi-squared estimate of the common odds ratio is used. An odds ratio &gt; 1 indicates an advantage for DVd.

c P-value from likelihood-ratio chi-squared test.

[TBMKMRD02D.RTF] [JNJ-54767414\\MMY3004\\DBR\\_CSR\\RE\\_CSR\\PROD\\TBMKMRD02D.SAS] 09JUN2016, 09:46

Secondary endpoint: Overall survival

Table 28 Overall Survival (unstratified analysis), Intent-to-Treat analysis set (study MMY3004)

|                                   | Vd               | DVd              |
|-----------------------------------|------------------|------------------|
| Ammlysis set: intent-to-treat     | 247              | 251              |
| Oveall survival                   |                  |                  |
| Number of events (%6)             | 36 (14.6%%)      | 29 (11.6%)       |
| Number of censored (76)           | 211 (85.4%)      | 222 (88.4%)      |
| Kaplhn-Meier estimate (months)    |                  |                  |
| 25% quantile (95% C)              | 12.19 (9.69. NE) | NE (11.60. NE)   |
| Median (95% C1)                   | NE (NE. NE)      | NE (NE.NE)       |
| 75% quantile (95% CI)             | NE (NE, NE)      | NE (NE, NE)      |
| P-value\"                          |                  | 0.2975           |
| Hazard ratio (95% C1)             |                  | 0.77 (0.47.1.26) |
| 12-month surviwalrale % (95%, CT) | 81.9 (74.7.87.3) | 82.2 (71.8.89.1) |
| 18-month suvimalrate % (95% CI)   | NE (NE. NE)      | NE (NE, NE)      |

Keys:Vd=bortezomib-dexamethasone;DVd=daratmumab-bortezomib-dexamethnsone.

Key: CI = confidence interval.

p-value is based on the log-rank test.

Hazard ratio and 95% CI from a Cox proportional hazards model with treatment as the sole explanatory wariable. A hazard ratio ≤ I indicates an advantage for DVd.

<div style=\"page-break-after: always\"></div>

Figure 18. Kaplan-Meier Plot for Overall Survival; Intent-to-Treat Analysis Set (Study MMY3004)

<!-- image -->

## Other efficacy analyses

The time to subsequent antimyeloma therapy was longer for patients in the DVd group compared with patients  in  the  Vd  group  (HR=0.30,  95%  CI:  0.20,  0.45;  p&lt;0.0001).  The  median  time  to  subsequent therapy or death due to progressive disease was not estimable for the DVd group and 9.8 months for the Vd group (data not shown).

---DVd

<div style=\"page-break-after: always\"></div>

## Best M-protein Response

The best M-protein response for the response-evaluable population is presented in Table 29.

Table 29 M protein Response, Response-evaluable Analysis Set (study MMY3004)

|                                   | P            | Dud          |
|-----------------------------------|--------------|--------------|
|                                   | n(26)        | n(26)        |
| Analysis set: response-ewalunble  | 234          | 240          |
| Best M-protein response in senum  |              |              |
| N                                 | 184          | 178          |
| 1009reduction                     | 49 (26.6%)   | 89 (50.0%)   |
| 290%to100:6reduction              | 9(4.926)     | 16 (9.096)   |
| 2 5076 to < 9096 reduction        | 78 (42.456)  | 57 (32.0%6)  |
| ≥259to50%reduction                | 20 (10.996)  | 6 (3.4%)     |
| ≥ 90s6 reduction                  | 58 (31.596)  | 105 (59.096) |
| 2 50k6 reduction                  | 136 (73.916) | 162 (91.096) |
| Best M-protein response in wrines |              |              |
| N                                 | EE           | 36           |
| 100sreduction                     | 12 (36.476)  | 21 (58.376)  |
| ≥ 909 to ≤ 100:% reduction        | 4 (12.194)   | 3(8.394)     |
| ≥50%to 90%reduction               | 8 (24.2%6)   | 8 (22.2%6)   |
| 29o%reduction                     | 16 (48.526)  | 24 (66.720)  |
| 2: 5or6 reduction                 | 24 (72.796)  | 32 (88.996)  |
| Best response in senum dFLcud     |              |              |
| N                                 | 14           | 24           |
| 100%6reduction                    |              | 0            |
| 2909 to <10096reduction           | 8 (57.196)   | 24 (100.09)  |
| 2 50 to < 909%reduction           | 4 (28.6%6)   | 0            |
| ≥9o%reduction                     | 8 (57.1%4)   | 24 (100.0%)  |
|                                   | 12 (85.796)  | 24 (100.0%)  |
| 2 5or6reduclion                   |              |              |

Keys: Vd = boniezomib-deramethasone: Dvd = darahmmmab-bortezomib-dexamethasone.

- The reference point is baseline.

Key: dFL C = difference between inwolved and wminvolved senum firee light chain.

Measuwred as percent change from baseline in serum M-protein for subjects with measuable heavy chain disease at baseline. pyw tng 'suieqp faeay eiqemsea jnom spalqns rog meiord-w anm u anlaseg mog aeuep juased se sanseew s

* Measures as percent change from baseline in the difference between inrolved and uminvolved senm FLC for subjects without measwable heavy chains and light chain disease at baseline.

measwable light chain disease at baseline.

Note: Response-evaluable set includes subjects who have a confimmed diagnosis of mwltiple myeloma and measurable disease at baseline or screening. In addition, subjects must have received at least 1 administration of study treatment and have at least 1 post baseline disease assessment.

[TEFMRSP01.RTF][NI-54767414MMY3004DBR\\_CSRURE\\_CSRUPRODNTEFMRSP01.SAS]05APR2016,15:02

## Patient-reported Outcomes

F unctional  status  and  well-being  were  assessed  using  PRO  measures,  the  EORTC-QLQ-C30  and  the EQ-5D-5L. Compliance was comparable between treatment groups and baseline scores on all subscales were comparable between treatment Groups. The PRO results indicated no statistically significant difference between DVd and Vd in change from baseline or median time to improvement or worsening in the Global Health Status/QOL subscale of the EORTC-QLQ-C30. For nearly all timepoints, no statistically significant differences between DVd and Vd were observed in change from baseline in the EQ-5D-5L Utility Score or EQ-5D-5L VAS and no statistically significant differences were observed between DVd and Vd in median time to worsening or improvement in the Utility Score or VAS (data not shown).

## Summary of main studies

The following table summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

<div style=\"page-break-after: always\"></div>

## Table 30 Summary of Efficacy for study MMY3003

| Title: Daratumumab in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.   | Title: Daratumumab in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.   | Title: Daratumumab in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.   | Title: Daratumumab in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.                                                      |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                          | MMY3003                                                                                                                                                                   | MMY3003                                                                                                                                                                   | MMY3003                                                                                                                                                                                                                      |
| Design                                                                                                                                                                    | Open-label, randomised (1:1) multicentre, phase 3                                                                                                                         | Open-label, randomised (1:1) multicentre, phase 3                                                                                                                         | Open-label, randomised (1:1) multicentre, phase 3                                                                                                                                                                            |
| Design                                                                                                                                                                    | Initiation of study Last subject started                                                                                                                                  | Initiation of study Last subject started                                                                                                                                  | 16-June-2014 15-July-2015                                                                                                                                                                                                    |
| Hypothesis                                                                                                                                                                | Superiority                                                                                                                                                               | Superiority                                                                                                                                                               | Superiority                                                                                                                                                                                                                  |
| Treatments groups                                                                                                                                                         | DRd                                                                                                                                                                       | DRd                                                                                                                                                                       | Daratumumab : C1 to C2 16 mg/kg weekly, C3 to C6 every other week, C7 and beyond every 4 weeks thereafter Lenalidomide : 25 mg on Days 1-21 per 28-day cycle Low Dose Dexamethasone : 40 mg per week                         |
| Treatments groups                                                                                                                                                         | Rd                                                                                                                                                                        | Rd                                                                                                                                                                        | Lenalidomide : 25 mg on Days 1-21 per 28-day cycle Low Dose Dexamethasone : 40 mg per week                                                                                                                                   |
| Endpoints and definitions                                                                                                                                                 | Primary endpoint                                                                                                                                                          | PFS                                                                                                                                                                       | The time from the date of randomization to either progressive disease, according to the IMWG response criteria, or death, whichever occurs first                                                                             |
| Endpoints and definitions                                                                                                                                                 | Secondary endpoint                                                                                                                                                        | TTP                                                                                                                                                                       | The time between the date of randomization and the date of first documented evidence of confirmed progressive disease, as defined in the IMWG response criteria, or death due to progressive disease, whichever occurs first |
| Endpoints and definitions                                                                                                                                                 | Secondary endpoint                                                                                                                                                        | ORR                                                                                                                                                                       | The proportion of subjects who achieve a partial response or better (i.e, PR, VGPR, CR or sCR), according to IMWG response criteria, during or after the study treatment                                                     |
| Endpoints and definitions                                                                                                                                                 | Secondary endpoint                                                                                                                                                        | MRD negativity                                                                                                                                                            | The proportion of subjects who had negative MRD assessment at any time point after the first dose of study drugs                                                                                                             |
| Data cut-off                                                                                                                                                              | 7 March 2016                                                                                                                                                              | 7 March 2016                                                                                                                                                              | 7 March 2016                                                                                                                                                                                                                 |

## Results and Analysis

Analysis description

Analysis population and time point

description

Descriptive statistics and estimate

variability/ Effect estimate per

comparison

Primary Analysis

Intent to treat (N=569)

Treatment group

Number of subject

PFS, median (months)

HR (95%CI)

p-value

TTP, median (months)

HR (95%CI)

p-value

ORR (95% CI)

(sCR+CR+VGPR+PR)

DRd

(daratumumab, lenalidomide and

dexamethasone)

286

NE

0.37(0.27, 0.52)

p&lt;0.0001

NE

0.34 (0.23, 0.48)

p&lt;0.0001

89,2%;95.6%

Rd

(lenalidomide and dexamethasone)

283

18,4 (13.9,NE)

18.4 (14.8, NE)

71.0%;81.3%

<div style=\"page-break-after: always\"></div>

| Odds ratio                                             | 4.6 (2.6;8.2) p<0.0001   |                 |
|--------------------------------------------------------|--------------------------|-----------------|
| MRD negative rate (95% CI) (10 -4 ) Odds ratio with CI | 29.0 (23.8, 34.7)        | 7.8 (4.9, 11.5) |
| 95%                                                    | 4.85 (2.93, 8.03)        |                 |
| p-value                                                | p<0.0001                 |                 |

## Table 31 Summary of Efficacy for study MMY3004

| Title: Daratumumab in combination with bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.   | Title: Daratumumab in combination with bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.   | Title: Daratumumab in combination with bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.   | Title: Daratumumab in combination with bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.                                                                           | Title: Daratumumab in combination with bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.                                                                           |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                         | MMY3004                                                                                                                                                                  | MMY3004                                                                                                                                                                  | MMY3004                                                                                                                                                                                                                                          | MMY3004                                                                                                                                                                                                                                          |
| Design                                                                                                                                                                   | Open-label, randomised (1:1), multicentre, phase 3 study                                                                                                                 | Open-label, randomised (1:1), multicentre, phase 3 study                                                                                                                 | Open-label, randomised (1:1), multicentre, phase 3 study                                                                                                                                                                                         | Open-label, randomised (1:1), multicentre, phase 3 study                                                                                                                                                                                         |
| Design                                                                                                                                                                   | Initiation of study Last subject started                                                                                                                                 | Initiation of study Last subject started                                                                                                                                 | 24-Sept-2014 5-Oct-2015                                                                                                                                                                                                                          | 24-Sept-2014 5-Oct-2015                                                                                                                                                                                                                          |
| Hypothesis                                                                                                                                                               | Superiority                                                                                                                                                              | Superiority                                                                                                                                                              | Superiority                                                                                                                                                                                                                                      | Superiority                                                                                                                                                                                                                                      |
| Treatments groups                                                                                                                                                        | DVd                                                                                                                                                                      | DVd                                                                                                                                                                      | Daratumumab : 16 mg/kg weekly C1-3, C 4-8 every 3 weeks, then C9 and beyond every 4 weeks Bortezomib : 1.3 mg/m2 Days 1, 4, 8 and 11 of each 21-day cycle for 8 cycles Dexamethasone : 80 mg per week in 2 out of 3 weeks for the first 8 cycles | Daratumumab : 16 mg/kg weekly C1-3, C 4-8 every 3 weeks, then C9 and beyond every 4 weeks Bortezomib : 1.3 mg/m2 Days 1, 4, 8 and 11 of each 21-day cycle for 8 cycles Dexamethasone : 80 mg per week in 2 out of 3 weeks for the first 8 cycles |
| Treatments groups                                                                                                                                                        | Vd                                                                                                                                                                       | Vd                                                                                                                                                                       | Bortezomib : 1.3 mg/m 2 Days 1, 4, 8 and 11 of each 21-day cycle for 8 cycles Dexamethasone a : 80 mg per week in 2 out of 3 weeks for the first 8 cycles                                                                                        | Bortezomib : 1.3 mg/m 2 Days 1, 4, 8 and 11 of each 21-day cycle for 8 cycles Dexamethasone a : 80 mg per week in 2 out of 3 weeks for the first 8 cycles                                                                                        |
| Endpoints and definitions                                                                                                                                                | Primary endpoint                                                                                                                                                         | PFS                                                                                                                                                                      | The time from the date of randomization to either progressive disease, according to the IMWG response criteria, or death, whichever occurs first                                                                                                 | The time from the date of randomization to either progressive disease, according to the IMWG response criteria, or death, whichever occurs first                                                                                                 |
| Endpoints and definitions                                                                                                                                                | Secondary endpoint                                                                                                                                                       | TTP                                                                                                                                                                      | The time between the date of randomization and the date of first documented evidence of confirmed progressive disease, as defined in the IMWG response criteria, or death due to progressive disease, whichever occurs first                     | The time between the date of randomization and the date of first documented evidence of confirmed progressive disease, as defined in the IMWG response criteria, or death due to progressive disease, whichever occurs first                     |
| Endpoints and definitions                                                                                                                                                | Secondary endpoint                                                                                                                                                       | ORR                                                                                                                                                                      | The proportion of subjects who achieve a partial response or better (ie, PR, VGPR, CR or sCR), according to IMWG response criteria, during or after the study treatment                                                                          | The proportion of subjects who achieve a partial response or better (ie, PR, VGPR, CR or sCR), according to IMWG response criteria, during or after the study treatment                                                                          |
| Endpoints and definitions                                                                                                                                                | Secondary endpoint                                                                                                                                                       | MRD negativity                                                                                                                                                           | The proportion of subjects who had negative MRD assessment at any time point after the first dose of study drugs                                                                                                                                 | The proportion of subjects who had negative MRD assessment at any time point after the first dose of study drugs                                                                                                                                 |
| Database cut-off                                                                                                                                                         | 11-Jan-2016                                                                                                                                                              | 11-Jan-2016                                                                                                                                                              | 11-Jan-2016                                                                                                                                                                                                                                      | 11-Jan-2016                                                                                                                                                                                                                                      |
| Results and Analysis                                                                                                                                                     | Results and Analysis                                                                                                                                                     | Results and Analysis                                                                                                                                                     | Results and Analysis                                                                                                                                                                                                                             | Results and Analysis                                                                                                                                                                                                                             |
| Analysis description                                                                                                                                                     | Primary Analysis                                                                                                                                                         | Primary Analysis                                                                                                                                                         | Primary Analysis                                                                                                                                                                                                                                 | Primary Analysis                                                                                                                                                                                                                                 |
| Analysis population and time point description                                                                                                                           | Intent to treat Intent to treat (N=498)                                                                                                                                  | Intent to treat Intent to treat (N=498)                                                                                                                                  | Intent to treat Intent to treat (N=498)                                                                                                                                                                                                          | Intent to treat Intent to treat (N=498)                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability/ Effect estimate per comparison                                                                                          | Treatment group                                                                                                                                                          | Treatment group                                                                                                                                                          | DVd (daratumumab, bortezomib and dexamethasone)                                                                                                                                                                                                  | Vd (bortezomib and dexamethasone)                                                                                                                                                                                                                |
| Descriptive statistics and estimate variability/ Effect estimate per comparison                                                                                          | Number of subject                                                                                                                                                        | Number of subject                                                                                                                                                        | 251                                                                                                                                                                                                                                              | 247                                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability/ Effect estimate per comparison                                                                                          | PFS, median (months)                                                                                                                                                     | PFS, median (months)                                                                                                                                                     | NE                                                                                                                                                                                                                                               | 7.2 (6.2;7.9)                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| HR (95%CI) p-value                         | 0.39 (0.28;0.53) p<0.0001   |              |
|--------------------------------------------|-----------------------------|--------------|
| TTP, median (months) HR (95%CI) p-value    | NE                          | 7.3(6.4;8.1) |
|                                            | 0.30(0.21;0.43) p<0.0001    |              |
| ORR (95% CI) (sCR+CR+VGPR+PR)              | 77.5%;87.5%                 | 56.7%;69.4%  |
| Odds ratio p-value                         | 3.13(1.97;4.97) p<0.0001    |              |
| MRD negative rate (95%CI) (10 -4 ) p-value | 13.5%                       | 2.8%         |
|                                            | p<0.0001                    |              |

<div style=\"page-break-after: always\"></div>

## Analysis performed across trials (pooled analyses and meta-analysis)

N/A.

## Clinical studies in special populations

N/A.

## Supportive studies

Study MMY1001

The  study  MMY1001  was  designed  to  evaluate  daratumumab  in  combination  with  various  background therapies, in this application the combination of daratumumab with pomalidomide and dexamethasone (DPd)  was  investigated.  Additional  data  from  bortezomib-containing  cohorts  are  included  in  the pharmacokinetic and immunogenicity analyses. After a median duration of follow-up of 9.8 months, the median DOR was 13.6 months. At the time of the clinical cut-off, 48% of subjects had experienced PFS events; median PFS was 10.4 months. The median OS was not reached, but based on the Kaplan-Meier estimate, the 12-month OS rate was 72%.

Table 32 Overall Best Response based on IDSMB Assessment: Daratumumab+ Pomalidomide and Dexamethasone treated (study MMY1001)

|                                          | D-Pom-dex   | D-Pom-dex      |
|------------------------------------------|-------------|----------------|
|                                          | n (%)       | % 10J I0 %56   |
| Analysis set::Dara +Pom/Dex treated      | 103         |                |
| Best response                            |             |                |
| Stringent complete response (sCR)        | 8 (7.8%)    | (3.4%, 14.7%)  |
| Complete response (CR)                   | 6 (5.8%)    | (2.2%, 12.2%)  |
| Very good partial response (VGPR)        | 29 (28.2%)  | (19.7%, 37.9%) |
| Partial response (PR)                    | 18 (17.5%)  | (10.7%, 26.2%) |
| Minimal response (MR)                    | 3 (2.9%)    | (0.6%, 8.3%)   |
| Stable disease (SD)                      | 26 (25.2%)  | (17.2%, 34.8%) |
| Progressive disease (PD)                 | 3 (2.9%)    | (0.6%, 8.3%)   |
| Not evaluable (NE)                       | 10 (9.7%)   | (4.8%, 17.1%)  |
| Overall response (sCR+CR+VGPR+PR)        | 61 (59.2%)  | (49.1%, 68.8%) |
| Clinical benefit (Overall response + MR) | 64 (62.1%)  | (52.0%, 71.5%) |
| VGPR orbetter (sCR +CR +VGPR)            | 43 (41.7%)  | (32.1%, 51.9%) |
| CR or better (sCR + CR)                  | 14 (13.6%)  | (7.6%, 21.8%)  |

Keys:CI=exact confidenceinterval;D-Pom-dex=daratumumab-pomalidomide-dexamethasone.

Note: Response was assessed by IDSMB, based on international Uniform Response Criteria Consensus Recommendations.

Note: Percentages are calculated with the number of subjects in each group as denominator.

[TEFRSP01.RTF][JNJ-54767414MMY1001IDBR\\_SBLA\\_2016RE\\_SBLA\\_2016PR0DITEFRSP01.SAS] 05MAY2016, 09:26

Study GEN503

The study GEN503 had 2 phases, phase 1 was a dose escalation study evaluating 4 doses of daratumumab (2-16 mg/kg), data are included in the pharmacokinetic and immunogenicity analyses. Patients in phase 2 received daratumumab with lenalidomide and dexamethasone (DRd). The ORR in the DRd group was 81%, consistent with the DRd group in Study MMY3003. Sixty-three percent of subjects had a response of VGPR

<div style=\"page-break-after: always\"></div>

or better. After a median duration of follow-up of 23.0 months, the median DOR was not reached. The median TTP was not reached, but 72% of the patients remained progression-free after 18 months. The median OS was not reached and the 18-month OS rate based on Kaplan-Meier estimate was 90%.

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

Both the MMY3003 and the MMY3004 studies were large randomized, controlled open-label Phase 3 study where daratumumab was added to 2 different current standard of care regimens in multiple myeloma. For the MMY3003, daratumumab was added to lenalidomide + dexamethasone and compared with lenalidomide +  dexamethasone  alone  and  in  the  MMY3004  study,  daratumumab  was  added  to  bortezomib  + dexamethasone and compared with bortezomib + dexamethasone. Both studies included  patients with relapsed or refractory multiple myeloma who have received at least 1 prior therapy. The study design was appropriate, as were the primary endpoint (PFS) and the secondary clinical endpoints. The clinical response was assessed based on IMWG criteria validated by computerized algorithm with 3 stratification factors: number of prior lines of therapy (1 vs. 2 and 2 vs. &gt;3), ISS score at screening and whether subjects had received prior lenalidomide/bortezomib treatment (no vs. yes) which is endorsed.

The study population with its baseline characteristics reflected the target population as well as all patients had received at least one, and up to 10-11 prior therapies generally accepted in this population and clinical setting. The inclusion and exclusion criteria adequately defined the population covered by the proposed indication. The final inclusion criteria for IgG Multiple Myeloma is a serum M-protein of ≥1 g/dL, for other types of Multiple Myeloma, IgA, IgD, IgE and IgM, the serum M-protein is ≥0.5 g/dL.

Selection of the dose regimens for daratumumab was based on previous monotherapy data and available preliminary  data  from  Study  GEN503,  where  the  dose  of  daratumumab  monotherapy,  16  mg/kg  in relapsed/refractory multiple myeloma, was approved weekly for 8 weeks, then every 2 weeks for 16 weeks, then  every  4  weeks  thereafter,  administered  intravenously  until  disease  progression  or  unacceptable toxicity.  The  dosing  schedule  of  daratumumab  in  the  two  combinations  was  adapted  to  align  with  the schedule of background therapies, this is considered acceptable.

## Efficacy data and additional analyses

## Study MMY3003

The primary efficacy analysis of PFS showed a statistically significant 63% reduction in the risk of disease progression or death for subjects, when daratumumab was added to the lenalidomide + dexamethasone regimen  in  subjects  with  relapsed  or  refractory  multiple  myeloma  and  compared  with  lenalidomide  + dexamethasone alone (MMY3003) (HR=0.37; 95% CI: 0.27 to 0.52; p&lt;0.0001). The median PFS was 18.4 months for the Rd group and was not reached for the DRd group. Sensitivity analyses of PFS were consistent across all prespecified subgroups of subjects tested.

The secondary efficacy analyses of TTP showed a statistically significant improvement for the DRd group (HR=0.34; 95% CI: 0.23 to 0.48) (p&lt;0.0001). The ORR was also significantly improved in the DRd group, 93% versus 76%; p&lt;0.0001. The rate of VGPR or better was 76% vs. 44%; p&lt;0.0001, and rate of CR or better also showed significant improvements for subjects treated with DRd, 43% versus 19%; p&lt;0.0001. The MRD negativity rate at 10 -4  was significantly higher in subjects treated with DRd compared with those who received Rd, 29% versus 8%, p&lt;0.0001. This data indicates a robust response. The ORRs and rates of VGPR or better for subgroups of subjects were consistent across the subgroups tested and showed an improvement for all subgroups for subjects in the DRd group. Daratumumab also induced more durable responses with the median duration of response not estimable (lower limit of the 95% CI was not estimable) for the DRd group versus 17.4 months for the Rd group. As of the clinical cutoff date of 7 March 2016,

<div style=\"page-break-after: always\"></div>

median OS was not reached for either treatment group. The 18-month overall survival rate was 86.1% (95% CI: 79.9, 90.5) in the DRd group and 75.6% (95% CI: 59.8, 85.9) in the Rd group.

No statistically significant difference was observed between DRd and Rd in change from baseline or median time to improvement or worsening in the Global Healts Status/QOL subscale of the EORTC-QLQ-C30 or the EQ-5D-5L Utility score or EQ-5D-5L Visual Analog Scale (VAS) data.

## Study MMY3004

When daratumumab was added to the bortezomib + dexamethasone regimen improved and compared to bortezomib + dexamethasone alone, the primary objective was met, PFS showed a 61% reduction in the risk of disease progression or death for subjects treated with DVd versus Vd (HR=0.39; 95% CI: 0.28, 0.53; p&lt;0.0001). The median PFS was not reached for the DVd group and was 7.2 months for the Vd group. As in the MMY3003 study, the PFS results were consistent for all sensitivity analyses and across all subgroups of subjects tested.

Results of secondary efficacy analyses were supportive in improving TTP for the DVd group (HR=0.30; 95% CI: 0.21, 0.43) (p&lt;0.0001). The effect on ORR was higher in the DVd group (83% versus 63%; p&lt;0.0001). The rate of VGPR or better (59% versus 29%; p&lt;0.0001), and rate of CR or better (19% versus 9.0%; p=0.0012) showed significant improvements for patients who received treatment with DVd. The ORRs and rates of VGPR or better for subgroups of subjects were consistent across the subgroups tested.  Additionally, the MRD negativity rate at the 10-4 threshold was significantly higher in subjects treated with DVd compared with subjects treated with Vd (14% versus 3%, p&lt;0.0001).

The effect of adding daratumumab seemed robust and deep, with the median duration of response of 7.9 months for the Vd group compared to not estimable (lower limit of the 95% CI was 11.5 months) for the DVd group. The time to subsequent therapy for multiple myeloma was 9.8 months in the Rd group compared with not estimable for the DRd group (HR= 0.30; p&lt;0.0001). As of the clinical cutoff date of 11 January 2016, median OS was not reached for either treatment group.

Regarding the patient-reported outcomes for nearly all time points, no statistically significant differences between DVd and Vd were observed in change from baseline in the EQ-5D-5L Utility Score or EQ-5D-5L VAS and no statistically significant differences were observed between DVd and Vd in median time to worsening or improvement in the Utility Score or VAS.

During the assessment, the CHMP raised a major objection about the indication  ''Daratumumab in the treatment of adult patients with multiple myeloma, who have received at least 1 prior therapy'' requesting for its restriction to include the combination treatments.

## 2.4.4. Conclusions on the clinical efficacy

Based on the results of studies MMY3003 and MMY3004 a PFS HR of 0.37 and 0.39 indicate a clinical benefit of adding daratumumab to standard of care regimens lenaliomide+dexamethasone and bortezomib+dexamethasone in relapsed and refractory multiple myeloma patients who have received at least one prior therapy.

## 2.5. Clinical safety

## Introduction

The assessment of safety was based on safety data from 4 studies (two Phase 3 studies and two Phase 1/2 studies). Safety data from a total of 1182 subjects are summarized; 664 subjects received daratumumab in combination with standard background therapies and 518 subjects received background therapies alone.

<div style=\"page-break-after: always\"></div>

-  Phase 3 Study MMY3003 (n=564), where daratumumab (D) was administered in combination with lenalidomide and low-dose dexamethasone (Rd) (DRd=283 versus Rd=281)
-  Phase  3  Study  MMY3004  (n=480),  where  daratumumab  was  administered  in  combination  with bortezomib and dexamethasone (Vd) (DVd=243 versus Vd=237)
-  Phase 1b Study MMY1001 (n=103), cohort of daratumumab in combination with pomalidomide and dexamethasone (DPd)
-  Phase 1/2 Study GEN503 (n=35), treatment group of daratumumab 16 mg/kg in combination with Rd; data from these subjects were pooled with the subjects receiving DRd in Study MMY3003.

From  these  4  studies,  664  subjects  were  treated  with  daratumumab  in  combination  with  background therapy and 518 were treated with background therapy alone. Data from all subjects in the Phase 3 Studies MMY3003 and MMY3004 are presented in Table 33. In the Phase 1/2 studies, only data from subjects who received 16 mg/kg daratumumab in Study GEN503 or who received daratumumab in combination with pomalidomide-dexamethasone in Study MMY1001 are included in the safety analysis.

Table 33 Data included in the Summary of Clinical Safety

|                   | Subject Data Included in SCS   | Subject Data Included in SCS    |
|-------------------|--------------------------------|---------------------------------|
| Study             | Background Therapy             | Daratumumab + BackgroumdTherapy |
| Phase 3 Studies   |                                |                                 |
| MMY3004           | 237 (Vd)                       | 243 (DVd)                       |
| MMY3003           | 281 (Rd)                       | 283 (DRd)                       |
| Phase 1/2 Studies |                                |                                 |
| MMY1001           |                                | 103 (DPd)                       |
| GEN503            |                                | 35 (DRd)                        |
| TOTALN            | 518                            | t99                             |

Due to similarities in subject population (relapsed/refractory multiple myeloma with at least 1 prior therapy) and study drugs administered (16 mg/kg daratumumab in combination with Rd), data from the DRd groups in Study MMY3003 and Study GEN503 were pooled. For subgroup analyses and AEs of interest, subjects receiving daratumumab in all 4 studies (n=664) were pooled for the all-daratumumab population.

## Patient exposure

Results on treatment duration and exposure for patients included in the safety analysis set are summarized in

<div style=\"page-break-after: always\"></div>

Table 34.

<div style=\"page-break-after: always\"></div>

Table 34 Summary of treatment duration and exposure; Safety analysis Set (studies: MMY3003, MMY3004, MMY1001 and GEN503)

|                                                              | MMY3004        | MMY3004         | MMY3003+GEN503   | MMY3003+GEN503   | MMY1001          |
|--------------------------------------------------------------|----------------|-----------------|------------------|------------------|------------------|
|                                                              | Vd             | DVd             | Rd               | DRd              | DPd              |
| Analysis set: safety                                         | 237            | 243             | 281              | 318              | 103              |
| Duration of teatment (month)                                 |                |                 |                  |                  |                  |
| N                                                            | 237            | 243             | 281              | 318              | 103              |
| Mean (SD)                                                    | 4.192 (1.6909) | 6.711 (3.0154)  | 10.591 (4.9213)  | 12.505 (4.4630)  | 6.324 (4.5097)   |
| Median                                                       | 5.224          | 6.472           | 12.287           | 13.306           | 6.012            |
| Range                                                        | (0.16; 8.02)   | (0.03; 14.78)   | (0.23; 20.14)    | (0.03; 24.54)    | (0.03; 16.89)    |
| < 1 month                                                    | 15 (6.3%)      | 16 (6.6%)       | 13 (4.6%)        | 8 (2.5%)         | 15 (14.6%)       |
| >=1-<3months                                                 | 42 (17.7%)     | 14 (5.8%)       | 13 (4.6%)        | 12 (3.8%)        | 16 (15.5%)       |
| =3-<6 months                                                 | 171 (72.2%6)   | 72 (29.6%)      | 39 (13.9%)       | 16 (5.0%)        | 20 (19.4%)       |
| =6-<9months                                                  | 9 (3.8%)       | 82 (33.7%6)     | 29 (10.3%)       | 20 (6.3%)        | 17 (16.5%)       |
| =9 -<12 months                                               | 0              | 49 (20.2%)      | 39 (13.9%6)      | 42 (13.2%)       | 21 (20.4%)       |
| =12 months                                                   | 0              | 10 (4.1%)       | 148 (52.7%)      | 220 (69.2%)      | 14 (13.6%)       |
| Total daratmumab dose received (3qam)                        |                |                 |                  |                  |                  |
| N                                                            | 口              | 243             | 0                | 318              | 103              |
| Mean (SD)                                                    |                | 235.82 (78.613) |                  | 358.70 (98.326)  | 223.90 (120.704) |
| Median                                                       |                | 249.09          |                  | 384.00           | 223.11           |
| Range                                                        |                | (0.4; 386.5)    |                  | (0.8; 554.6)     | (0.2; 448.0)     |
| Total nuumberof daratumumab infusions                        |                |                 |                  |                  |                  |
| N                                                            |                | 243             | 0                | 318              | 103              |
| Mean (SD)                                                    |                | 14.8 (4.88)     |                  | 22.6 (6.20)      | 14.0 (7.56)      |
| Median                                                       |                | 16.0            |                  | 24.0             | 14.0             |
| Range                                                        |                | (1: 24)         |                  | (1; 36)          | (1; 28)          |
| Daratumuab relative dose intensity (%)                       |                |                 |                  |                  |                  |
| N                                                            |                | 243             | 0                | 318              | 103              |
| Meam (SD)                                                    |                | 93.36 (14.340)  |                  | 95.66 (11.681)   | 90.12 (17.474)   |
| Median                                                       |                | 99.16           |                  | 99.42            | 96.82            |
| Range                                                        |                | (0.8; 105.3)    |                  | (1.2; 104.9)     | (1.3; 104.8)     |
| Bortezomib/Lenalidomide/Pomali domiderelative dose intensity |                |                 |                  |                  |                  |
| (96)                                                         |                |                 |                  |                  |                  |
| N                                                            | 237            | 242             | 280              | 317              | 97               |
| Mean(SD)                                                     | 87.11(15.237)  | 81.75(19.128)   | 85.90(18:417)    | 79.25(22.483)    | 74.69 (21.614)   |
| Medien                                                       | 93.48          | 86.54           | 95.77            | 90.87            | 77.50            |
| Range                                                        | (32.7;112.2)   | (25.2;103.6)    | (16.8;100.0)     | (13.2;100.0)     | (5.7;100.0)      |
| Dexamethasone relative dose                                  |                |                 |                  |                  |                  |
| intensity (%)                                                |                |                 |                  |                  |                  |
| N                                                            | 237            | 243             | 281              | 283              | 103              |
| Mean (SD)                                                    | 91.00(15.833)  | 87.35 (18.848)  | 99.38(4253)      | 99.00 (4.290)    | 84.60 (17.891)   |
| Median                                                       | 100.00         | 98.18           | 100.00           | 100.00           | 90.00            |
| Range                                                        | (20.6:104.7)   | (20.3:103.1)    | (50.0:104.2)     | (63.9;111.3)     | (14.3:106.3)     |

Key:D=Daratumuumab,Vd=bortezomib-dexamethasone,Rd=lenalidomide-dexamethasone,Pd-pomalidomide-dexamethasone.

Rd isonlyfromMMY3003

Note:Percentages arecalculated with thenumber of subjects im eachgroup as denominator.

GEN503was excluded as relative doseintensity is hard to calculate due to the complexity on the planned dexamethasone dose.

Note:MMY3004:Vdanm treated for8cyclesandDVdarm treated umtil PDperprotocol

## Adverse events

## Common AEs

Only the TEAEs defined as: any AE with an onset date and time on or after that of the first dose of study drug through 30 days after the last study drug administration or any AE that was considered related to study drug regardless of the start date of the event were summarized. The severity of TEAEs was assessed using National Cancer Institute Common Terminology Criteria (NCI-CTC). Adverse event terms were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 17.0 and were summarized by system organ class (SOC) and preferred term (PT) in table presentations.

Adverse events were summarized by frequency counts and percentages of subjects with a particular event. An exposure-adjusted analysis was performed for adverse events in the  System Organ Class (SOC) of Infections and Infestations.

<div style=\"page-break-after: always\"></div>

The adverse event profile for daratumumab in combination with background therapies demonstrates a manageable side effect profile as summarized below:

 Discontinuations and deaths due to TEAEs were low and balanced in the randomized studies.

 The  most  frequently  reported  TEAEs  across  treatment  groups  were  cytopenias.  Daratumumab  may increase  cytopenias  associated  with  background  therapies,  with  thrombocytopenia  the  most  common preferred  term  reported  for  subjects  receiving  bortezomib-based  regimens  and  neutropenia  the  most common preferred term reported for subjects receiving lenalidomide- or pomalidomide-based regimens.

 IRRs were reported in approximately half of subjects; mainly Grade 1 or 2. Most IRRs occurred during the first infusion only, and rarely led to treatment discontinuation.

 Although the overall incidence of infections were reported by a higher percentage of subjects in the daratumumab  containing  groups  compared  to  the  respective  background  therapy,  the  majority  of  all infections were mild (Grade 1 or 2) and did not require hospitalization.

- -The incidence of Grade 3 or 4 infection was similar between the daratumumab combinations and the background therapies, with the most common being pneumonia.
- -Discontinuations  from  treatment  and  deaths  due  to  infection  were  low  and  balanced  between groups.

 Second primary malignancies (SPM) were reported at a low frequency in the daratumumab combination groups (&lt;4%).

Frequently reported TEAEs (by at least 10% of subjects in any treatment group) are summarized in Table 356 below.

<div style=\"page-break-after: always\"></div>

Table 35 Number of Subjects with 1 or More TEAE with frequency of at least 10% in either treatment group by MedDRA System-Organ Class and Preferred Term: Safety Analysis Set (studies MMY3003, MMY3004, MMY1001 and GEN503)

| Table7:                                             | Nunberof SubjectsWithlorMforeTreatinent-emergentAdverseEventsWithFrequency ofat Least10%inEitherIreatinentGroup byMfedDRASystem-OrganClassandPreferredTerm;SafetyAnalysisSet(Studies:MIAfY3003,AMfY3004,AAIY100landGEN503)   | Nunberof SubjectsWithlorMforeTreatinent-emergentAdverseEventsWithFrequency ofat Least10%inEitherIreatinentGroup byMfedDRASystem-OrganClassandPreferredTerm;SafetyAnalysisSet(Studies:MIAfY3003,AMfY3004,AAIY100landGEN503)   | Nunberof SubjectsWithlorMforeTreatinent-emergentAdverseEventsWithFrequency ofat Least10%inEitherIreatinentGroup byMfedDRASystem-OrganClassandPreferredTerm;SafetyAnalysisSet(Studies:MIAfY3003,AMfY3004,AAIY100landGEN503)   | Nunberof SubjectsWithlorMforeTreatinent-emergentAdverseEventsWithFrequency ofat Least10%inEitherIreatinentGroup byMfedDRASystem-OrganClassandPreferredTerm;SafetyAnalysisSet(Studies:MIAfY3003,AMfY3004,AAIY100landGEN503)   | Nunberof SubjectsWithlorMforeTreatinent-emergentAdverseEventsWithFrequency ofat Least10%inEitherIreatinentGroup byMfedDRASystem-OrganClassandPreferredTerm;SafetyAnalysisSet(Studies:MIAfY3003,AMfY3004,AAIY100landGEN503)   |
|-----------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                     |                                                                                                                                                                                                                              | MMY3004                                                                                                                                                                                                                      | MMY3003+GEN503                                                                                                                                                                                                               | MMY3003+GEN503                                                                                                                                                                                                               | MMY1001                                                                                                                                                                                                                      |
|                                                     |                                                                                                                                                                                                                              | vd                                                                                                                                                                                                                           | DVd Rd                                                                                                                                                                                                                       |                                                                                                                                                                                                                              | Paa                                                                                                                                                                                                                          |
| Analysis set: safety                                | Analysis set: safety                                                                                                                                                                                                         | 237 243                                                                                                                                                                                                                      | 281                                                                                                                                                                                                                          | 318                                                                                                                                                                                                                          | 103                                                                                                                                                                                                                          |
| Total numberof subjectswith TEAE                    | Total numberof subjectswith TEAE                                                                                                                                                                                             | 226(95.49)                                                                                                                                                                                                                   | 240(98.8%) 274 (97.5%)                                                                                                                                                                                                       | 313(98.4%)                                                                                                                                                                                                                   | 103(100.0%)                                                                                                                                                                                                                  |
| MedDRA system organclass/Preferred tenm             |                                                                                                                                                                                                                              |                                                                                                                                                                                                                              |                                                                                                                                                                                                                              |                                                                                                                                                                                                                              |                                                                                                                                                                                                                              |
| Infections and infestations                         | Infections and infestations                                                                                                                                                                                                  | 126 (53.2%)                                                                                                                                                                                                                  | 164 (67.5%) 204(72.6%)                                                                                                                                                                                                       | 265(83.396)                                                                                                                                                                                                                  | 72 (69.9%)                                                                                                                                                                                                                   |
| Upperrespiratory ract infection                     | Upperrespiratory ract infection                                                                                                                                                                                              | 43(18.1%6)                                                                                                                                                                                                                   | 60 (24.7%) 58(20.6%)                                                                                                                                                                                                         | 98(30.896)                                                                                                                                                                                                                   | 26(25.296)                                                                                                                                                                                                                   |
| Nasopharyngitis                                     | Nasopharyngitis                                                                                                                                                                                                              | 9(3.89)                                                                                                                                                                                                                      | 17 (7.096) 43(15.396)                                                                                                                                                                                                        | 76(23.9%6)                                                                                                                                                                                                                   | 8(7.89)                                                                                                                                                                                                                      |
| Bronchitis                                          | Bronchitis                                                                                                                                                                                                                   | 13(5.5%)                                                                                                                                                                                                                     | 28(11.5%) 34(12.19)                                                                                                                                                                                                          | 46(14.59)                                                                                                                                                                                                                    | 10 (9.7%)                                                                                                                                                                                                                    |
| Puetmonia                                           | Puetmonia                                                                                                                                                                                                                    | 28(11.896)                                                                                                                                                                                                                   | 37(13.296)                                                                                                                                                                                                                   | 41(12.9%6)                                                                                                                                                                                                                   | 11(10.796)                                                                                                                                                                                                                   |
| Respiratory tact infection                          | Respiratory tact infection                                                                                                                                                                                                   | 3(1.396)                                                                                                                                                                                                                     | (%661167 0 10 (4.19)                                                                                                                                                                                                         | 33(10.4%)                                                                                                                                                                                                                    | 0                                                                                                                                                                                                                            |
| Sinmsitis                                           | Sinmsitis                                                                                                                                                                                                                    | 3(1.396)                                                                                                                                                                                                                     | 22(7.8%) 10(3.6%)                                                                                                                                                                                                            | 19 (6.0%)                                                                                                                                                                                                                    | 13(12.696)                                                                                                                                                                                                                   |
| Castrointestinaldisorders                           | Castrointestinaldisorders                                                                                                                                                                                                    | 110 (46.49)                                                                                                                                                                                                                  | 164(58.4%)                                                                                                                                                                                                                   | 242 (76.196)                                                                                                                                                                                                                 | (9698)18                                                                                                                                                                                                                     |
| Diahoea                                             | Diahoea                                                                                                                                                                                                                      | 53(22.496)                                                                                                                                                                                                                   | 143 (58.89) 77(31.7%) 69(24.6%6)                                                                                                                                                                                             | 136(42.896)                                                                                                                                                                                                                  | 39(37.996)                                                                                                                                                                                                                   |
| Constipation                                        | Constipation                                                                                                                                                                                                                 | 37(15.6%)                                                                                                                                                                                                                    | 48(19.8%) 71(25.396)                                                                                                                                                                                                         | 90(28.396)                                                                                                                                                                                                                   | 34(33.096)                                                                                                                                                                                                                   |
| Nausea                                              | Nausea                                                                                                                                                                                                                       | 26(11.0%6)                                                                                                                                                                                                                   | 34(14.0%) 40(14.29)                                                                                                                                                                                                          | 77 (24.29)                                                                                                                                                                                                                   | 31(30.196)                                                                                                                                                                                                                   |
| Vomiting                                            | Vomiting                                                                                                                                                                                                                     | 9(3.8%)                                                                                                                                                                                                                      | 26 (10.7%) 15(5.396)                                                                                                                                                                                                         | 51(16.0%)                                                                                                                                                                                                                    | 22(21.49)                                                                                                                                                                                                                    |
| Bloodand lymphatic system clisorders                | Bloodand lymphatic system clisorders                                                                                                                                                                                         | 135 (57.096)                                                                                                                                                                                                                 | 163 (67.196) 43(17.7%)                                                                                                                                                                                                       | 231(72.69)                                                                                                                                                                                                                   | (96E88)16                                                                                                                                                                                                                    |
| Neutropenia                                         | Neutropenia                                                                                                                                                                                                                  | 22(9.396)                                                                                                                                                                                                                    | 184(65596) 121(43.196)                                                                                                                                                                                                       | 197 (61.996)                                                                                                                                                                                                                 | 81(78.696)                                                                                                                                                                                                                   |
| Anaemia                                             | Anaemia                                                                                                                                                                                                                      | 74(31.29)                                                                                                                                                                                                                    | 64(26.396) 98(34.996)                                                                                                                                                                                                        | 97(30.596)                                                                                                                                                                                                                   | 54(52.496)                                                                                                                                                                                                                   |
|                                                     |                                                                                                                                                                                                                              | 104(43.9%)                                                                                                                                                                                                                   | 77(27.49) 17(6.0%)                                                                                                                                                                                                           | 86(27.096)                                                                                                                                                                                                                   | 42(40.896)                                                                                                                                                                                                                   |
| Thrombocytopenia Leukopenia                         | Thrombocytopenia Leukopenia                                                                                                                                                                                                  | 11(4.6%)                                                                                                                                                                                                                     | 143(58.8%) 19(7.896)                                                                                                                                                                                                         | 28(8.8%)                                                                                                                                                                                                                     | 38(36.996)                                                                                                                                                                                                                   |
| Lymphopenia                                         | Lymphopenia                                                                                                                                                                                                                  | 9(3.896)                                                                                                                                                                                                                     | 32(13.2%)                                                                                                                                                                                                                    | 21(6.6%)                                                                                                                                                                                                                     | 22(21.49)                                                                                                                                                                                                                    |
| Generaldisorders and administration site conditions | Generaldisorders and administration site conditions                                                                                                                                                                          | 123(51.996)                                                                                                                                                                                                                  | 15(5.396) 131(53.9%) 156(55.596)                                                                                                                                                                                             | 226(71.19)                                                                                                                                                                                                                   | 82(79.696)                                                                                                                                                                                                                   |
| Fatigue                                             | Fatigue                                                                                                                                                                                                                      | 58(24.596)                                                                                                                                                                                                                   | 52(21.4%) 38(15.6%)                                                                                                                                                                                                          | 112(35.296)                                                                                                                                                                                                                  | 51(49.596)                                                                                                                                                                                                                   |
| Pyrexia                                             | Pyrexia                                                                                                                                                                                                                      | 27(11.4%)                                                                                                                                                                                                                    | 78(27.896) 31(11.0%)                                                                                                                                                                                                         | 67 (21.196)                                                                                                                                                                                                                  | 26(25.296)                                                                                                                                                                                                                   |
| Oedema peripheral                                   | Oedema peripheral                                                                                                                                                                                                            | 19(8.0%)                                                                                                                                                                                                                     | 37(13.296) 36(12.896)                                                                                                                                                                                                        | 54(17.096)                                                                                                                                                                                                                   | 16(15.596)                                                                                                                                                                                                                   |
| Asthenia                                            | Asthenia                                                                                                                                                                                                                     | 37(15.6%)                                                                                                                                                                                                                    | 40(16.59) 21(8.696) 11(4.59)                                                                                                                                                                                                 | 50 (15.796)                                                                                                                                                                                                                  | 15(14.696)                                                                                                                                                                                                                   |
| Chills                                              | Chills                                                                                                                                                                                                                       | (96E1)E                                                                                                                                                                                                                      | 9(3.296)                                                                                                                                                                                                                     | 18 (5.7%)                                                                                                                                                                                                                    | 21 (20.49)                                                                                                                                                                                                                   |
|                                                     |                                                                                                                                                                                                                              | 1(0.49)                                                                                                                                                                                                                      | 1(0.49) 5(1.896)                                                                                                                                                                                                             | 11(3.5%)                                                                                                                                                                                                                     | 15(14.696)                                                                                                                                                                                                                   |
| Non-cardiac chest pain Pain                         | Non-cardiac chest pain Pain                                                                                                                                                                                                  | 5(2.196)                                                                                                                                                                                                                     | 9(3.796) 4 (1.496)                                                                                                                                                                                                           | 4(1.39)                                                                                                                                                                                                                      | 11 (10.7%)                                                                                                                                                                                                                   |
| Respiratory,thoracicandmediastinal disorders        | Respiratory,thoracicandmediastinal disorders                                                                                                                                                                                 | 77(32.596)                                                                                                                                                                                                                   | 114(40.696)                                                                                                                                                                                                                  | 196 (61.696)                                                                                                                                                                                                                 | 80(77.796)                                                                                                                                                                                                                   |
| Cough                                               | Cough                                                                                                                                                                                                                        | 30 (12.7%6) 21(8.996)                                                                                                                                                                                                        | 35(12.5%6) 32(11.49)                                                                                                                                                                                                         | 99 (31.146) 56(17.69)                                                                                                                                                                                                        | 37 (35.996) 31(30.196)                                                                                                                                                                                                       |
|                                                     |                                                                                                                                                                                                                              |                                                                                                                                                                                                                              | 130(53.5%6) 58 (23.9%6) 45(18.5%)                                                                                                                                                                                            |                                                                                                                                                                                                                              |                                                                                                                                                                                                                              |
| Dyspnoea Nasal congestion Productive cough          | Dyspnoea Nasal congestion Productive cough                                                                                                                                                                                   | (%6EDE                                                                                                                                                                                                                       | 8(2.896)                                                                                                                                                                                                                     | 16(5.0%)                                                                                                                                                                                                                     | 16(15.596)                                                                                                                                                                                                                   |
|                                                     |                                                                                                                                                                                                                              | (96EDE                                                                                                                                                                                                                       | 12(4.996) (%6+D)+ 9(3.7%6)                                                                                                                                                                                                   | 16 (5.0%)                                                                                                                                                                                                                    | 12(11.796)                                                                                                                                                                                                                   |
| Musculoskeletal and connective tissue disorders     | Musculoskeletal and connective tissue disorders                                                                                                                                                                              | 87(36.7%) 5(2.196)                                                                                                                                                                                                           | 111 (45.7%) 154(54.89) 19 (7.89) 52(18.5%)                                                                                                                                                                                   | 187(58.8%)                                                                                                                                                                                                                   | 74 (71.8%) 27(26.296)                                                                                                                                                                                                        |
| Backpain                                            | Backpain                                                                                                                                                                                                                     |                                                                                                                                                                                                                              | 48(17.196)                                                                                                                                                                                                                   |                                                                                                                                                                                                                              |                                                                                                                                                                                                                              |
| Muscle spasms                                       | Muscle spasms                                                                                                                                                                                                                | 24(10.1%)                                                                                                                                                                                                                    | 33(13.6%)                                                                                                                                                                                                                    | 90(28.3%) 57 (17.9%)                                                                                                                                                                                                         | 26(25.296)                                                                                                                                                                                                                   |
| Arliralgia Pain in extremity                        | Arliralgia Pain in extremity                                                                                                                                                                                                 | 11(4.6%)                                                                                                                                                                                                                     | 23(9.596) 21(7.59)                                                                                                                                                                                                           | 26(8.296)                                                                                                                                                                                                                    | 23(22.3%)                                                                                                                                                                                                                    |
|                                                     |                                                                                                                                                                                                                              | 16(6.896)                                                                                                                                                                                                                    | 22 (9.196) 30(10.796)                                                                                                                                                                                                        | 26(8.296) 24(7.596)                                                                                                                                                                                                          | 15 (14.6%)                                                                                                                                                                                                                   |
| Bone pain                                           | Bone pain                                                                                                                                                                                                                    | 14(5.996)                                                                                                                                                                                                                    | 14(5.8%) 12(4.396)                                                                                                                                                                                                           |                                                                                                                                                                                                                              | 13(12.6%)                                                                                                                                                                                                                    |
| Musculoskeletal chestpain                           | Musculoskeletal chestpain                                                                                                                                                                                                    | 5(2.19)                                                                                                                                                                                                                      | 16 (6.6%) 17 (6.096)                                                                                                                                                                                                         | 16(5.096)                                                                                                                                                                                                                    | 13(12.69)                                                                                                                                                                                                                    |
| Nervous system disorders                            | Nervous system disorders                                                                                                                                                                                                     | 131 (55.396)                                                                                                                                                                                                                 | 153 (63.0%) 124 (44.196)                                                                                                                                                                                                     | 160 (50.396)                                                                                                                                                                                                                 | 62(60.296)                                                                                                                                                                                                                   |
| Headache                                            | Headache                                                                                                                                                                                                                     | 14(5.99)                                                                                                                                                                                                                     | 25(10.39) 19 (6.896)                                                                                                                                                                                                         | 43 (13.596)                                                                                                                                                                                                                  | 17(16.5%)                                                                                                                                                                                                                    |
|                                                     |                                                                                                                                                                                                                              | 89(37.6%)                                                                                                                                                                                                                    | 115(47.39) 19(6.896)                                                                                                                                                                                                         | 31(9.796)                                                                                                                                                                                                                    | (9682)8                                                                                                                                                                                                                      |
| Peripheral sensory neturopathy Tremor               | Peripheral sensory neturopathy Tremor                                                                                                                                                                                        |                                                                                                                                                                                                                              | 24(8.596)                                                                                                                                                                                                                    | 28(8.896)                                                                                                                                                                                                                    | 20(19.4%)                                                                                                                                                                                                                    |
| Dizziness Neuralgia                                 | Dizziness Neuralgia                                                                                                                                                                                                          | 8(3.496) 24(10.19)                                                                                                                                                                                                           | 3(1.29) 24(9.996) 24(8.596)                                                                                                                                                                                                  | 24(7.596)                                                                                                                                                                                                                    | 22(21.49)                                                                                                                                                                                                                    |
|                                                     |                                                                                                                                                                                                                              | 26 (11.0%) 66(27.89)                                                                                                                                                                                                         | 33(13.696) 3(1.196) 93(38.39)                                                                                                                                                                                                | 4(1.396) 127 (39.99)                                                                                                                                                                                                         | (9601                                                                                                                                                                                                                        |
| Metabolism andnutrition disorders                   | Metabolism andnutrition disorders                                                                                                                                                                                            |                                                                                                                                                                                                                              | 95(33.896)                                                                                                                                                                                                                   |                                                                                                                                                                                                                              | 49 (47.6%)                                                                                                                                                                                                                   |
| Decreased appetite                                  | Decreased appetite                                                                                                                                                                                                           | 12(5.196)                                                                                                                                                                                                                    | 22 (9.196) 29 (10.39)                                                                                                                                                                                                        | 34(10.7%)                                                                                                                                                                                                                    | 11 (10.7%)                                                                                                                                                                                                                   |
| Hypokalaenia Hyperglycaemia                         | Hypokalaenia Hyperglycaemia                                                                                                                                                                                                  | 11(4.696) 18(7.696)                                                                                                                                                                                                          | 22 (9.196) 22 (7.896) 19(6.896)                                                                                                                                                                                              | 33 (10.496) 27(8.596)                                                                                                                                                                                                        | 16(15.596) 13(12.696)                                                                                                                                                                                                        |
| Skin and subcutaneous tissue disorders Rash         | Skin and subcutaneous tissue disorders Rash                                                                                                                                                                                  | 32(13.5%) 7(3.0%)                                                                                                                                                                                                            | 21(8.6%) 49 (20.2%) 83(29.596)                                                                                                                                                                                               | 125 (39.396)                                                                                                                                                                                                                 | 39(37.9%6)                                                                                                                                                                                                                   |
|                                                     |                                                                                                                                                                                                                              |                                                                                                                                                                                                                              | 13(5.396)                                                                                                                                                                                                                    | 38 (11.9%6)                                                                                                                                                                                                                  | 3(2.996)                                                                                                                                                                                                                     |
|                                                     |                                                                                                                                                                                                                              |                                                                                                                                                                                                                              | 29(10.396)                                                                                                                                                                                                                   |                                                                                                                                                                                                                              |                                                                                                                                                                                                                              |
| Prurinus                                            | Prurinus                                                                                                                                                                                                                     | 3(1.396)                                                                                                                                                                                                                     | 29(10.396)                                                                                                                                                                                                                   | 29(9.196)                                                                                                                                                                                                                    | 10(9.796)                                                                                                                                                                                                                    |
| Psychiatric disorders                               | Psychiatric disorders                                                                                                                                                                                                        | 53(22.49)                                                                                                                                                                                                                    | 5(2.196) 67(27.696) 93(33.196)                                                                                                                                                                                               | 106(33.396)                                                                                                                                                                                                                  | 47(45.6%6)                                                                                                                                                                                                                   |
| Insomnia                                            | Insomnia                                                                                                                                                                                                                     | 35(14.89)                                                                                                                                                                                                                    | 41(16.996) 55(19.696) 3(1.29)                                                                                                                                                                                                | 60(18.996)                                                                                                                                                                                                                   | 24(23.39)                                                                                                                                                                                                                    |
| Anxiety                                             | Anxiety                                                                                                                                                                                                                      | 6(2.59)                                                                                                                                                                                                                      | 12(4.396)                                                                                                                                                                                                                    | 18(5.796)                                                                                                                                                                                                                    | 13(12.6%)                                                                                                                                                                                                                    |

Key.D=Daratumumab,Vd=bortezomib-dexamethasone,Rd=lenalidomide-dexamethasone,Pd=pomalidomide-dexamethasone.

Keys:TEAE=treatment-emergentadverse event.

Rd isonly fromMMY3003.

Note:Percentagesarecalculatedwiththentamberof subjects ineachgroup asdenominator.

Grade 3 or 4 TEAEs that occurred in at least 5% of subjects in any treatment group are summarized in Table 36 below.

<div style=\"page-break-after: always\"></div>

Table 36 Number of subjects with 1 or more Toxicity Grade 3 or 4 TEAE with frequency of at least 5% in either treatment group by MedDRA System- Organ Class and Preferred Term, Safety Analysis Set (studies: MMY3003, MMY3004, MMY1001 and GEN503)

|                                                     | 10.0Y3004    | 10.0Y3004   | MMY3003+GEN503   | MMY3003+GEN503   | MLY1001      |
|-----------------------------------------------------|--------------|-------------|------------------|------------------|--------------|
|                                                     | PA           | DVd         | Rd               | DRd              | DPd          |
| Analysis set. safety                                | 237          | 243         | 281              | 318              | 103          |
| Total number ofsubjectswith toxicitygrade3 or4TEAE  | 148 (62.496) | 185 (76.19) | 206(73.396)      | 260(81.89)       | 102 (99.096) |
| MecDRAsystemorganclass/Preferted tenm               |              |             |                  |                  |              |
| Bloodand lyzphaticsystem disorders                  | 94 (39.796)  | 131 (53.99) | 145 (51.6%)      | 191(60.196)      | 87(84.596)   |
| Neutropenia                                         | 10 (4.296)   | 31 (12.89)  | 104 (37.0%)      | 174(54.796)      | 79 (76.796)  |
| Thrombocytopenia                                    | 78 (32.996)  | 110(45.396) | 38 (13.596)      | 40 (12.696)      | 18(17.596)   |
| Anaemia                                             | 38 (16.096)  | 35 (14.496) | 55 (19.696)      | 39(12.396)       | 28 (27.296)  |
| Lymphopenia                                         | 6(2.596)     | 23 (9.596)  | 10 (3.696)       | 19 (6.096)       | 14(13.696)   |
| Febrile neutropenia                                 | 1 (0.496)    | 4(1.6%)     | 7(2.596)         | 17 (5.396)       | 7(6.896)     |
| Leukopenia                                          | 4(1.796)     | 5(2.196)    | 7(2.596)         | 11(3.596)        | 25(24.396)   |
| Infectionsandinfestations                           | 45 (19.0%6)  | 52 (21.496) | 64 (22.896)      | 86 (27.096)      | 29(28.296)   |
| Pneumonia                                           | 23 (9.796)   | 20 (8.296)  | 23(8.296)        | 23(7.296)        | 8(7.896)     |
| Metabolismandnutritiondisorders                     | 24 (10.1%)   | 33 (13.696) | 27 (9.6%)        | 43 (13.5%)       | 16 (15.59)   |
| Hyperglycaenlia                                     | 6 (2.5%)     | 8(3.396)    | 9(3.296)         | 10 (3.19)        | 6 (5.896)    |
| General disordersand adninistration site conditions | 22(9.396)    | 19 (7.8%)   | 21 (7.5%)        | 36 (11.39)       | 15(14.69)    |
| Fatigue                                             | 8 (3.496)    | 11 (4.59)   | 7(2.596)         | 18 (5.796)       | 10 (9.7%)    |
| Respiratory,thoracicand mediastinal                 |              |             |                  |                  |              |
| disorders                                           | 11 (4.696)   | 27 (11.196) | 18(6.496)        | 27 (8.596)       | 19(18.496)   |
| Dyspnoea                                            | 2(0.896)     | 9(3.796)    | 2(0.796)         | 9(2.896)         | 7(6.896)     |
| Gastrointestinaldisorders                           | 9(3.896)     | 18 (7.49)   | 16 (5.796)       | 26(8.296)        | 8(7.896)     |
| Diamhoea                                            | 3 (139)      | 9(3.796)    | 9(3.296)         | 16 (5.096)       | 3(2.996)     |
| Nervous system disorders                            | 25(10.59)    | 23(9.596)   | 15(5.396)        | 21 (6.696)       | 13(12.696)   |
| Peripheral sensory neturopathy                      | 16 (6.896)   | 11 (4.5%)   | 1(0.496)         | 2(0.696)         | 2(1.996)     |
| Vasculardisorders                                   | 11 (4.6%)    | 21 (8.696)  | 8(2.896)         | 19 (6.0%6)       | 6(5.896)     |
| Hypertension                                        | 2(0.89)      | 16 (6.6%)   | 1(0.49)          | 12 (3.896)       | 3(2.996)     |
| Musculoskeletal and couneclive tissue               |              |             |                  |                  |              |
| disorders                                           | 12(5.196)    | 18 (7.49)   | 18(6.49)         | 18(5.796)        | 18(17.596)   |
| Backpain                                            | 3 (1.396)    | 3 (1.2%)    | 4(1.49)          | 4(1.3%)          | 6(5.896)     |
| Injury,poisoningand procedural complications        | 5(2.196)     | 7(2.9%)     | 9(3.296)         | 5 (1.6%)         | 10 (9.7%)    |
| Fall                                                | 0            | 0           | 1(0.496)         | 0                | 6(5.896)     |

Key:D=Daratwuumab,Vd=bortezomib-dexamethasone,Rd=lenalidomide-dexamethasone,Pd=pomalidomidedexamethasone.

Keys:TEAE=teahment-emergentadverseevent

Rdis onlyfrom MMY3003.

Note:Adverse events are Teported usingMedDRA version 18.0.

Note:Percentages arecalculated with thenmumber of subjects in eachgtoup as denominator.

[TSFAE03IRTF][NJ-54767414Z\\_SCSDBR\\_MIY\\_RR\\_2016REMMYRR\\_2016PRODTSFAE03ISAS]01JUN2016.10:37

## Drug-related Adverse Events

For adverse drug reactions summarized across daratumumab  monotherapy  studies (16  mg/kg daratumumab, n=156) and combination studies (all-daratumumab population, n=664), assessment of ADR terms was based on the terms identified in the randomized controlled studies. The occurrence of ADRs summarized across daratumumab monotherapy and combination studies (n=820) is provided in Table 37 (see also section 4.8 of the SmPC).

<div style=\"page-break-after: always\"></div>

Table 37 Adverse reactions in multiple myeloma patients treated with DARZALEX 16 mg/kg

|                                                    | All Gndes    | All Gndes   | Gnde 3-4    |
|----------------------------------------------------|--------------|-------------|-------------|
| Infections amnd infestations                       |              |             |             |
| Upper respiratory tact infection*                  | Very Comwon  | 52%6        | 5%6         |
| Pneumonia*                                         | Very Common  | 16%         | 10%         |
| Infhuenza                                          | Common       | 596         | 1%***       |
| Blood and byuphatic system                         |              |             |             |
| disorders                                          |              |             |             |
| Neutropenia                                        | Very Comwon  | 44%         | 37%6        |
| Throubocytopenia                                   | Very Common  | 37%6        | 23%%        |
| Annemia                                            | Very Common  | 31%%        | 16%         |
| Lyuphopenin                                        | Very Common  | 10%         | 8%%         |
| Nervous system disorders                           |              |             |             |
| Pariphenl sensory neuropathy Hendache              | Very Common  | 1376        | 27,** ≤1%** |
| Cardiac disorders                                  | Very Conmon  |             |             |
| Amial fibnillation                                 | Conmon       | 396         | 1%          |
| Respiratory, thorncic and mediastinal              |              |             |             |
| disorders Couzh*                                   | Very Common  | 31%%        | c1%**       |
| Dyspnoea*                                          | Very Commion | 22%6        | 37.         |
| Gastointestinal disorders                          |              |             |             |
| Dianhoea                                           | Very Common  | 34%.        | 4%.         |
| Nausea                                             | Very Common  | 22%6        | 1'.+*       |
| Vouiting                                           | Very Common  | 15%         | 17***       |
| Musculoskeletal and commective tissue disorders    |              |             |             |
| Musde spasms                                       | Very Coumon  | 18%         | c1%**       |
| Geneal disorders and administation site conditions |              |             |             |
| Fatigue                                            | Very Common  | 34%6        | 5%          |
| Pyreria                                            | Very Common  | 20%6        | 19,**       |
| Oedenn peripheral*                                 | Very Common  | 19%         | 19,**       |

**No gnde4

*Indicates a grouping of prefemed tems.

ITSFAE42 SMPCRTF1INI-S476741IZ SMPCD6R. MOMY RR. 2016RE MMY RR 2016IPRODITSFAE42 SMPCISAS] 14JUL2016,18:25

In  the  DVd  group,  the  most  frequently  reported  TEAEs  that  the  investigator  considered  related  to daratumumab were thrombocytopenia (30%), dyspnea (13%), and cough, lymphopenia, and fatigue (11% each). The most frequently reported TEAEs that the investigator considered related to other study drugs were thrombocytopenia (DVd: 51%, Vd: 34%) and peripheral sensory neuropathy (DVd: 47%, Vd: 35%).

In  the  DRd  group,  the  most  frequently  reported  TEAEs  that  the  investigator  considered  related todaratumumab were neutropenia (19%), cough (14%), fatigue (12%), and dyspnea and diarrhea (11% each). The most frequently reported TEAEs that the investigator considered related to other study drugs were neutropenia (DRd: 58%, Rd: 38%), fatigue (DRd: 29%, Rd: 20%) and diarrhea (DRd: 29%, Rd: 11%).

In  the  DPd  cohort,  the  most  frequently  reported  TEAEs  that  the  investigator  considered  related  to daratumumab  were  neutropenia  (44%),  anemia  (31%),  thrombocytopenia  (26%),  leukopenia  (25%), lymphopenia (16%), cough (14%), fatigue (12%), and dyspnea and diarrhea (11% each).

## Adverse Events of Special Interest (AESI)

## Infusions related reactions

As  was  observed  with  daratumumab  monotherapy,  infusion  related  reactions  (IRR)  were  frequently observed among the daratumumab-treated subjects in the combination studies. In all 4 studies, 47% of the 664 subjects who received daratumumab experienced an IRR. The vast majority of IRRs occurred during the first infusion and most subjects had IRRs only once at the first infusion and did not continue to experience IRRs with subsequent infusions. Only 3% of subjects had an IRR in more than 1 infusion. The majority of IRRs were mild (Grade 1 or 2). Grade 3 IRRs were reported by 6% of subjects. No Grade 4 or 5 IRRs

<div style=\"page-break-after: always\"></div>

occurred. Infusion-related reactions were managed with supportive medications, a pause in infusion or a decrease in infusion rate, and did not usually result in treatment discontinuation.

The most frequently reported AE terms used to describe IRRs were respiratory disorders: dyspnea (10%), cough (9%), and bronchospasm (5%). Other common IRRs were chills (6%), nausea (5%), and vomiting (5%).  The  most  frequently  reported  Grade  3  IRRs  were  hypertension  (2%),  dyspnea  (1%),  and bronchospasm (1%).

Of the 315 subjects who experienced IRRs, 307 subjects (97%) had the reaction during their first infusion. Nine subjects (1%) had an IRR in their second infusion and 21 subjects (3%) in subsequent infusions. The range of AE terms used to describe IRRs was similar between those that occurred in the first, second, and subsequent infusions. The median time to onset of an IRR was 85 minutes while delayed IRRs (onset more than 24 hours after start of infusion) were rare and only reported in two subjects. One subject with Grade 2 pyrexia after about 1 day and one subject with Grade 1 pruritus after about 3 days.

Pre-infusion medications required to manage infusion reactions included antihistamines, analgesics, and corticosteroids before each daratumumab infusion. In all 3 daratumumab containing treatment groups, 100% of subjects received an antihistamine, usually diphenhydramine, chlorpheniramine, dexchlorpheniramine, or clemastine. All but 1 subject in the DRd group and 2 subjects in the DVd group received paracetamol. The cortisteroids were administered per protocol as part of the background therapy.

In addition to regular administration of background corticosteroids as part of post-infusion medications, subjects at higher risk for respiratory complications were also recommended to use additional post-infusion medication. Only a small percentage of subjects were treated with such post-infusion medications. In the DRd  and  DVd  groups,  6%  to  7%  of  subjects  received  an  antihistamine  and  2%  of  subjects  received salbumatol. Such post-infusion medications were not used by any subjects in the DPd cohort.

Treatment modifications in response to IRR included infusion interruption, infusion aborted/drug withdrawn, or infusion rate decrease. Nearly all subjects who experienced IRRs (280/315) had their infusion interrupted, aborted (or drug withdrawn in GEN503), or the infusion rate decreased. The TEAEs that led to infusion modifications, are nearly the same as the ones already identified as IRRs.

## Neutropenia

More subjects receiving daratumumab combination therapy reported neutropenia compared to background therapy alone (DVd: 18%, Vd: 9%, DRd: 62%, Rd: 43%). Neutropenia was reported for 79% of subjects in the  DPd  cohort.  Most  frequently,  neutropenia  occurred  in  the  first  2  or  3  cycles.  Incidence  of  febrile neutropenia was low, 2% for the DVd group and 0.4% for the Vd group, 5% for the DRd group and 3% for the Rd group and 7% for DPd group, all were rade 3 or 4. Neutropenia was managed by dose modifications and growth factor use and rarely led to treatment discontinuation.

## Infections and infestations

In the 4 daratumumab studies, adverse events in the Infections and Infestations SOC were overall among the most frequently reported TEAEs. Infections were reported by a higher percentage of subjects in the daratumumab containing groups (DVd: 68%, DRd: 83%) compared to the respective background therapy (Vd: 53%, Rd: 73%). However, Grade 3 or 4 infections were similar (DVd: 21%, Vd: 19%, DRd: 27%, Rd: 23%). In the DPd cohort, 70% of subjects had infections (28% Grade 3 or 4). The majority of infections were mild (Grade 1 or 2) and did not require hospitalization. The most common infections were respiratory disorders such as upper respiratory tract infection, bronchitis, sinusitis, or nasopharyngitis, which were common across all regimens.

Discontinuations from treatment (2% to 5%) and deaths (0.8% to 2%) due to infection were rare and balanced between groups. Pneumonia occurred in 11% to 13% of the study population and was the most

<div style=\"page-break-after: always\"></div>

commonly reported severe (Grade 3 or 4) infection (7% to 10%) and also the most commonly reported serious infection (7% to 9%). The occurrence of pneumonia was balanced between treatment groups, and seldom resulted in treatment discontinuations or deaths (0.4% to 2%).

## Herpes zoster

Bortezomib  and  lenalidomide  exposure  poses  a  known  risk  of  herpes  zoster  reactivation  and  antiviral prophylaxis is recommended. The protocols recommended, but did not require, anti-viral prophylaxis for all study subjects.

## Daratumumab with Bortezomib-Dexamethasone (DVd)

Herpes zoster as an adverse event was reported for 13 subjects (5%) in the DVd group (8 of these subjects received  prophylactic  anti-viral  therapy)  and  7  subjects  (3%)  in  the  Vd  group  (1  subject  received prophylactic antiviral therapy). Grade 3 or 4 TEAEs of herpes zoster was reported for 4 subjects (1.6%) in the DVd group and 1 subject (0.4%) in the Vd group.

## Daratumumab with Lenalidomide-Dexamethasone (DRd)

In Study 3003, Herpes zoster as an adverse event was reported for 6 subjects (2%) in the DRd group and 5 subjects (2%) in the Rd group. Two subjects in each group received prophylactic antiviral therapy. Grade 3 or 4 TEAEs of herpes zoster was reported for no subjects in the DRd group and 1 subject (0.4%) in the Rd group.

## Daratumumab with Pomalidomide-Dexamethasone (DPd)

Two subjects (2%) had TEAEs of herpes zoster. Both events were Grade 3, neither was serious and neither led to treatment discontinuation. One of these 2 subjects was taking antiviral prophylaxis medication.

## Thrombocypenia and bleeding

Thrombocytopenia was similar between the DRd  group and Rd group (27%  in each group). Thrombocytopenia was reported by more subjects in the DVd group (59%) compared to the Vd group (44%), but bleeding events were low and the majority were Grade 1 or 2 events. In the DPd cohort, thrombocytopenia was reported by 41% of subjects. Grade 3 or 4 bleeding events were experienced by 1% or less of subjects in all treatment groups.

## Hemolysis and interference with blood typing

Daratumumab  binds  to  CD38  found  at  low  levels  on  red  blood  cells  and  could  theoretically  result  in hemolysis. One subject (in the DPd cohort, Study MMY1001) experienced a Grade 1 TEAE of hemolysis on Study Day 70 which was diagnosed based on the presence of schistocytes on peripheral blood smear. The TEAE occurred 13 days after the last blood transfusion and 12 days after the last daratumumab infusion. There was no immediate exacerbation of anemia. No new cases of daratumumab interference with blood typing have been reported.

## Cardiac events -atrial fibrillation

Atrial fibrillation was observed in 2% to 7% of subjects across all studies. Atrial fibrillation was balanced between the DRd and Rd groups but was slightly higher in the DVd group compared to the Vd group. The majority of subjects with atrial fibrillation had a prior history of atrial fibrillation or cardiac risk factors.

## Cardiac events -QT prolongation

No subjects in DVd, Vd, or DPd groups had an AE of QT prolongation. QT prolongation was reported as an AE for 6 subjects (2%) in the DRd group and 1 subject (0.4%) in the Rd group. All were Grade 1 or 2. Only 1

<div style=\"page-break-after: always\"></div>

subject, in the DRd group, had a corrected QT interval greater than 500 msec. This subject had an ongoing history of heart failure, and a one-time QTcF reading of 532 msec was reported on Study Day 50 as an AE of electrocardiogram  QT  prolonged.  Baseline  electrocardiogram  findings  were  normal.  The  investigator considered  this  event  as  very  likely  related  to  lenalidomide  and  not  related  to  daratumumab  or dexamethasone. The event was considered resolved 7 days later and the subject continues to receive study treatment. No further QT prolongation has been reported.

## Hepatobiliary disorders

A review of all AEs from hepatobiliary disorders showed the incidence of AEs to be very low and balanced between daratumumab combination therapy and background therapy alone. There is no specific AE event associated with hepatobiliary disorders identified. Liver enzymes were within the normal range for over 95% of subjects across all studies.

## Second primary malignancies

Second primary malignancies (SPMs) were collected using a separate eCRF page in the Phase 3 studies throughout the study including long term follow-up. SPMs have been identified as a rare but important consideration in the treatment of multiple myeloma. A recent review evaluated the reports of SPM from several  retrospective  and  prospective  studies  identified  lenalidomide  and  alkylating  agent  exposure  as potential (but not exclusive) risk factors. The incidence of SPMs is likely between 0.5% and 4.5% with a latency period of &gt;12 months. Hematologic SPMs were more common than nonhematologic SPMs with a higher prevalence of myelodysplastic syndrome and acute myeloid leukemia. Based on data from all 4 studies, no increased risk of SPM due to daratumumab treatment has been observed.

## Serious adverse event/deaths/other significant events

## Serious adverse event

An overview of the SAEs occurred with frequency of at least 3% in MMY3003, MMY3004, MMY1001 and GEN503 studies is reported in Table 38 below:

<div style=\"page-break-after: always\"></div>

Table 38  Number of Subjects with 1 or More Treatment-emergent SAE with frequency of at least 3% in either treatment group by MedDRA System Organ Class and Preferred Term: Safety Analysis Set (Studies: MMY3003, MMY3004, MMY1001 and GEN503)

|                                                     | MOMY3004   | MOMY3004    | MMY3003+GEN503   | MMY3003+GEN503   | MY1001     |
|-----------------------------------------------------|------------|-------------|------------------|------------------|------------|
|                                                     | vd         | DVd         | Rd               | DRd              | DPd        |
| Analysis set. safery                                | 237        | 243         | 281              | 318              | 103        |
| TotalmumberofsubjeciswithseriousTEAE                | 80(33.8%)  | 102 (42.0%) | 118 (42.096)     | 156(49.196)      | 50(48.59)  |
| MedDRAsystemorganclass/Preferred term               |            |             |                  |                  |            |
| Infections and infestations                         | 43(18.19)  | 48(19.89)   | 64 (22.896)      |                  | 21 (20.49) |
| Puemonia                                            | 22 (9.396) | 19 (7.896)  | 24(8.596)        | 24(7.596)        | 7 (6.896)  |
| Sepsis                                              | 2(0.896)   | 2(0.896)    | 5 (1.8%)         | 2(0.6%)          | 4(3.996)   |
| Blood and lymphaticsystem disorders                 | 2(0.896)   | 15 (6.29)   | 11 (3.9%)        | 21 (6.6%)        | 8 (7.8%)   |
| Febrile neutropemia                                 | 0          | 2(0.89)     | 4(1.4%)          | 12(3.896)        | 4(3.996)   |
| Anaemia                                             | 1(0.49)    | 8(3.39)     | 2(0.796)         | (660)            | 3 (2.996)  |
| General disordersand administration site conditions | 12 (5.1%)  | 9(3.796)    | 8(2.896)         | 16 (5.096)       | 4 (3.996)  |
| Pyrexia                                             | 4(1.796)   | 4(1.696)    | 4(1.49)          | 10 (3.196)       | 0          |
| Injury,poisoningand procedural complications        | 5 (2.19)   | 7 (2.996)   | 8(2.896)         | 8 (2.59)         | 7(6.896)   |
| Fall                                                | 0          | 0           | 1(0.49)          |                  | 4(3.996)   |

Key.D=Daratmumab,Vd=bortezomib-dexamethasone,Rd=lenalidonide-dexamethasone,Pd=pomalidomidedexamethasone.

Keys:TEAE=teabment-emergentadverseevent

Rdisonlyfrom MMfY3003.

Note:Adverse eventsarereported usingMedDRAversion18.o.

Note:Percentages arecalculatedwith thenummber of subjectsimeachgroup as denominator.

[TSFAE05IRTF][NJ-54767414Z\\_SCSDBRMOYRR\\_2016REMMYRR\\_2016PRODTSFAE0SISAS]01JUN2016,10:38

## Deaths

Table  39    Summary  of  Death  and  Cause  of  death:  Safety  Analysis  Set(studies  MMY3003, MMY3004, MMY1001 and GEN503)

|                                                              | MY3004    | MY3004     | MMIY3003+GEN503   | MMIY3003+GEN503   | MOY1001   |
|--------------------------------------------------------------|-----------|------------|-------------------|-------------------|-----------|
|                                                              | vd        | DVd        | Rd                | DRd               | DPd       |
| Analysis seti safety                                         | 237       | 243        | 281               | 318               | 103       |
| Totalnuumberof subjects who died within30 daysoflast study   |           |            |                   |                   |           |
| teatment dose                                                | 13 (5.5%) | 13 (5.3%6) | 16 (5.7%)         | 13 (4.196)        | 7(6.8%)   |
| Adverse events                                               | 10 (4.29) | 11(4.5%)   | 12 (4.396)        | 12 (3.89)         | 5 (4.9%)  |
| Disease progression                                          | 3 (1.396) | 2 (0.896)  | 4 (1.496)         | 1(0.39)           | 2 (1.996) |
| Other                                                        | 0         | 0          | 0                 | 0                 | 0         |
| Total nuumberof subjeclswho died within 60 daysof first stdy |           |            |                   |                   |           |
| teatmentdose                                                 | 9(3.896)  | 7(2.996)   | 7(2.596)          | 3 (0.9%6)         | 7 (6.89)  |
| Adverse events                                               | 5 (2.19)  | 7(2.996)   | 6 (2.196)         | 3 (0.9%6)         | 5 (4.996) |
| Disease progression                                          | 4 (1.7%)  | 0          | 1(0.49)           | 0                 | 2 (1.9%)  |
| Other                                                        | 0         |            |                   | 0                 | 0         |

Key:D=Daratumunab,Vd=bortezomib-dexamethasone,Rd=lenalidomide-dexamethasoue,Pd=pomalidomidedexamethasone.

RdisonlyfromMMY3003

Note:Percentages arecalculated with themumber of subjects imeach goup as denominator.

<div style=\"page-break-after: always\"></div>

Table 40 Number of Subjects with 1 or More TEAEs with outcome death by Preferred Term and Relationship; Safety Analysis Set (Studies : MMY3003, MMY3004, MMY1001 and GEN503)

|                                                          | MMY3004                 | MMY3004   | MMY3004    | MMY3004                 | MMY3003+GEN503   | MMY3003+GEN503   | MMY3003+GEN503   | MMY3003+GEN503          | MMY3003+GEN503    | IOOLUAUN                | IOOLUAUN   | IOOLUAUN   |
|----------------------------------------------------------|-------------------------|-----------|------------|-------------------------|------------------|------------------|------------------|-------------------------|-------------------|-------------------------|------------|------------|
|                                                          | PA                      | PA        |            | DVd                     | DVd              | Rd               | Rd               | DRd                     | DRd               | DPd                     | DPd        | DPd        |
|                                                          |                         |           |            |                         |                  |                  |                  |                         |                   | Related                 | Related    | Related    |
|                                                          |                         |           | Total      | Related                 | Related          |                  | Related          | Total                   | Related Related   |                         |            |            |
|                                                          | Total                   | Related   |            | to                      |                  | Total            |                  |                         | to                | Total                   | to         | Related    |
| Analysis set safety                                      | n(6) 237                | to Other  | (96)u 243  | DARA                    | toOther          | (6）u 281         | toOther          | (96) 318                | DARA to Other     | n(%) 103                | DARA       | to Other   |
| Total numberof subjeciswithTEAE with outcome death       | 14 (5.9%)               | 2(0.8%)   | 13 (5.396) |                         | 3(1.29)5(2.196)  | 15 (5.396)       | 1(0.4%)          | 12 (3.896)              |                   | 3（0.9%)7(2.296)7（6.896) | 0          | 1 (1.09)   |
| MedDRA system organ                                      |                         |           |            |                         |                  |                  |                  |                         |                   |                         |            |            |
| class/Preferred temm                                     |                         |           |            |                         |                  |                  |                  |                         |                   |                         |            |            |
| Infections and infestations                              | 4（1.79)2（0.896)2（0.8%6) |           |            | 1(0.496)                | 1(0.4%)          | 4(1.4%)          | 0                | 7(2.296)                | 2(0.696) 5(1.696) | 2(1.99)                 | 0          | 1(1.090)   |
| Septic shock                                             | 1(0.496)                | 0         | 0          | 0                       | 0                | 1(0.4%)          | 0                | 3(0.996)                | 1(0.3%) 1(0.396)  | 0                       | 0          | 0          |
| Puenmonia                                                | 2（0.896)1（0.49)1(0.496) |           |            | 1（0.496)1（0.496)2（0.7%） |                  |                  | 0                | 2(0.696)                | 0 2(0.6%6)        |                         | 0          | 0          |
| Pneummonin bacterial                                     | 0                       | 0         | 0          | 0                       | 0                | 0                |                  | 1(0.396)                | 0 1(0.396)        | 0                       | 0          | 0          |
| Pneumonia viral                                          | 0                       | 0         | 0          | 0                       | 0                | 0                | 0                | 1(0.396)1（0.3%)1(0.396) |                   | 0                       | 0          | 0          |
| Progressive multifocal                                   |                         |           |            |                         |                  |                  |                  |                         |                   |                         |            |            |
| leukoencephalopathy                                      | 0                       | 0         | 0          | 0                       | 0                | 0                | 0                | 0                       | 0 0               | 1(1.09)                 | 0          | 1(1.09)    |
| Pulmonary sepsis                                         |                         | 0         | 1(0.4%)    | 0                       | 0                | 0                |                  | 0                       | 0 0               | 0                       | 0          | 0          |
| Sepsis                                                   |                         |           | 0          | 0                       | 0                | 1(0.4%)          | 0                | 0                       | 0 0               | 1(1.0%)                 |            | 0          |
| Tracheobronchitis                                        | 1(0.49)                 | 1(0.4%)   | 0          | 0                       | 0                | 0                | 0                | 0                       | 0 0               |                         | 0          | 0          |
| Cardiac disorders                                        | 1(0.496)                | 0         | 3(1.2%)    | 1(0.496)                | 1(0.49)          | 1(0.4%)          | 0                | 1(0.396) 0 0            | 0                 |                         | 0          | 0          |
| Cardiopulmonary failure                                  | 0                       | 0         | 0          | 0                       | 0                | 0                | 。                | 1(0.39)                 | 0                 |                         |            | 0          |
| Acute coronary syudrome                                  | 0                       | 0         | 1(0.49)    |                         | 1(0.49)1(0.49)   | 0                | 0                | 0 0                     | 0 0               | 0                       | 0          | 0          |
| Cardiac alrest Carcliogenic shock                        | 1(0.49)                 | 0         | 1(0.496)   | 0                       | 0 0              | 1(0.4%)          | 0                | 0 0                     | 0 0               | 0 0                     | 0 0        | 0 0        |
| General disorders and                                    |                         | 0         | 1(0.4%)    | 0                       |                  | 0                | 0                | 0                       |                   |                         |            |            |
| advinistation site conditions                            | 4(1.796)                | 0         | 1(0.49)    |                         | 0                | 0                | 0                | 1(0.396)1(0.396)1(0.3%) |                   | 1(1.0%)                 | 0          | 0          |
| Multi-organ failure                                      | 0                       | 0         | 0          | 0                       | 0                | 0                | 0                | 1 (0.396)               | 1(0.3%)1(0.3%)    | 0                       |            | 0          |
| Condition aggravated                                     | 1 (0.496)               | 0         | 0          | 0                       | 0                | 0                | 0                | 0                       | 0 0               | 0                       | 0          | 0          |
| General physical health deterioration                    | (96EDE                  | 0         | 1(0.496)   | 0                       | 0                | 0                | 0                | 0                       | 0 0               | 1(1.0%)                 | 0          | 0          |
| Neoplasms benign,malignant and specified (incl cysts and |                         |           |            |                         |                  |                  |                  | 1(0.396)                |                   |                         |            |            |
| polyps)                                                  | 0                       | 0         | 0          | 0                       | 0                | 2(0.7%)          | 0                | 0                       | 1(0.3%)           | 0                       | 0          | 0          |
| Acute monocyticleukaemia                                 | 0                       | 0         | 0          | 0                       | 0                | 0                | 0                | 1(0.396)                | 0 1(0.39)         | 0                       | 0          | 0          |
| Lumg adenocarcinoma                                      | 0                       | 0         | 0          | 0                       | 0                | 1(0.4%)          | 0                | 0                       | 0 0               | D                       | 0          | 0          |
| Plasma cell leukaemia                                    |                         | 0         | 0          | 0                       | 0                | 1(0.4%)          | 0                | 0                       | 0 0               |                         | 0          | 0          |
| Renal and urinary disorders                              | 1 (0.49)                | 0         | 0          | 0                       | 0                | 4(1.496)         | 1(0.496)         | 1(0.396)                | 0 0               | 0                       | 0          | 0          |
| Acute kidney injury                                      | 0                       | 0         | 0          | 0                       | 0                | 3(1.1%)          | 1(0.496)         | 1(0.396)                | 0 0               | 0                       | 0          | 0          |
| Myeloma cast nephropathy                                 | 1(0.496)                | 0         | 0          | 0                       | 0                | 0                | 0                | 0 0                     | 0 0               | 0                       | 0          | 0          |
| Renal failure Respiratory,thoracicand                    | 0                       | 0         | 0          | 0                       |                  | 1(0.49)          | 0                |                         | 0 0               | 0                       | 0          | 0          |
| mediastinal disorders                                    | 2(0.8%)                 | 0         | 3(1.29)    |                         | 1(0.49)1(0.4%)   | 2(0.7%)          | 0                | 1(0.396)                | 0 0               | 3(2.9%6)                | 0          | 0          |
| Puimonary oedema                                         | 1(0.496)                | 0         | 0          | 0                       | 0                | 1(0.496)         | 0                | 1(0.396)                | 0 0               |                         | 0          | 0          |
| Acuterespiratory failture                                | 0                       | 0         | 0          | 0                       |                  | 1(0.49)          | 0                |                         | 0 0               | 0                       | 0          | 0          |
| Interstitial lumg disease                                | 0                       | 0         | 0          | 0                       | 0                | 0                | 0                |                         | 0 0               | 1(1.096)                | 0          | 0          |
| Organisingpneuwonia                                      | 0                       | 0         | 1(0.4%)    | 1(0.49)                 | 1(0.4%)          | 0                | 0                | 0                       | 0 0               | 0                       | 0          | 0          |
| Pletural effusion                                        | 0                       | 0         | 0          | 0                       | 0                | 0                | 0                | 0                       | 0 0               | 1(1.0%)                 | 0          | 0          |
| Pulmonary embolism                                       | 1(0.49) 0               | 0 0       | 0 2(0.896) | 0                       | 0                | 0                | 0                | 0 0                     | 0 0 0             | 0                       | 0          | 0          |
| Respiratory failure                                      |                         |           |            | 0                       | 0                | 0                | 0                |                         | 0                 | 1(1.09)                 | 0          | 0          |
| Gastrointestinal disorders                               | 0                       | 0         | 1(0.4%)    |                         |                  | 0                | 0                | 0                       | 0 0               | 0                       |            | 0          |
| Duodenal ulcer                                           | 0                       | 0         | 1(0.4%)    | 0 0                     | 1(0.496) 1(0.4%) | 0                | 0                |                         | 0 0               | 0                       | 0          | 0          |
| Metabolism andnutrition disorders                        | 1(0.496)                | 0         | 0          | 0                       | 0                | 0                | 0                | 0                       | 0 0               | 0                       | 0          | 0          |
| Hyponatraemia                                            |                         | 0         | 0          |                         |                  |                  |                  | 0 0                     | 0 0               | 0                       |            | 0          |
|                                                          | 1(0.496) 1(0.4%)        | 0         | 3(1.2%)    | 0                       | 0                | 0                | 0                |                         | 0 0               |                         | 0          | 0          |
| Nervous system isorders Cerebral haemorrhage             | 0                       |           | 0          | 0                       | 1(0.4%)          | 2(0.79) 1(0.49)  | 0 0              | 0                       | 0 0               | 1(1.0%) 0               | 0 0        | 0          |
| Cerebral infarction                                      | 0                       |           | 1(0.49)    | 0 0                     | 0                | 0                | 0                | 0                       | 0                 | 0                       | 0          | 0 0        |
| Cerebrovascular accident Ischaemic stroke                | 1(0.496)                | 0 0       | 0          | 0                       | 0                | 0                | 0                | 0 0                     | 0 0               | 1(1.09)                 | 0          |            |
|                                                          | 0                       |           |            |                         |                  | 0                | 0                |                         | 0 0               | 0                       |            |            |
| Nervous system cisorder                                  | 0                       | 0         | 2(0.89) 0  | 0 0                     | 1(0.49) 0        | 1(0.4%)          | 0                | 0                       | 0 0               | 0                       | 0 0        | 0 0        |

Key.D=Daranumumab,Vd=bortezomib-dexamethasone,Rd=lenalidomide-dexamethasone,Pd=pomalidomide-dexamethasone.

Keys:TEAE=treament-emergent adverseevent.

Rd is onlyfomMMY3003.

Note:Adverseevents arereported tusingMedDRA version 18.0.

Note:Percentages are calculated with thenumber ofsubjects ineach group as denominator.

<div style=\"page-break-after: always\"></div>

## Laboratory findings

## Hematology values

## Daratumumab with Bortezomib-Dexamethasone

Low platelets are a common laboratory abnormality in subjects treated with bortezomib. The most common Grade 3 or 4 hematology abnormalities for both treatment groups were low platelets (DVd: 48%; Vd: 36%) and low lymphocytes (DVd: 51%; Vd: 30%).  Grade 3 or 4 low neutrophils were 16% in the DVd group and 6% in the Vd group. Similar proportion of subjects in both treatment groups had Grade 3 low hemoglobin (DVd: 17%; Vd: 16%). No Grade 4 hemoglobin was reported in any of the treatment groups.

## Daratumumab with Lenalidomide-Dexamethasone

The most common Grade 3 or 4 hematology laboratory abnormalities were low neutrophils (DRd group: 54%; Rd group: 41%) and low lymphocytes (DRd group: 54%; Rd group: 40%), with higher proportions reported in the DRd group compared with the Rd group. The percentage of subjects with Grade 3 or 4 low platelets was similar between the 2 treatment groups (DRd group: 14%; Rd group: 16%). Grade 3 hemoglobin low was reported for 14% of subjects in the DRd group and 21% of subjects in the Rd group. No Grade 4 low hemoglobin was reported in either treatment group.

## Daratumumab with Pomalidomide-Dexamethasone

The most common Grade 3 or 4 hematology laboratory abnormalities were low neutrophils (82%) and lymphocytes (73%). Grade 3 or 4 low platelets was reported by 20% of subjects. Grade 3 low hemoglobin was reported for 32% of subjects, no Grade 4 low hemoglobin was reported.

## Clinical Chemistry

The incidence of chemistry laboratory abnormalities was low, and the majority was Grade 0 or 1.

## Daratumumab with Bortezomib-Dexamethasone

Changes in chemistry values to Grade 4 were uncommon, and did not exceed 5% of the population. Changes to Grade 3 values were also uncommon, and rarely exceeded 5% of the population except for Grade 3 low sodium levels (DVd: 5%, Vd: 6%) and Grade 3 low phosphate levels (DVd: 9%, Vd: 5%). The majority of Grade 3 and Grade 4 values represented shifts from Grade 0 or Grade 1 at baseline. Mean creatinine levels were generally lower for the DVd group compared with the Vd group over time during the study and reciprocally, creatinine clearance values were higher for the DVd group compared with the Vd group and increased over time for both treatment groups. This observation of improving creatinine clearance over time supports a beneficial impact of treatment since renal failure is a notable complication of untreated or poorly controlled multiple myeloma.

Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin levels were normal throughout the study for over 98% of subjects. Grade 4 AST high and ALT high were recorded for 1 subject (0.4%) each in the DVd and Vd groups, no subjects had Grade 4 bilirubin high. Grade 3 ALT high was reported for 5 subjects (2%) in the DVd group and 1 subject (0.4%) in the Vd group. Grade 3 AST high was reported for 2 subjects (0.8%) in the DVd group and no subjects in the Vd group. Grade 3 bilirubin high was reported for no subjects in the DVd group and 1 subject (0.4%) in the Vd group.

## Daratumumab with Lenalidomide-Dexamethasone

Changes in chemistry values to Grade 4 were uncommon, and did not exceed 5% of the population. Changes to Grade 3 values were also rare, and rarely exceeded 5% of the population except for Grade 3 low

<div style=\"page-break-after: always\"></div>

potassium levels (DRd: 5%, Rd: 3%)  and  Grade 3 low phosphate levels (DRd: 12%, Rd: 11%). The majority of Grade 3 and Grade 4 values represented shifts from Grade 0 or Grade 1 at baseline.

Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin levels were normal throughout the study for over 95% of subjects. No Grade 4 values for these laboratory parameters were reported. Grade 3 ALT high was reported for 8 subjects (3%) in the DRd group and 5 subjects (2%) in the Rd group. Grade 3 AST high was reported for 3 subjects (1%) in the DVd group and no subjects in the Rd group. Grade 3 bilirubin high was reported for 2 subjects (0.6%) in the DRd group and 1 subject (0.4%) in the Rd group.

## Daratumumab with Pomalidomide-Dexamethasone

Hypercalcemia (9%) was the only Grade 4 biochemistry value that was reported by more than 5% of subjects. Other frequently reported Grade 3 biochemistry parameters were low sodium (11%) and low phosphate levels (10%).

Alanine aminotransferase (ALT), AST, and bilirubin levels were normal throughout the study for over 95% of subjects. No Grade 4 values for these laboratory parameters were reported. Grade 3 AST high and ALT high were recorded for 3 subject (3%) each. Grade 3 bilirubin high was reported for 2 subjects (2%).

## Immunogenicity Assessments

Evaluation of anti-daratumumab antibodies was conducted for all subjects participating in the 4 studies included in this submission. Evaluable blood samples were obtained after the first dose of daratumumab from 298 subjects. Results are summarized in the Table 41.

Table 41 Summary and Anti- Daratumumab Antibodies: Immune Response-evaluable Analysis Set (Studies: MMY3003, MMY3004, MMY1001 and GEN503)

|                                                  | MDMY3004     | MMY3003   | GEN503   | MMYI001   |                                           |
|--------------------------------------------------|--------------|-----------|----------|-----------|-------------------------------------------|
| Analysisset:immmuneresponse-evaluable            | 102          | 96        | 37       | 64        | 299                                       |
| Subjects with appropniate samples                | 102          | 95        | 37       | 64        | 298                                       |
| Subjectspositiveforanni-daranmmumab sntibodieshe |              | 1 (1.196) | 0        | 1 (1.6%)  | 2 (0.796)                                 |
| Titers 1:20                                      |              |           |          |           | 2                                         |
| Subjectspositive forneunalizingantibodiesd       |              |           |          |           |                                           |
| Subjectsnegativeforanti-daratummumab antibodies  | 102 (100.0%) |           |          |           | 94(98.996)37(100.096)63(98.49)296(99.396) |

Subjectswith appropriatesampleshad I ormore sanplesobtained aftertheir firstdaranmunab administration.

Denominatoris subjectswithappropriate samples.

dOnly samplespositive forantibodies to daratumumabwere asseyed for neutralizingantibodies.

Includesall subjectswhohadat least lpositive sample at any time after start of treatmeut andbaselinepositivesubjects whobadpost-treabnentsampletitersincreaseat least2-foldcompared tobaseline.

MOIY3004 includespatients intheDVd am0MrY3003includespatients ntheDRdanmGEN503includespatients treated wiihDRd2mgkgto16mgkg.ML.rY1001includespatientstreatedwithDVdDVTd.DVMP.orDPd.

As shown in the table above, one subject in Study MMY1001, in the DVTd cohort, was positive for ADA at the Week 9 Follow-Up visit; the antibodies were non-neutralizing. This subject was negative for ADA on 2 other

<div style=\"page-break-after: always\"></div>

visits (predose on Cycle 1 Day 1 and Week 3 Follow-up) and was on treatment for 4 cycles. This subject was not evaluable for response per protocol and discontinued due to autologous stem cell transplantation. There were no notable safety signals observed in this subject.

Daratumumab  binds  to  CD38  found  at  low  levels  on  red  blood  cells  and  could  theoretically  result  in haemolysis. One subject (in the DPd cohort, Study MMY1001) experienced a Grade 1 TEAE of hemolysis on Study Day 70 which was diagnosed based on the presence of schistocytes on peripheral blood smear. There was no immediate exacerbation of anemia and this TEAE occurred 13 days after blood transfusion and 12 days after daratumumab infusion. No other TEAEs related to hemolysis have been reported.

Interference  with  blood  typing  is  already  included  in  the  Warnings  and  Precautions  section  of  the daratumumab Product Information, however, no new cases of daratumumab interference with blood typing have been reported in the present pivotal studies.

Vital signs, physical findings, and other observations related to safety

A review of vital signs in the randomized, controlled studies did not identify any safety signals.

## Safety in special populations

A separate analysis of TEAEs was performed for the daratumumab groups (DVd, DRd, DPd) combined from all 4 studies to evaluate potential differences in the safety of daratumumab in subgroups of subjects defined by age, gender, race, baseline renal function, baseline hepatic function, and geographic region.

Table 42 Subgroup analyses on Overview of TEAEs; Safety Analysis Set (Studies: MMY3003, MMY3004, MMY1001 and GEN503)

|                                        |                                   | Dara Combined   | Dara Combined   | Dara Combined   | Dara Combined     | Dara Combined   | Dara Combined           |
|----------------------------------------|-----------------------------------|-----------------|-----------------|-----------------|-------------------|-----------------|-------------------------|
|                                        |                                   | N               | TEAE            | Senious TEAE    | Grade 3 or 4 TEAE | TD due to TEAE\" | TEAE with outcome Death |
| Allsubjects                            |                                   | 664             | 656 (98.8%)     | 308 (46.4%)     | 547 (82.4%6)      | 53 (8.0%)       | 32 (4.8%)               |
| Age:                                   | 18 to ≤ 65 years                  | 336             | 332 (98.8%)     | 140 (41.7%)     | 270 (80.4%)       | 16 (4.8%)       | 15 (4.5%)               |
| Age:                                   | 65 to < 75 years                  | 269             | 266 (98.9%)     | 135 (50.2%6)    | 227 (84.496)      | 28 (10.4%)      | 15 (5.6%)               |
| Age:                                   | = 75 years                        | 59              | 58 (98.3%)      | 33 (55.9%6)     | 50 (84.7%6)       | 9 (15.3%)       | 2 (3.4%)                |
| Sex.                                   | Male                              | 382             | 378 (99.0%)     | 191 (50.0%)     | 317 (83.0%)       | 36 (9.4%)       | 21 (5.5%)               |
| Sex.                                   | Female                            | 282             | 278 (98.6%)     | 117 (41.5%)     | 230 (81.6%)       | 17 (6.0%)       | 11 (3.9%)               |
| Race:                                  | White                             | 527             | 519 (98.5%)     | 253 (48.0%)     | 430 (81.6%)       | 45 (8.5%6)      | 28 (5.3%6)              |
| Race:                                  | Other                             | 137             | 137 (100.0%)    | 55 (40.1%)      | 117 (85.4%)       | 8 (5.8%)        | 4 (2.9%6)               |
| Renal Impaiment (Creatinine Clearance) | Nonmal (CrCl ≥= 90 mL/min)        | 240             | 238 (99.2%)     | 99 (41.3%)      | 194 (80.8%6)      | 16 (6.7%)       | 12 (5.0%)               |
| Renal Impaiment (Creatinine Clearance) | Mild (CrC1 60 to ≤ 90 mL/min)     | 249             | 245 (98.4%)     | 104 (41.8%)     | 202 (81.1%)       | 17 (6.8%)       | 9 (3.6%)                |
| Renal Impaiment (Creatinine Clearance) | Moderate (CrC1 30 to < 60 mL/min) | 159             | 157 (98.7%)     | 93 (58.5%)      | 135 (84.9%6)      | 17 (10.7%)      | 11 (6.9%)               |
| Renal Impaiment (Creatinine Clearance) | Severe (CrCl<30 mL/min)           | 12              | 12 (100.0%)     | 10 (83.3%)      | 12 (100.0%)       | 3 (25.0%)       | 0                       |
| Hepatic Function                       | Nonmal                            | 570             | 563 (98.8%6)    | 263 (46.1%6)    | 470 (82.596)      | 47 (8.2%6)      | 29 (5.1%)               |
| Hepatic Function                       | Impaired                          | 86              | 85 (98.8%6)     | 39 (45.3%6)     | 70 (81.4%)        | 6 (7.0%)        | 3 (3.596)               |
| Geographic Regiou:                     | West EU+NA+CAN                    | 86E             | 396 (99.5%6)    | 190 (47.7%)     | 342 (85.996)      | 32 (8.0%)       | 18 (4.5%)               |
| Geographic Regiou:                     | Other Regions                     | 266             | 260 (97.7%6)    | 118 (44.4%6)    | 205 (77.19%6)     | 21 (7.9%6)      | 14 (5.3%6)              |

Key: D=Darahumumab, Vd=bortezomib-dexamethasone, Rd=lenalidomide-dexamethasone, Pd=pomalidomide-dexamethasone

Keys: TEAE = teahment-emergent adverse event. TD = teatment discontinuation.

Note: Percentages are calculated with the mumber of subjects in each subgroup as denominator.

bTEAE with outcome death on the AE CRF page.

'Treatment discontinuation due to adverse event on the end of treatment CRF page.

Hepatic fimction is classified as nonmal and impaired groups. The impaired group includes subjects of 82 mildly. 3 moderately and 1 severely hepatic impainment per NCI Organ Dysfiumction criteria.

West EU+US+CAN includes Belgium, Demmark,Greece,Netherlands,France, Great Britain, Sweden, Italy, Spain,USA,and Canada. Otherregion includes Australia, Israel, Japan, South Korea, Tukey, Taiwan, Poland, Brazil, Czech Republic, Humgary, Mexico, Russia, and Ukraine.

<div style=\"page-break-after: always\"></div>

## Intrinsic Factors

## Adverse Events by Age Group

Of the 664 subjects, 336 (51%) were 18 to &lt;65 years of age, 269 (41%) were 65 to&lt;75 years, and 59 (9%) were≥75 years of age. The incidence of TEAEs by age subgroup was similar to the total population. The safety profile observed in elderly subjects was consistent with the expected age-related morbidity in this population. Subjects ≥ 75 years, had an incidence of deaths due to TEAEs (3.4%) compared to all subjects (4.8%). However, the sample size in this subgroup was too small to make meaningful comparison.

## Adverse Events by Sex

Of the 664 subjects treated with the combination regimen with daratumumab, 282 (42%) were female and 382 (58%) were male. The incidence of TEAEs by sex was similar to the overall population.

## Adverse Events by Race

Of the 664 subjects treated with the combination regimen with daratumumab, 527 (79%) were White, and 137 (21%) were non-White. The incidence of TEAEs by race was similar to the overall population.

## Adverse Events by Baseline Renal Function

240 subjects (36%) had a normal baseline creatinine clearance (CrCl) of ≥90 mL/min, 249 (38%) had a baseline CrCl of 60 to &lt;90 mL/min and 159 (24%) had a baseline CrCl of 30 to &lt;60 mL/min. The incidence of TEAEs in the ≥60 mL/min was similar to the overall population. However subjects with moderate renal impairment with (baseline CrCl of 30 to &lt;60 mL/min) had a higher incidence of serious TEAE, 59% compared to 46% in the overall population, mostly due to Infections and Infestations SOC (31% versus 24% in the overall population). Subjects with severe renal impairment (CrCl of &lt;30 mL/min) were too small in number (n=12) to make a clinically meaningful conclusion.

## Adverse Events by Baseline Hepatic Function

Daratumumab being an IgG1қ mAb, is presumably biotransformed  in  the  same  manner  as  any  other endogenous IgG, and is subject to similar  elimination.  Hepatic  enzyme-mediated  metabolism  of  intact daratumumab is therefore unlikely to represent major elimination routes. As such, variations in hepatic function are not expected to affect the elimination of daratumumab. 570 (87%) subjects treated with a daratumumab containing regimen had a normal hepatic function at baseline, and 86 (13%) had mildly impaired hepatic function. In general, the incidence of TEAEs by baseline hepatic function was similar to the overall population. No clear pattern in the incidence of TEAEs for subjects with normal versus mildly impaired hepatic function was reported. The differences may be due to the small number of subjects with mild hepatic impairment, precluding any meaningful comparisons.

## Extrinsic Factors

## Adverse Events by Geographic Region

In general, the incidence of TEAEs by geographic region was similar to the overall population. 398 (60%) of the subjects were from Western Europe, US and Canada, and 40% were from other regions, such as Asia, Australia, Mexico and Eastern Europe.

## Overdose

There has been no experience of overdose in clinical studies. Doses up to 24 mg/kg have been administered intravenously in a clinical study (GEN501) without reaching the maximum tolerated dose.

There is no known specific antidote for daratumumab overdose. In the event of an overdose, the patient should be monitored for any signs or symptoms of adverse effects and appropriate symptomatic treatment be instituted immediately.

<div style=\"page-break-after: always\"></div>

## Use in Pregnancy and Lactation

There are no data available on the use of daratumumab in pregnant women and no animal data to assess the potential  effects  of  daratumumab  to  increase  the  risk  of  developmental  abnormalities  or  feto/neonatal toxicities.

Women of childbearing potential using the drug should use effective contraception during and up to 3 months after treatment. The 3-month washout for females is related to the linear terminal half-life of daratumumab  in  plasma  of  about  18  days,  which  can  be  expected  upon  complete  saturation  of target-mediated  clearance  and  with  repeated  dosing  of  daratumumab.  Theoretically,  daratumumab  is expected to be eliminated from the body in approximately 5 half-lives (90 days). The recommendation for women  to  avoid  becoming  pregnant  until  3  months  after  the  last  dose  of  daratumumab  is  a  fairly conservative approach which is supported.

It is not known whether daratumumab is secreted into human or animal milk or affects milk production. There are no studies to assess the effect of daratumumab on the breast-fed infant. Maternal IgG is excreted in human milk; however, published data suggest that antibodies in breast milk do not enter the neonatal and infant circulations in substantial amounts.

## Drug Abuse

Daratumumab is administered in a controlled setting by healthcare providers. There is no known drug abuse potential with daratumumab.

## Withdrawal and Rebound

No clinical studies of the withdrawal or rebound effects of daratumumab have been conducted. Treatment is to be continued until disease progression.

## Effects on Ability to Drive or Operate Machinery or Impairment of Mental Ability

No clinical information is available related to the effect of daratumumab on the ability to drive, operate machinery, or the impairment of mental ability. The effect of daratumumab on the ability to drive or operate machinery or the impairment of mental ability has not been formally studied; however, in the integrated safety  population,  TEAEs,  such  as  fatigue,  that  could  potentially  affect  the  ability  to  drive  or  operate machinery should be considered.

## Safety related to drug-drug interactions and other interactions

No  formal  drug-drug  interaction  studies  have  been  performed  with  daratumumab.  It  is  expected  that daratumumab is metabolized in the same manner as any other endogenous immunoglobulin (degraded into small peptides and amino acids via catabolic pathways) and is subject to similar elimination. Renal excretion and hepatic enzyme-mediated metabolism of intact daratumumab are therefore unlikely to represent major elimination routes. As such, variations in renal and hepatic function or drug metabolizing enzymes are not expected to affect the elimination of daratumumab. As a monoclonal antibody that binds with high affinity to a unique epitope on CD38, daratumumab is also not anticipated to alter drug metabolizing enzymes.

As part of Study MMY1001, PK profiles of combination agents (bortezomib, pomalidomide, and thalidomide) were assessed and compared to literature values. Pharmacokinetic values for daratumumab are assessed and compared with monotherapy values. Overall, there is no indication of clinically relevant drug-drug interactions between daratumumab and small molecules typically used in treatment of multiple myeloma.

## Discontinuation due to adverse events

A summary of the reasons for discontinuation from study treatment is presented in Table 47. A lower percentage of subjects receiving DVd (31%) or DRd (24%) have discontinued treatment compared to those

<div style=\"page-break-after: always\"></div>

receiving  background therapies alone (Vd: 44%; Rd: 47%). In the DPd cohort, 57% of subjects have discontinued treatment.

Table 43 Summary of Subject Disposition of Study Treatment: Safety Analysis Set (Studies: MMY3003, MMY3004, MMY1001 and GEN503)

|                                     | MMY3004     | MMY3004     | MMY3003+GEN503   | MMY3003+GEN503   | MMY1001    |
|-------------------------------------|-------------|-------------|------------------|------------------|------------|
|                                     | Vd          | DVd         | Rd               | DRd              | DPd        |
| Amalysis set: safety                | 237         | 243         | 281              | 318              | 103        |
| Subjects who had teatment ongoing   | 20 (8.4%)   | 169 (69.5%) | 149 (53.0%)      | 241 (75.8%)      | 44 (42.7%) |
| Subjects who discontinued treatment | 104 (43.9%) | 74 (30.5%)  | 132 (47.0%)      | 77 (24.2%)       | 59 (57.3%) |
| Reason for discontinuation          |             |             |                  |                  |            |
| Progessive disease                  | 60 (25.3%)  | 47 (19.3%)  | 96 (34.2%)       | 46 (14.5%)       | 34 (33.0%) |
| Adverse event                       | 23 (9.7%)   | 19 (7.8%)   | 23 (8.2%)        | 22 (6.9%)        | 14 (13.6%) |
| Physician decision                  | 0           | 0           | 2 (0.7%)         | 5 (1.6%)         | 4 (3.9%)   |
| Death                               | 4 (1.7%)    | 4 (1.6%)    | 1 (0.4%)         | 2 (0.6%)         | 2 (1.9%)   |
| Non-compliance with study dhug      | 8 (3.4%)    | 3 (1.2%)    | 5 (1.8%)         | 1 (0.3%)         | 0          |
| Withdrawal by subject               | 9 (3.8%)    | 1(0.4%)     | 5 (1.8%)         | 1 (0.3%)         | 4 (3.9%)   |
| Other                               | 0           | 0           | 0                | 0                | 1 (1.0%)   |

Key: D=Daratmumab, Vd=bortezomib-dexamethasone, Rd=lenalidomide-dexamethasone, Pd=pomalidomide-

dexamethasone.

Rdis only from MMY3003

Percentages are caleulated with the number of subjects in each group as denominator.

'Based on reason 'Subjectrefuved to futher shudy heatment' on 'End of Treatment' CRF page.

Note: MMY3004: Vd arm heated for 8 cycles and DVd aum heated umtil PD per protocol. Subjects in Vd arm who were

treated for S cycles are not considered as treatment discontinuation.

## Adverse Events Leading to Discontinuation of Treatment

Discontinuation of all study treatment due to TEAEs was low and balanced between treatment groups (Table 48). Across all groups, pneumonia was the most common reason for discontinuation of all study treatment. Discontinuation of daratumumab alone was infrequent (1% to 2%) across all studies.

<div style=\"page-break-after: always\"></div>

Table 44 TEAEs leading to discontinuation of Study Treatment of More than 1 Subjec by MedDRA System Organ Class and Preferred Term; Safety Analysis Set (Studies: MMY3003, MMY3004, MMY1001 and GEN503)

|                                               | MMY3004   | MMY3004   | MMY3003+GEN503   | MMY3003+GEN503   | MMY1001    |
|-----------------------------------------------|-----------|-----------|------------------|------------------|------------|
|                                               | PL        | DVd       | Rd               | DRd              | DPd        |
| Analysis set: safety                          | 237       | 243       | 281              | 318              | 103        |
| Total mumber of subjects with TEAE leading to |           |           |                  |                  |            |
| discontinuation of study treatment            | 22 (9.3%) | 18 (7.4%) | 22 (7.8%)        | 22 (6.9%6)       | 13 (12.6%) |
| MedDRA system organ class/Prefermed temm      |           |           |                  |                  |            |
| Infections And Infestations                   | 5 (2.1%)  | 6 (2.5%)  | 5 (1.8%)         | 8 (2.5%)         | 5 (4.9%)   |
| Pueumonia                                     | 1 (0.4%)  | 3 (1.2%)  | 2 (0.7%6)        | 3 (0.9%%)        | 1 (1.0%)   |
| Septic Shock                                  | 1 (0.4%)  | 0         | 0                | 2 (0.6%)         | 0          |
| Gangrene                                      | 1 (0.4%)  | 0         | 0                | 0                | 0          |
| Sepsis                                        | 0         | 1 (0.4%)  | 1 (0.4%)         | 0                | 1 (1.0%)   |
| General Disorders And Administration Site     |           |           |                  |                  |            |
| Conditions                                    | 2 (0.8%)  | 0         | 0                | 3 (0.9%6)        | 0          |
| General Physical Health Deterioration         | 1 (0.4%)  | 0         | 0                | 3 (0.9%6)        | 0          |
| Neoplasms Benign, Maliguant And               |           |           |                  |                  |            |
| Unspecified (Incl Cysts And Polyps)           | 0         | 1 (0.4%)  | 3 (1.1%%)        | 3 (0.996)        | 0          |
| Nervous System Disorders                      | 10 (4.2%) | 3 (1.2%)  | 2 (0.7%6)        | 2 (0.6%)         | 0          |
| Cerebral Infarction                           | 0         | 1 (0.4%)  | 1 (0.4%)         | 1 (0.3%6)        | 0          |
| Peripheral Sensory Neuropathy                 | 6 (2.5%)  | 1 (0.4%)  | 0                | 0                | 0          |
| Cardiac Disorders                             | 2 (0.8%)  | 4 (1.6%)  | 2 (0.7%6)        | 1 (0.3%)         | 2 (1.9%)   |
| Cardiac Arest                                 | 1 (0.4%)  | 1 (0.4%)  | 1 (0.4%)         | 0                | 0          |
| Cardiac Failure Congestive                    | 0         | 2 (0.8%)  | 0                | 0                | 1 (1.0%)   |
| Renal And Urinary Disorders                   | 0         | 0         | 2 (0.7%)         | 1 (0.3%)         | 0          |
| Renal Failure                                 | 0         | 0         | 2 (0.7%)         | 1 (0.3%)         | 0          |
| Respiratory, Thoracic And Mediastinal         |           |           |                  |                  |            |
| Disorders                                     | 1 (0.4%)  | 5 (2.1%)  | 5 (1.8%)         | 1 (0.3%)         | 4 (3.99)   |
| Laryngeal Oedema                              | 0         | 1 (0.4%)  | 0                | 1 (0.3%)         | 0          |
| Dyspnoea                                      | 0         | 1 (0.4%)  | 0                | 0                | 1 (1.0%)   |
| Pulmonary Embolism                            | 1 (0.4%)  | 0         | 3 (1.1%)         | 0                | 0          |
| Respiratory Failue                            | 0         | 1 (0.4%)  | 0                | 0                | 1 (1.0%)   |
| Blood And Lymphatic System Disorders          | 0         | 0         | 3 (1.1%%)        | 0                | 1 (1.0%)   |
| Thrombocytopenia                              | 0         | 0         | 1 (0.4%)         | 0                | 1 (1.0%)   |
| Vascular Disorders                            | 2 (0.8%)  | 0         | 1 (0.4%6)        | 0                | 1 (1.0%)   |
| Orthostatic Hypotension                       | 2 (0.8%)  | 0         | 0                | 0                | 0          |

Key. D=Darahumumab, Vd=bortezomib-dexamethasone, Rd=lenalidomide-dexamethasone, Pd=pomalidomide-dexamethasone.

Keys: TEAE = treahment-emergent adverse event.

Includes those subjects indicated as having discontinued teatment due to an adverse event on the end of teatment CRF page.

Rdis only from MMY3003.

Note: Adverse events are reported using MedDRA version 18.0.

Note: Percentages are calculated with the number of subjects in each group as denominator.

## Dose modifications due to AEs

Daratumumab dose modifications consisted of dose delays and dose skips. The TEAEs that led to a delay or skip prior to the start of the infusion in 2 or more subjects are summarized in Table 17. For all daratumumab groups combined, the most frequent reasons for interruption of daratumumab dosing were neutropenia and thrombocytopenia.

In the DVd group, 87 subjects (36%) had modifications to daratumumab dosing. The single most common reason for daratumumab dose modification was thrombocytopenia, reported for 28 subjects (12%). Pneumonia was the next most common reason, reported for 11 subjects (5%).

In  the  DRd  group  (excluding  GEN503  as  this  information  was  not  collected),  105  subjects  (37%)  had modifications to daratumumab dosing. The single most common reason for daratumumab dose modification was neutropenia, reported for 29 subjects (10%). Pneumonia was the next most common reason, reported for 10 subjects (4%).

In the DPd cohort, 50 subjects (49%) had modifications to daratumumab dosing. The single most common reason was neutropenia, reported for 24 subjects (23%). Thrombocytopenia was the next most common reason, reported for 9 subjects (9%).

<div style=\"page-break-after: always\"></div>

## Dose Modification of Background Therapy

A higher proportion of subjects from the DVd group were reported with a TEAE leading to dose modifications (dose delays, dose skipping, schedule change, or dose reduction) of bortezomib (DVd: 64%, Vd: 54%) and dexamethasone (DVd: 46%, Vd: 39%) compared with the Vd group. The most commonly reported TEAE leading to dose modifications was peripheral sensory neuropathy for bortezomib (DVd: 32%, Vd: 23%) and upper respiratory tract infection for dexamethasone (DVd: 3%, Vd: 5%).

In Study MMY3003, a higher proportion of subjects from the DRd group were reported with a TEAE leading to dose modifications (dose delay, dose skip, dose reduction) of lenalidomide (DRd: 71%, Rd: 54%) and dexamethasone (DRd: 58%, Rd: 44%) compared with the Rd group. The most commonly reported TEAE leading  to  dose  modifications  was  neutropenia  for  both  lenalidomide  (DRd:  34%,  Rd:  22%)  and dexamethasone (DRd: 7%, Rd: 4%).

Seventy-three percent (73%) of subjects experienced TEAEs leading to pomalidomide dose modification (ie, dose  delays,  dose  skipping,  dose  re-escalation,  or  dose  reduction);  the  most  common  reason  was neutropenia (48%).

## Table 45 TEAEs leading to infusion Modification prior to infusion Start in Two or More subjects by System Organ Class, Prederred Term and Relationship; Safety Analysis Set (Studies MMY3003, MMY3004, MMY1001 and GEN503)

|                                                                                        | MMY3004    | MMY3003+GEN503   | MMY1001    | Total         |
|----------------------------------------------------------------------------------------|------------|------------------|------------|---------------|
|                                                                                        | DVd        | DRd              | DPd        | Dara Combined |
| Analysisset. safety                                                                    |            | 283              | 103        | 629           |
| Total nmberof subfects with TEAE leadingto infusion modificationpnior to infusion stan | 87(35.8%)  | 105 (37.1%)      | 50 (48.5%) | 242(38596)    |
| MedDRAsystem organclass/Preferred tenm                                                 |            |                  |            |               |
| Infections and infestations                                                            | 34(14.0%)  | 61(21.696)       | 18(17.5%)  | 113(18.0%)    |
| Pueumonia                                                                              | 11(4.5%)   | 10(3.59)         | 3(2.9%)    | 24(3.8%)      |
| Upper respiratory tract infection                                                      | 4(1.6%)    | 6(2.1%)          | 3(2.9%)    | 13(2.196)     |
| Bronchitis                                                                             | 5(2.19)    | 5(1.896)         | 0          | 10(1.6%)      |
| Imfiuenza                                                                              | 2(0.89)    | 5(1.8%)          | (%0D1      | (06E')8       |
| Lowerrespiratory tact infection                                                        | 1(0.496)   | 5(1.89)          | 0          | (%601）9       |
| Nasopbaryngitis                                                                        | 0          | 5(1.896)         | 0          | 5(0.8%)       |
| Respiratory syncytial virusinfection                                                   | 1(0.496)   | 1(0.4%)          | 3(2.9%)    | 5(0.89)       |
| Urinary tactinfection                                                                  | 0          | 4(1.49)          | (%60D)1    | 5(0.89)       |
| Herpes zoster                                                                          | 3(1.29)    | 0                | 1 (1.0%)   | 4(0.6%)       |
| Lumg infection                                                                         | 1(0.4%)    | 2(0.7%)          | (%0D       | 4(0.6%)       |
| Parainfnenzae vinus infection                                                          | 1(0.496)   | 1(0.4%6)         | 2 (1.9%)   | 4(0.6%)       |
| Puewmonia influenzal                                                                   | 0          | 3(1.1%)          | 0          | 3(0.596)      |
| Sepsis                                                                                 | 0          | 1(0.4%)          | 2(1.9%)    | 3(0.5%)       |
| Gastoenteritis                                                                         | 1(0.49)    | 1(0.496)         | 0          | 2(0.396)      |
| Repiratory tractinfection                                                              | 0          | 2(0.7%6)         | 0          | 2(0.3%)       |
| Rhinitis                                                                               | 1(0.49)    | 1(0.496)         | 0          | 2(0.396)      |
| Simsitis                                                                               | 1(0.496)   | 1 (0.49)         | 0          | 2(0.3%6)      |
| Blood cnd lyuphatic systemdisorders                                                    | 32(13.296) | 33(11.796)       | 27(26.2%)  | 92(14.696)    |
| Neutropenia                                                                            | 5(2.196)   | 29 (10.29)       | 24 (23.3%) | 58(9.29)      |
| Thrombocytovenia                                                                       | 28(11.59)  | 5(1.89)          | 9(8.7%)    | 42(6.796)     |
| Febrile neutropenia                                                                    | 3(1.296)   | 4(1.496)         | 3(2.9%)    | 10 (1.6%)     |
| Anaemia                                                                                | 2(0.8%)    | 2(0.796)         | 4(3.9%)    | (%%1)8        |
| Leukopenia                                                                             | 0          | 1(0.496)         | 3(2.9%)    | 4(0.6%)       |
| Gastroiutestinaldisorders                                                              | 9(3.7%)    | 12(4.2%)         | (%0D)1     | 22(3.596)     |
| Diarrhoea                                                                              | 5(2.19)    | 7(2.5%)          | (0D1       | 13(2.1%)      |
| Nausea                                                                                 | 0          | 2(0.796)         | 0          | 2(0.3%)       |
| Voniting                                                                               | 0          | 2 (0.7%)         | 0          | 2(0.39)       |

<div style=\"page-break-after: always\"></div>

| Generaldisorders and administration site conditions   | 7(2.9%)   | 13(4.6%)   | 2(1.9%)   | 22(3.59)   |
|-------------------------------------------------------|-----------|------------|-----------|------------|
| Pyrexia                                               | 5(2.1%)   | 7(2.59)    | 2(1.9%)   | 14(229)    |
| Asthenia                                              | 0         | 3(1.196)   | 0         | 3(0.5%)    |
| Fatigue                                               | 1(0.4%)   | 2(0.796)   | 0         | 3(0.59)    |
| Influenza lke illness                                 | 1(0.4%6)  | 1(0.496)   | 0         | 2(0.39)    |
| Respiratory,thoracicand mediastinal disorders         | 5(2.196)  | 2(0.796)   | 5(4.9%)   | 12 (1.9%)  |
| Dyspnoea                                              | 1(0.496)  | 1(0.496)   |           | 4(0.6%)    |
| Cough                                                 | 1(0.49)   | 1 (0.496)  | 1(1.0%)   | 3(0.5%)    |
| Investigations                                        | 2(0.896)  | 4(1.49)    | 4(3.9%)   | 10 (1.69)  |
| Alanine aminotransferase increased                    | 1(0.49)   | 3(1.19)    | (%60D1    | 5(0.8%)    |
| Aspartate aminotransferase Lncreased                  | 0         | 2(0.796)   |           | 4(0.6%)    |
| Blood alkaline phosphatase increased                  | 0         | 2(0.79)    | 1(1.0%)   | 3(0.59)    |
| Blood creatinine increased                            | 1(0.496)  | 0          | 1(1.0%)   | 2(0.396)   |
| Gamma-glutamyltransferase increased                   | 1(0.4%)   | 1 (0.49)   | 0         | 2(0.396)   |
| Nervous system dlisorders                             | 3(1.29)   | 3(1.196)   | 4(3.0%)   | 10 (1.69)  |
| Peripheral sensory neturopathy                        | 1(0.4%)   | 0          | 1(1.0%)   | 2(0.396)   |
| Syacope                                               | 0         | 1 (0.49)   | (%60D1    | 2(0.396)   |
| Metabolism and mtrition disorders                     | 2(0.896)  | 2(0.796)   | 3(2.9%)   | 7(1.19)    |
| Hyperglycaemia                                        | 1(0.496)  | 1 (0.49%6) | 0         | 2(0.39)    |
| Skin and subcutameous tissue disorders                | 0         | 4(1.496)   | 2(1.9%)   | (60D）)9    |
| Rash generalised                                      | 0         | 1 (0.496)  | 1(1.0%)   | 2(0.396)   |
| Hepatobiliary disorders                               | 0         | 2(0.796)   |           | 4(0.6%)    |
| Hyperbilirubinnemia                                   | 0         | 1(0.496)   | 2(1.9%)   | 3(0.59)    |
| Musculoskeletal and connectivetissue disorders        | 2(0.896)  | 2(0.796)   | 0         | 4(0.6%)    |
| Renal and urinary disorders                           | 2(0.896)  | 2(0.796)   | 0         | 4(0.69)    |
| Acute kidney injury                                   | 2(0.896)  | 1(0.496)   | 0         | 3(0.59)    |

Key.D=Daratmumb,Vd=bortezomib-dexamethasone,Rd=lenalidomide-dexamethasone,Pd=pomelidomide-dexamethasone

Keys:TEAE=teatment-emergent adverse event.

Tnfusionmodification prior to infusion stait includes infision skippingordelay.

GEN503isexcludedfromthis summaryas it did notcollectdosedelay and dose skipinformation

Note: Adverse events are reported using MedDRA version 18.0.

Note:Percentagesarecalculated with thenumber of subjects in eachgroup asdenominator.

## Post marketing experience

A cumulative review was performed on all post-marketing spontaneous cases of daratumumab and all events received by the MAH and entered into global safety database cumulatively through 15 May 2016. The results suggest that the drug's post-marketing safety profile is consistent with the known safety profile of daratumumab as a single agent indicated for the treatment of patients with relapsed and refractory multiple myeloma.

The search of the global safety database retrieved a total of 289 cases. Of these, 266 were further analyzed. Among the 266 cases, 138 were serious and 128 were non serious. Of the cases reporting patient sex, 52% (93/179) concerned males. The patients ranged in age from 38 to 88 years (mean age 64.4 years, median age 65 years). The outcome was non-fatal in majority of the cases (92.1%; 245/266).

Review of the serious cases (n=138), which reported 366 events, revealed that the following 4 events were reported with greatest frequency: IRRs (9.6%; 35/366), dyspnoea (4.4%; 16/366), death (4.1%; 15/366) and decreased platelet count/thrombocytopenia (5.2%; 19/366). In many of the cases, the reported events are consistent with listed events in the company core data sheet for daratumumab.

Of the 138 serious cases reviewed, event outcome was fatal in 21 cases, in 13 cases the cause of death was unspecified and in 8 cases, the fatal MedDRA PTs reported were: death, pancytopenia, plasma cell myeloma, and  sepsis  (reported  twice  each);  acute  respiratory  failure,  asthenia,  cardiac  disorder,  cardiac  failure congestive,  central  nervous  system  necrosis,  cerebrovascular  accident,  disease  progression,  febrile neutropenia, leukocytosis, leukoencephalopathy, metabolic acidosis, plasmablastic lymphoma, tachycardia, and tachypnoea (reported once each).

## 2.5.1. Discussion on clinical safety

Safety  data  from  a  total  of  1182  subjects  were  collected  in  order  to  evaluate  the  safety  profile  of daratumumab  together  with  standard  background  therapy,  664  subjects  received  daratumumab  in combination with standard background therapies and 518 subjects received background therapies alone.

<div style=\"page-break-after: always\"></div>

The proposed treatment dose applied (16 mg/kg) corresponds to the treatment dose of the majority of subjects included in the studies. Long term data (&gt;6 months) was obtained from 141/243 subjects in the DVd group and 282/318 subjects in the DRd group, including a total of 158 subjects who received treatment for more than a year. The number of exposed subjects and degree of exposure is considered sufficient to evaluate the safety of daratumumab in combination with the background therapies.

The majority of subjects in the studies experienced AEs. Most notably, infusion related reactions were common and justify the recommendation of pre- and post-infusion steroid treatment. Other frequently occurring  AEs  were  fatigue,  nausea,  anaemia,  neutropenia,  thrombocytopenia,  upper  respiratory  tract infection, diarrhoea and peripheral sensory neuropathy.

The TEAEs reported for subjects in the daratumumab+ background group were similar to those reported in the background group, and included known toxicities of lenalidomide/bortezomib and those of daratumumab as  monotherapy.  In  the  daratumumab+lenalidomide+dexamethssone  (DRd  and  Rd)  group,  the  most commonly  reported  TEAEs  were:  neutropenia,  diarrhea,  fatigue,  upper  respiratory  tract  infection,  and anemia. Neutropenia was more often observed as a TEAE in the DRd group compared with the Rd group (DRd: 59%; Rd: 43%) particularly in the first 2 cycles of treatment (DRd: 48%; Rd: 26%) and in subjects ≥ 65 years (DRd: 60%, Rd: 41%). This difference could be due to a more frequent dosing of daratumumab treatment during this period. For the daratumumab+bortezimib+dexamethasone (DVd and Vd) group, the most commonly reported TEAEs were: thrombocytopenia, peripheral sensory neuropathy, anemia, and fatigue. Peripheral neuropathy is a well-known adverse effect due to bortezomib, this may also be affected by comorbidities or underlying multiple myeloma.

Grade 3 and 4 adverse events seemed to be higher in the DVd group (76% and versus 62%, respectively). This increase in Grade 3 or 4 TEAEs was mainly due to haematologic TEAEs as thrombocytopenia (45% versus 33%), neutropenia (13% versus 4%) and lymphopenia (10% versus 3%) and was more prominent in early cycles of the treatment. However the incidence of bleeding was low during the study (DVd: 7%; Vd: 4%). The cytopenias are more prominent in the early cycles of treatment.

Infusion-related reactions are usually associated with administration of daratumumab. The TEAE terms used to describe IRRs and the timing of the IRRs with respect to the start of the daratumumab infusion were consistent with the IRRs previously reported for daratumumab in monotherapy studies. Most IRRs were Grade 1 or 2 and were experienced on Day 1 of the first infusion of daratumumab. In the MMY3003 and MMY3004 studies, IRRs were reported in 48% and 45% of subjects respectively in the daratumumab+lenalidomide+dexamethasone (DRd) and the daratumumab+bortezomib+dexamethasone studies (DVd). Few subjects discontinued daratumumab due to IRRs, 1 subject in the DRd group, and 2 in the DVd group.

Infections and infestations, a common problem in the treatment of patients with multiple myeloma, were reported in 83% of subjects in the DRd group vs. 73% in the Rd group, and 68% in the DVd group vs. 53% in the Vd group. However the incidence of grade 3 or 4 infections was the same between the treatment groups, both in the DRd/Rd group (28% and 23% respectively) and in the DVd/Vd groups (21% and 19% respectively). The majority of infections were mild (Grade 1 or 2) and did not require hospitalization. The most common infections were respiratory disorders such as upper respiratory tract infection, bronchitis, sinusitis, or nasopharyngitis, which were common across all regimens.

Daratumumab may increase neutropenia and thrombocytopenia induced by background therapy. Complete blood cell counts should be monitored periodically during treatment according to manufacturer's prescribing information for background therapies. Patients with neutropenia should be monitored for signs of infection. Daratumumab  delay  may  be  required  to  allow  recovery  of  blood  cell  counts.  No  dose  reduction  of daratumumab is recommended. Supportive care with transfusions or growth factors should be considered (SmPC section 4.4). Based on the above, both neutropenia and thrombocytopenia have been classified as important identified risks in the Risk Management Plan (RMP).

<div style=\"page-break-after: always\"></div>

Patients treated with daratumumab combination therapy (n = 299) were evaluated for anti-therapeutic antibody responses to daratumumab at multiple time points during treatment and up to 8 weeks following the end of treatment. Following the start of daratumumab treatment, 2 (0.7%) of the combination therapy patients tested positive for anti daratumumab antibodies; 1 of the combination therapy patients developed transient neutralizing antibodies against daratumumab (SmPC section 5.1).

Daratumumab binds to CD38 found at low levels on red blood cells (RBCs) and may result in a positive indirect Coombs test. Daratumumab mediated positive indirect Coombs test may persist for up to 6 months after the last daratumumab infusion. It should be recognised that daratumumab bound to RBCs may mask detection of antibodies to minor antigens in the patient's serum. The determination of a patient's ABO and Rh blood type are not impacted. Patients should be typed and screened prior to starting daratumumab treatment. Phenotyping may be considered prior to starting daratumumab treatment as per local practice. Red blood cell genotyping is not impacted by daratumumab and may be performed at any time. In the event of  a  planned  transfusion  blood  transfusion  centres  should  be  notified  of  this  interference  with  indirect antiglobulin tests. If an emergency transfusion is required, non-cross matched ABO/RhD compatible RBCs can be given per local blood bank practices (SmPC, sections 4.4 and 4.5). Educational materials will be distributed to Health Care Professionals (HCPs) and blood banks to advise on the risk of and solutions for interference for blood typing. Patient ID cards will be distributed to increase awareness to patients about the interference of blood typing occurring with daratumumab. A survey to measure awareness of blood banks and HCPs on the interference of blood typing is requested and results are expected to be provided in the PSUR (please see RMP section 2.6).

No subjects in DVd, Vd, or DPd groups had an AE of QT prolongation. QT prolongation was reported as an AE for 6 subjects (2%) in the DRd group and 1 subject (0.4%) in the Rd group. QT prolongation has been added as an important potential risk and the secondary objective of study SMM2001 which is a randomised Phase 2 trial to evaluate 3 daratumumab dose schedules in smouldering multiple myeloma, is to determine if daratumumab has an effect on QT interval. The study results are expected to be submitted by the end of 2018 (please see RMP section 2.6).

Discontinuations from treatment (2% to 5%) and deaths (0.8% to 2%) due to infection were rare and balanced between groups.

Pneumonia occurred in 11% to 13% of the study population and was the most commonly reported, severe (Grade 3 or 4) infection (7% to 10%) and also the most commonly reported serious infection (7% to 9%). The occurrence of pneumonia was balanced between treatment groups, and did not result in a high rate of treatment discontinuations (DRd/DVd: 3 subjects in each group, Rd/Vd: 2/1 subjects) or deaths (DRd/DVd: 2/1 subjects, Rd/Vd: 2 subjects in each group). The rate of opportunistic infections across all groups was generally low.

Dose modifications of daratumumab typically were dose delays or skipped doses prior to the start of an infusion. In the DVd group, 36% of subjects had modifications to daratumumab dosing, the 2 most common TEAEs  were  thrombocytopenia  (12%)  and  pneumonia  (5%).  In  the  DRd  group  37%  of  subjects  had modifications to daratumumab dosing, the 2 most common TEAEs were neutropenia (10%) and pneumonia (4%).

The tolerability of the DRd combination is supported by the low frequency of study treatment discontinuation due to TEAEs (DRd 7%, Rd 8%) and the DVd combination, DVd 7% and Vd 9% respectively).

Both bortezomib and lenalidomide increase the risk of herpes zoster reactivation, but despite prophylactic antiviral therapy was administered; herpes zoster was reported in some of the subjects. However not all subjects received prophylactic antiviral treatment. The incidence of herpes zoster reactivation was low and balanced between treatment groups. Although small numbers, herpes zoster reactivation was lower in subjects who received prophylactic treatment than in those who did not. This is reflected in the SmPC.

<div style=\"page-break-after: always\"></div>

Peripheral neuropathy which is a well-known adverse effect due to bortezomib and also might be due to underlying disease was reported in 46% of the DVd group and 38% in the Vd group. The MAH analysed possible risk factors of peripheral neuropathy, in conclusion, the higher rate of peripheral neuropathy was due to longer exposure to bortezomib, but factors such as prior history of peripheral neuropathy, diabetes mellitus,  prior  exposure  to  thalidomide  and  older  age  might  potentially  contribute  to  the  symptoms, although no statistical significant difference was noted.

Overall the frequency of severe AEs is considered acceptable. Of note, 21/138 patients died, and it may be questioned whether this number is higher than expected. It is endorsed, that the patient population was heavily pretreated with refractory/relapsed disease. The MAH has reviewed the post marketing data for the cause of death as reported in spontaneous reports, 18 deaths among 2711 patients/months exposure were reported. A detailed analysis of fatal TEAEs showed that cause of death could be attributed to end stage disease or events associated with the underlying malignant disease, eg. infection and multi-organ failure. Thus the numbers of death are not higher than what could be expected in this clinical setting.

Blood samples from the study participants were analysed for anti-daratumumab antibodies. In 2 out of 298 evaluable patients anti-daratumumab antibodies were detected, however the titer for the positive samples (1:20) demonstrated detection only at the minimum required dilution of the method, and thus was near the lower limit of the antidaratumumab antibody detection method. In order to improve the immunogenicity method's  ability  to  detect  anti-daratumumab  antibodies  in  the  presence  of  high  trough  levels  of daratumumab, a study has been requested for which study results are expected by the end of 2018 (please see RMP section 2.6).

No drug-drug interaction studies were performed. However, as daratumumab is an IgG, renal excretion and hepatic enzyme-mediated metabolism is considered unlikely.

## 2.5.2. Conclusions on clinical safety

Based  on  data  from  664  subjects  included  in  the  pivotal  and  supportive  studies,  the  safety  profile  is consistent with the known  toxicities  of  the  respective  background  therapies  and  daratumumab monotherapy.  Daratumumab  may  increase  the  rate  of  cytopenias  known  to  be  associated  with  each background  therapy  (neutropenia  with  lenalidomide  or  pomalidomide  and  thrombocytopenia  with bortezomib). However they appeared to be manageable by supportive care and dose modifications, and did not  result  in  an  increase  in  discontinuation  of  study  treatments  or  deaths.  Both  neutropenia  and thrombocytopenia have been classified as important identified risks in the Risk Management Plan (RMP).

Thus, overall daratumumab in combination with standard background therapies as lenalidomide+dexamethasone and bortezomib+dexamethasone is well tolerated, with a manageable side effect profile.

## 2.5.3. PSUR cycle

The PSUR cycle remains unchanged.

## 2.6. Risk management plan

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 2.0 could be acceptable if the applicant implements the changes to the RMP as described in the PRAC endorsed PRAC Rapporteur assessment report.

<div style=\"page-break-after: always\"></div>

The CHMP endorsed the Risk Management Plan version 2.1 with the following content, as per PRAC advice:

## Safety concerns

Table 46. Summary of Safety Concerns

| Important Identified Risks   | Important Identified Risks                                                     |
|------------------------------|--------------------------------------------------------------------------------|
|                              | Infusion Related Reactions (IRRs)                                              |
|                              | Interference for blood typing (minor antigen) (Positive Indirect Coombs' test) |
|                              | Neutropenia                                                                    |
|                              | Thrombocytopenia                                                               |
| Important Potential Risks    | Important Potential Risks                                                      |
|                              | Infections                                                                     |
|                              | Prolonged decrease in NK cells                                                 |
|                              | QTc prolongation                                                               |
|                              | Immunogenicity                                                                 |
|                              | Intravascular haemolysis                                                       |
| Missing Information          | Missing Information                                                            |
|                              | Use in pregnancy and lactation                                                 |
|                              | Reproductive and developmental toxicity                                        |
|                              | Use in the elderly ≥75 years                                                   |
|                              | Use in patients with moderate or severe hepatic impairment                     |
|                              | Long term use (>2 years)                                                       |

<div style=\"page-break-after: always\"></div>

## Pharmacovigilance plan

## Table 47. Summary of the Pharmacovigilance Plan

| Study/activity type, title and category (1-3)                                                                                    | Objectives                                                                                                                             | Safety concerns addressed                                                      | Status (planned, started)   | Date for submission of interim or final reports (planned or actual)                                                                                                                                                   |
|----------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|-----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Survey of additional risk minimisation measures for interference of blood typing (category 3)                                    | To measure awareness of blood banks and HCPs on the interference of blood typing                                                       | Interference for blood typing (minor antigen) (Positive Indirect Coombs' test) | Planned                     | Protocol to be submitted: 3 months after EC decision Initial evaluation: 18 months following the launch of the product Final Report: Final results will be presented in the next PSUR/PBRER after the survey has been |
| Trial SMM2001: A randomised Phase 2 trial to evaluate 3 daratumumab dose schedules in smouldering multiple myeloma. (category 3) | As a secondary objective to determine if daratumumab has an effect on QT interval                                                      | Effect of daratumumab on QT interval                                           | Started                     | 4 th Quarter 2018                                                                                                                                                                                                     |
| Investigate new method for detecting antidrug antibodies (category 3)                                                            | Improve the immunogenicity method's ability to detect anti-daratumumab antibodies in the presence of high trough levels of daratumumab | Immunogenicity                                                                 | Planned                     | 4 th Quarter of 2018                                                                                                                                                                                                  |

## Risk minimisation measures

Table 48. Summary table of risk minimisation measures

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                                 | Routine Risk Minimisation Measures   | Additional Risk Minimisation Measures                                                                                                                                                                                                                                                                   |
|--------------------------------------------------------------------------------|--------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks:                                                    | Important identified risks:          |                                                                                                                                                                                                                                                                                                         |
| Infusion Related Reactions (IRRs)                                              | SmPC sections 4.2, 4.4, 4.8          | None                                                                                                                                                                                                                                                                                                    |
| Interference for blood typing (minor antigen) (Positive Indirect Coombs' test) | SmPC section 4.4                     | Educational materials will be distributed to HCPs and blood banks to advise regarding the risk of and solutions for interference for blood typing. As well as patient ID cards will be distributed to increase awareness to patients about the interference of blood typing occurring with daratumumab. |
| Neutropenia                                                                    | SmPC sections 4.4 and 4.8            | None                                                                                                                                                                                                                                                                                                    |
| Thrombocytopenia                                                               | SmPC section 4.4 and 4.8             | None                                                                                                                                                                                                                                                                                                    |
| Important potential risks:                                                     | Important potential risks:           |                                                                                                                                                                                                                                                                                                         |
| Infections                                                                     | SmPC section 4.8                     | None                                                                                                                                                                                                                                                                                                    |
| Prolonged decrease in NK cells                                                 | SmPC section 5.1                     | None                                                                                                                                                                                                                                                                                                    |
| QTc prolongation                                                               | SmPC section 5.1                     | None                                                                                                                                                                                                                                                                                                    |
| Immunogenicity                                                                 | SmPC section 5.1                     | None                                                                                                                                                                                                                                                                                                    |
| Intravascular haemolysis                                                       | SmPC section 4.8                     | None                                                                                                                                                                                                                                                                                                    |
| Missing Information:                                                           | Missing Information:                 |                                                                                                                                                                                                                                                                                                         |
| Use in pregnancy and lactation                                                 | SmPC section 4.6                     | None                                                                                                                                                                                                                                                                                                    |
| Reproductive and developmental toxicity                                        | SmPC sections 4.6 and 5.3            | None                                                                                                                                                                                                                                                                                                    |
| Use in the elderly ≥75 years                                                   | SmPC sections 4.2 and 5.2            | None                                                                                                                                                                                                                                                                                                    |
| Use in patients with moderate or severe hepatic impairment                     | SmPC sections 4.2 and 5.2 .          | None                                                                                                                                                                                                                                                                                                    |
| Long term use (>2 years)                                                       | None proposed.                       | None                                                                                                                                                                                                                                                                                                    |

The MAH is reminded that, within 30 calendar days of the receipt of the Opinion, an updated version of Annex

<div style=\"page-break-after: always\"></div>

I of the RMP template, reflecting the final RMP agreed at the time of the Opinion should be submitted to h-eurmp-evinterface@emea.europa.eu.

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.5, 5.1 and 5.2 of the SmPC have been updated. Particularly, a new warning with regard to neutropenia/thrombocytopenia induced by background therapy has been added to the product information. The Package Leaflet has been updated accordingly.

Furthermore, Annex II is updated to reflect on the fulfilment of the specific obligations following submission of the final results of studies MMY3003 and MMY3004. As a consequence, the conditional marketing authorisation is switched to a full marketing authorisation (see section 3.7 and section 4).

## 2.7.1. User consultation

A justification for not performing a new user consultation with target patient groups on the package leaflet has been submitted by the applicant and has been found acceptable for the following reasons:

- The package leaflet included in this current application has the same format as the one previously tested.
- With the proposed indication extension, minimal changes have been introduced to the package leaflet and the proposed changes reflect language and a format that is consistent with that in the currently approved leaflet.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Multiple myeloma is an incurable malignant disorder of the plasma cells, characterised by uncontrolled and progressive proliferation of a plasma cell clone. The median age of patients at diagnosis is 65 years. The abnormal plasma cell proliferation accumulates in the bone marrow, displacing the normal hematopoietic tissue. The plasma cells produce a monoclonal antibody, paraprotein (M-protein and free-light chain), which is an immunoglobulin (Ig) or a fragment of one that has lost its function (Kyle 2009, Palumbo 2011). The normal immunoglobulins (Ig) are compromised leading to increased susceptibility to infections.

## 3.1.2. Available therapies and unmet medical need

Current treatment options for patients with relapsed or refractory multiple myeloma include combination chemotherapy, proteasome inhibitors (PIs; eg, bortezomib, carfilzomib, ixazomib), immunomodulatory agents (IMiDs; eg, thalidomide, lenalidomide, and pomalidomide), histone deacetylase inhibitors (eg, panobinostat); monoclonal antibodies (mAb) (eg, daratumumab and elotuzumab), high-dose chemotherapy, and autologous stem cell transplantation (ASCT).

## 3.1.3. Main clinical studies

The clinical package of daratumumab for the treatment of subjects with relapsed or refractory multiple myeloma is primarily supported by data from 2 pivotal phase 3 randomised open-label studies, MMY3003 and MMY3004, where daratumumab is added to one of two established standard of care background

<div style=\"page-break-after: always\"></div>

regimens. In the MMY3003 study, the efficacy of daratumumab when combined with lenalidomide and low-dose dexamethasone (DRd) was compared with lenalidomide and low-dose dexamethasone (Rd), and in the MMY3004 study, the efficacy of daratumumab when combined with bortezomib and dexamethasone (DVd) was compared with bortezomib and dexamethasone (Vd). Both studies were performed in patients with relapsed or refractory multiple myeloma, who had received at least one prior therapy.

## 3.2. Favourable effects

Study MMY3003 (daratumumab in combination with lenalidomide (DRd) compared with Rd):

Treatment with DRd resulted in a 63% reduction in the risk of disease progression or death compared with Rd alone (HR=0.37; 95% CI: 0.27, 0.52; p&lt;0.0001). The median PFS was not reached for the DRd group and was 18.4 months for the Rd group. The PFS results were consistent among all pre-planned sensitivity analyses and across different clinically relevant pre-specified subgroups, such as number and type of prior lines of therapy, staging, cytogenetic risk group, and whether refractory to last treatment.

The ORR was higher in the DRd group, 93% compared with 76% in the Rd group (p&lt;0.0001).

The rate of VGPR or better was 76% in the DRd group compared with 44% in the Rd group (p&lt;0.0001). Subjects in the DRd group had higher rate of CR or better (43%) compared with the Rd group (19%) (p&lt;0.0001).

More subjects were MRD negative at the 10 -4  threshold who received DRd, 29% compared with those who received Rd, 8% (chi-squared odds ratio 4.85; 95% CI: 2.93, 8.03; p&lt;0.0001).

The 18-month OS rate was 86.1% (95% CI: 79.9, 90.5) in the DRd group and 75.6% (95% CI: 59.8, 85.9) in the Rd group.

Study MMY3004 (daratumumab in combination with bortezomib (DVd) compared with Vd):

Treatment with DVd resulted in a 61% reduction in the risk of disease progression or death compared with Vd (HR=0.39; 95% CI: 0.28, 053; p&lt;0.0001). The median PFS was not reached for the DVd group and was 7.2 months for the Vd group. The PFS result were consistent among all pre-planned sensitivity analyses and across different clinically relevant prespecified subgroups, such as number and type of prior lines of therapy, staging, cytogenetic risk group, and whether refractory to last treatment.

The ORR was higher in the DVd group, 83% compared with 63% in the Vd group (p&lt;0.0001).

The rate of VGPR or better was 59% in the DVd group, compared with 29% in the Vd group (p&lt;0.0001). Subjects in the DVD group had a higher rate of CR or better, 19% vs. 9% in the Vd group (p=0.0012).

More subjects were MRD negative at the 10-4 threshold in the DVd group, 14% compared with 3% in the Vd group (chi-square odds ratio =5.37; 95% CI: 2.33, 12.37; p&lt;0.0001).

The 12-month survival rates were 82% for both treatment groups.

Generally the subgroup analyses and the secondary endpoints support the robustness and clinical meaningfulness of adding daratumumab to standard background therapies as lenalidomide + dexamethasone and bortezomib + dexamethasone.

## 3.3. Uncertainties and limitations about favourable effects

There are no uncertainties and limitations about favourable effects.

<div style=\"page-break-after: always\"></div>

## 3.4. Unfavourable effects

The safety profile of daratumumab in combination with lenalidomide/dexamethasone and bortezomib/dexamethasone was generally consistent with the known safety profiles of daratumumab and the respective background therapies.

Treatment with daratumumab induced a relatively high incidence of IRRs, 47% subjects experienced an IRR, the majority (approximately 95%) occurred during the first infusion and the incidence is reduced during subsequent cycles of treatment. The majority of IRRs are mild (Grade 1 or 2) and no Grade 4 or 5 IRRs occurred. Both acute and delayed onset infusion-related reactions have been observed and for this reason both pre-and post-infusion treatment with steroids is recommended.

Overall, other frequently occurring AEs were: fatigue, nausea, anaemia, neutropenia, thrombocytopenia, upper respiratory tract infection and diarrhoea.

While the incidence of Grade 3 or 4 TEAEs and serious TEAEs was slightly  higher in the daratumumab combination groups, TEAEs were managed by supportive care and dose modifications, and did not result in an increase in discontinuation of study treatments or deaths. Discontinuation of treatment due to TEAEs was low and balanced between treatment groups, the most common cause being infections.

The incidence of death within 30 days of the last dose of study drug was relatively low and balanced between treatment groups, the most common reason was due to infections (1% to 2%).

## 3.5. Uncertainties and limitations about unfavourable effects

Daratumumab may increase the rate of cytopenias known to be associated with each background therapy (neutropenia with lenalidomide or pomalidomide and thrombocytopenia with bortezomib). However they appeared to be manageable by supportive care and dose modifications, and did not result in an increase in discontinuation of study treatments or deaths. Both neutropenia and thrombocytopenia have been classified as important identified risks in the Risk Management Plan (RMP).

## 3.6. Effects Table

Table 49. Effects Table for daratumumab in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy

| Effect                                          | Short Description                                       | Unit                 | Treatment            | Control                             | Uncertainties/ Strength of evidence                                        | References                                                                                    |
|-------------------------------------------------|---------------------------------------------------------|----------------------|----------------------|-------------------------------------|----------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| Favourable Effects                              | Favourable Effects                                      | Favourable Effects   | Favourable Effects   | Favourable Effects                  | Favourable Effects                                                         | Favourable Effects                                                                            |
| PFS                                             | Median time from randomizatio n to progression or death | Months               | DRd NE DVd NE        | Rd 18.4 (13.9,NE) Vd 7.2 (6.2, 7.9) | HR=0.37; 95% CI: 0.27, 0.52; p<0.0001 HR=0.39; 95% CI: 0.28, 053; p<0.0001 | Numbers presented were taken from studies MMY003 and MMY004 (see 'clinical efficacy' section) |
| Unfavourable Effects                            | Unfavourable Effects                                    | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                | Unfavourable Effects                                                       | Unfavourable Effects                                                                          |
| TEAEs of at least 10% in either treatment group |                                                         | %                    | DRd: 98.4 DVd:98.8   | Rd:92.5 Vd:95                       |                                                                            | See 'clinical safety' section                                                                 |

<div style=\"page-break-after: always\"></div>

| Effect                     | Short Description                | Unit   | Treatment       | Control       | Uncertainties/ Strength of evidence        | References   |
|----------------------------|----------------------------------|--------|-----------------|---------------|--------------------------------------------|--------------|
| Infusion Related Reactions | Incidence of grade 3 or 4 events | %      | DRd 5.3 DVd 9   | NA            |                                            |              |
| Neutropenia                | Incidence of grade 3 or 4 events | %      | DRd 52 DVd 12.8 | Rd 37 Vd 4.2  | Increased rate in lenalidomide combination |              |
| Thrombocyt openia          | Incidence of grade 3 or 4 events | %      | DRd 13 DVd 45.3 | Rd 13 Vd 32.9 | Increased rate in bortezomib combination   |              |
| Infections                 | Incidence of grade 3 or 4 events | %      | DRd 28 DVd 21.4 | Rd 23 Vd 19%  |                                            |              |

Abbreviations: Abbreviations: AE: adverse event, CR:Complete response,  DRd: daratumumab-lenalidomide-dexamethasone, DVd :daratumumab-bortezomib-dexamethasone, HR: hazard ratio,  MRD: minimal residual disease,  NE: not evaluable, ORR: overall response rate, PFS: progression-free surviva, PR: Partial response,  Rd: lenalidomide-dexamethasone, Scr: Stringent complete response, TEAEs: treatment-emergent adverse events, Vd: bortezomib-dexamethasone, VGPR: Very good partial response

Data cut-off dates: MMY003: 7 March 2016, MMY004: 11 January 2016.

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The two pivotal studies demonstrated a positive effect on PFS. This endpoint and the effects observed are considered clinically significant, when compared to background therapies alone. The effects are convincing and supported by secondary endpoints including response rate and MRD negativity. Although mature OS data are still not available it is reasonable to exclude a possible detrimental effect. Overall, the effect observed in PFS is sufficient to establish the efficacy of the combination of daratumumab, lenalidomide and dexamethasone, and of the combination daratumumab, bortezomib, and dexamethasone in the proposed indications.

The safety profile is as expected in the context of the patient population and for standard background anti-myeloma therapies and manageable.

## 3.7.2. Balance of benefits and risks

The efficacy of daratumumab in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone in the target population is considered clinically relevant and, in the view of the manageable, and consistent with the known safety profile of daratumumab and the two background therapies, the benefits are considered to outweigh the combined risks.

## Additional considerations on the benefit-risk balance

The initial marketing authorisation application for Darzalex was based on an ORR of 29% obtained with daratumumab in pivotal study MMY2002. This effect was considered significant and clinically relevant in patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last

<div style=\"page-break-after: always\"></div>

therapy despite the absence of confirmatory controlled data. Patients were heavily pretreated, and 79.8% and 69.4% had received more than 3 lines of prior therapy in the MMY2002 and GEN501 studies respectively, further 95% and 95.8% respectively were refractory to both PI's and IMiD's. Together with an acceptable safety-profile in patients in the proposed indication, the benefit-risk balance was considered positive. However, there was a need to provide controlled data in a larger target population within the same condition in order to further define the benefit-risk of daratumumab in the initial indication as follows:

-  In order to address the uncertainties related to the single arm design of the pivotal study supporting the approval of Darzalex, the MAH should submit the results of study MMY3003, a phase III randomised study investigating lenalidomide and dexamethasone with or without daratumumab in patients with previously treated multiple myeloma.
-  In order to address the uncertainties related to the single arm design of the pivotal study supporting the approval of Darzalex, the MAH should submit the results of study MMY3004, a phase III randomised study investigating bortezomib and dexamethasone with or without daratumumab in patients with previously treated multiple myeloma.

With the current application, given the convincing effect and manageable safety profile, comprehensive clinical data has been provided to confirm efficacy and safety of daratumumab in the initial indication. Even if Study MMY 3003 and Study MMY 3004 were conducted in combination, the results are relevant in view of the overlapping populations and the design of the study allows assess the effect of daratumumab in the studied combinations.

In conclusion, the controlled data confirm the efficacy and safety of daratumumab monotherapy, and that the risk-benefit balance of daratumumab in the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy is favourable.

## 3.8. Conclusions

The overall B/R of daratumumab in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy is positive.

In conclusion, the controlled data of studies MMY3003 and MMY3004 confirm the efficacy and safety of daratumumab monotherapy, and that the risk-benefit balance of daratumumab in the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy is favourable. The CHMP agreed on the fulfilment of the specific obligations.

## 4. Recommendations

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Darzalex is not similar to Thalidomide Celgene, Revlimid, Imnovid, Farydak, Kyprolis and Ninlaro within the meaning of Article 3 of Commission Regulation (EC) No. 847/200. See appendix 1.

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends by consensus the variation to the terms of the Marketing Authorisation, concerning

<div style=\"page-break-after: always\"></div>

the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of Indication for Darzalex in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 5.1 and 5.2 of the SmPC are updated in order to update the information on the target patient population, posology, warnings, interactions, efficacy and pharmacokinetics. A new warning is introduced in section 4.4 regarding neutropenia/thrombocytopenia induced by background therapy.

Furthermore, the CHMP is of the opinion that all specific obligations have been fulfilled following submission of the final results of studies MMY3003 and MMY3004 and in light of the data generated and the evidence of compliance with the specific obligations, the CHMP recommends the granting of a marketing authorisation in accordance with Article 14(1) of Regulation No 726/2004.

The Package Leaflet and Risk Management Plan (RMP version 2.1) are updated in accordance.

In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.

As a result of the fulfilment of the specific obligations, they are removed from the Annex II:

| Description                                                                                                                                                                                                                                                                                                                                         | Due date          |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| In order to address the uncertainties related to the single arm design of the pivotal study supporting the approval of DARZALEX, the MAH should submit the results of study MMY3003, a phase III randomised study investigating lenalidomide and dexamethasone with or without daratumumab in patients with previously treated multiple myeloma.    | 30 September 2017 |
| In order to address the uncertainties related to the single arm design of the pivotal study supporting the approval of DARZALEX, the MAH should submit the results of study MMY3004, a phase III randomised study investigating bortezomib and dexamethasone with or without daratumumab in patients with previously treated multiple myeloma. 2016 | 31 December       |

The variation leads to amendments to the Summary of Product Characteristics, Annex II and Package Leaflet and to the Risk Management Plan (RMP).

This CHMP recommendation is subject to the following conditions, amended to reflect on the deletion of the above table from the Annex II.E:

## Conditions and requirements of the marketing authorisation

##  Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation.

<div style=\"page-break-after: always\"></div>

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## · Risk management plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

-  At the request of the European Medicines Agency;
-  Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## · Additional risk minimisation measures

Prior to the launch of Darzalex (daratumumab) in each Member State (MS) the Marketing Authorisation Holder (MAH) must agree about the content and format of the educational materials, aiming at increasing awareness about the Important Identified Risk of 'Interference for blood typing (minor antigen) (Positive Indirect Coombs' test)' and providing guidance on how to manage it.

The MAH shall ensure that in each MS where Darzalex (daratumumab) is marketed, all HCPs and patients who are expected to prescribe, dispense and receive this product have access to/are provided with the below.

## The HCPs and Blood Banks educational materials , shall contain the following key elements:

-  The guide for HCPs and Blood Banks, to advice about the risk of interference for blood typing and how to minimise it;
-  The Patient Alert Card.

The Guide for HCP and Blood Banks shall contain the following key elements:

-  All patients should be typed and screened prior to start treatment with daratumumab; alternatively, phenotyping may also be considered;
-  Daratumumab-mediated positive indirect Coombs test (interfering with cross-matching of blood) may persist for up to 6 months after the last product's infusion, therefore, the HCP should advise the patient to carry the Patient Alert Card until 6 months after the treatment has ended;
-  Daratumumab bound to Red Blood Cells (RBCs) may mask the detection of antibodies to minor antigens in the patient's serum;
-  The determination of a patient's ABO and Rh blood type are not impacted;
-  The interference mitigation methods include treating reagent RBCs with dithiothreitol (DTT) to disrupt daratumumab binding or other locally validated methods. Since the Kell Blood group system is also sensitive to DTT treatment, Kell-negative units should be supplied after ruling out or identifying alloantibodies using DTT-treated RBCs. Alternatively, genotyping may also be considered;
-  In case of urgent need for transfusion, non-cross matched ABO/RhD compatible RBC units can be administered as per local bank practices;
-  In the event of a planned transfusion, the HCPs should notify blood transfusion centres about the interference with indirect antiglobulin tests;
-  Reference to the need to consult the Summary of Product Characteristics (SmPC);
-  Reference to the need of giving the Patient Alert Card to the patients and to advise them to consult the Package Leaflet (PL).

<div style=\"page-break-after: always\"></div>

The Patient Alert Card , shall contain the following key elements:

-  A warning message for HCPs treating the patient at any time, including in conditions of emergency, that the patient is using Darzalex (daratumumab), and that this treatment is associated with the Important Identified Risk of Interference for blood typing (minor antigen) (Positive Indirect Coombs' test), which might persist for up to 6 months after the last product's infusion, and a clear reference that the patient should continue to carry this card until 6 months after the treatment has ended;
-  Contact details of the Darzalex (daratumumab) prescriber;
-  Reference to the need to consult the Package Leaflet (PL).

These conditions fully reflect the advice received from the PRAC.

## Additional market protection

Furthermore, the CHMP reviewed the data submitted by the MAH, taking into account the provisions of Article 14(11) of Regulation (EC) No 726/2004, and considers by consensus that the new therapeutic indication brings significant clinical benefit in comparison with existing therapies (see appendix 2).

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Extension of Indication for Darzalex in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 5.1 and 5.2 of the SmPC are updated in order to update the information on the target patient population, posology, warnings, interactions, efficacy and pharmacokinetics. A new warning is introduced in section 4.4 regarding neutropenia/thrombocytopenia induced by background therapy.

Furthermore, the CHMP is of the opinion that all specific obligations have been fulfilled following submission of the final results of studies MMY3003 and MMY3004 and in light of the data generated and the evidence of compliance with the specific obligations, the CHMP recommends the granting of a marketing authorisation in accordance with Article 14(1) of Regulation No 726/2004. Annex II is updated to remove the fulfilled specific obligations.

The Package Leaflet and Risk Management Plan (RMP version 2.1) are updated in accordance. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.

## Summary

Please refer to the Scientific Discussion Darzalex EMEA/H/C/004077/II/0002.

## REFERENCES

Kyle RA, Rajkumar SV 2009,  Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma. 2009 Aug; 9(4):278-88

<div style=\"page-break-after: always\"></div>

Palumbo A, Anderson K, Multiple Myeloma N Engl J Med 2011; 364:1046-60.

Kyle RA, Gertz MA, Witzig TE, et al.  2003   Review of 1027 Patients With Newly Diagnosed Multiple Myeloma. Mayo clin Proc. 2003; 78(1):21.

Sonneveld  P,  Verelst  SG,  Lewis  P,  et  al.  Review  of  health-related  quality  of  life  data  in  multiple myelomapatients treated with novel agents. Leukemia 2013; 27: 1959-1969.

## Appendix

CHMP AR on the novelty of the indication/significant clinical benefit in comparison with existing therapies dated 23 February 2017

<div style=\"page-break-after: always\"></div>

<!-- image -->

23 February 2017 EMA/CHMP/112064/2017 Committee for Medicinal Products for Human Use (CHMP)

CHMP assessment report on the significant clinical benefit in comparison with existing therapies in accordance with Article 14(11) of Regulation (EC) No 726/2004

Invented name: Darzalex

International non-proprietary name: Daratumumab

Procedure no.: EMEA/H/C/004077/II/0002

Marketing authorisation holder (MAH): Janssen-Cilag International N.V.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## 1. Introduction

In accordance with the provisions of Article 14(11) of Regulation (EC) No 726/2004, Marketing authorisation holder (MAH) Janssen-Cilag International N.V. has applied for an additional one year marketing protection period in the framework of Darzalex procedure (EMEA/H/C/004077/II/0002).

The request  was  based  on  the  MAH's  position  that  Darzalex  represents  a  significant  clinical  benefit  in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy in comparison with existing therapies.

## 2. Justification of significant clinical benefit as presented by the MAH

## 2.1. Demonstration of new therapeutic indication

A conditional marketing authorization was approved by the European Commission on 20 May 2016 for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) and who have demonstrated disease progression on the last therapy.

The Marketing Authorisation Holder (MAH) is now seeking to expand the indication for daratumumab based primarily on data from 2 comparator controlled Phase 3 studies: MMY3003 (daratumumab plus lenalidomide and dexamethasone) and MMY3004 (daratumumab plus bortezomib and dexamethasone). Based on results from these trials, the MAH is seeking to update the indication to include the treatment of subjects with DARZALEX in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone with relapsed or refractory multiple myeloma who have received at least one prior therapy.

In accordance with the reference to Article 14(11) of Regulation (EC) No 726/2004, the applicant wishes to claim an additional one year of marketing protection as the new therapeutic  indication for daratumumab (DARZALEX  is  indicated  in  combination  with  lenalidomide  and  dexamethasone,  or  bortezomib  and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy) represents a significant clinical benefit in comparison with existing therapies.

## 2.2. Details of existing therapies

Please see below

## 2.3. Significant clinical benefit based on improved efficacy

The  treatment  of  multiple  myeloma  has  emerged  covering  a  number  of  treatment  options,  such  as proteasome  inhibitors  (PIs):  bortezomib,  carfilzomib,  ixazomib;  immunomodulatory  drugs  (IMiDs): thalidomide, lenalidomide, and pomalidomide; histone deacetylase (HDAC) inhibitors such as panobinostat, as well as monoclonal antibodies (mAb) such as Elotuzumab.

For the treatment of relapsed or refractory multiple myeloma, strategies involving PIs or IMiDs used in combination with a steroid have become the standard of care treatment because they have demonstrated good clinical efficacy along with acceptable and manageable safety profiles.

## Immunomodulatory Agents

Two agents in particular (lenalidomide and pomalidomide), have been used to treat patients with relapsed or refractory multiple myeloma, especially patients who are bortezomib-refractory or intolerant. Progression-free survival from 2 phase 3 trials of lenalidomide and high dose dexamethasone (RD) versus dexamethasone alone (D) demonstrated a PFS of approximately 11 months for RD and 4.7 months for D (Weber et al. 2007). Clinical studies of lenalidomide and low-dose dexamethasone (Rd) compared to RD, showed a survival advantage and a significantly reduced toxicity profile compared with the RD treatment

<div style=\"page-break-after: always\"></div>

(Rajkumar  et  al.  2010).  Toxicity  associated  with  the  Rd  combination  are  myelosuppression  and thromboembolic events, which are usually manageable (Latif et al. 2012). Rd therefore became one of the standard options for patients with multiple myeloma.

Pomalidomide as a single agent has a low anti-myeloma activity, but in combination with dexamethasone (Pd) to patients with relapsed or refractory multiple myeloma (≥2 prior therapies, including lenalidomide andbortezomib), the clinical outcome was improved. The PFS was prolonged, 4.2 months vs. 2.7 months for pomalidomide alone and the response rates were 33% vs 18%, respectively (Richardson 2014). After a median  follow-up  of  10.0  months  in  a  separate  Phase  3  study  which  compared  Pd  to  high-dose dexamethasone, the median PFS for Pd was 4·0 months versus 1·9 months for highdose dexamethasone (HR=0·48 [95% CI 0·39-0·60]; p&lt;0·0001). (SanMiguel 2013).

Similar to lenalidomide, the manageable toxicity risks of pomalidomide include thromboembolic events and myelosuppression and also neutropenia (including febrile neutropenia) infection, anemia, and thrombocytopenia.

## Proteasome Inhibitors

Three agents in particular (bortezomib, carfilzomib and ixazomib), have been used to treat patients with relapsed or refractory multiple myeloma. The bortezomib-dexamethasone (Vd) combination is widely used and has yielded ORRs of 62% to 70% (Dimopoulous 2015, Kropff 2005) compared with 38% to 50% when bortezomib was administered as a single-agent (Jagannath 2004, Orlowski 2007). In a Phase 3 study of Vd versus dexamethasone, the PFS was 6.2 months and 3.5 months respectively.

Retreatment of bortezomib in subjects previously exposed to bortezomib who now have relapsed disease demonstrated a 40% ORR (Petrucci 2013). Toxicities associated with bortezomib use include peripheral neuropathy, hematologic toxicities, diarrhea, fatigue, dyspnea, and zoster reactivation (Merin 2014).

Carfilzomib  administered  in  combination  with  lenalidomide  and  dexamethasone  (KRd)  resulted  in significantly  improved  PFS  (26.3  months)  compared  with  Rd  alone  (17.6  months)  (HR=0.69)  (Stewart 2015). The ORR was 87% vs 67% in the KRd vs Rd groups, respectively, with 38% and 9% of patients having a CR or better, and 14% and 4% of patients, respectively, having a stringent CR (sCR). Separately, carfilzomib administered in combination with dexamethasone (Kd) resulted in significantly improved PFS (18.7 months) compared with bortezomib and dexamethasone (Vd, 9.4 months) (HR=0.53) (Dimopoulos 2016).  The  percentage  of  patients  having  a  CR  or  better  was  11%  and  4%  in  the  Kd  vs  Vd  groups, respectively, with 2% of patients in each group having a stringent CR. Hematologic toxicities, pneumonia, hyponatremia, fatigue, hypophosphatemia, infusion reactions, chest pain, and heart failure are common toxicities associated with carfilzomib (Merin 2014). Carfilzomib product labels carry a warning due to risk of cardiac  arrest,  congestive  heart  failure,  myocardial  ischemia,  sudden  cardiac  death  and  pulmonary hypertension (Kyprolis Product Information).

Ixazomib is an oral PI, when administered in combination with Rd, PFS was 20.6 months compared to 14.7 months when compared with Rd alone [HR=0.74]); ORR was 78% vs 72%, respectively, with 48% and 39% of patients, respectively achieving VGPR or better (Moreau 2016). Hematologic toxicities, fatigue, rash, decreased appetite, diarrhea, and vomiting are common toxicities associated with ixazomib (Merin 2014).

## Therapies With Other Mechanisms of Action

Other agents such as Panobinostat, an oral pan-decetylase inhibitor, is a more recent anti-myeloma agent for patients with relapsed or refractory multiple myeloma. Although a positive effect on PFS and OR was demonstrated when combined with Vd, panobinostat is associated with severe and dose limiting toxicities. The drug seems more effective in more heavily pretreated population i.e., patients who have received a median of 2 prior therapies, including treatment with both bortezomib and an IMiD.

Elotuzumab, a monoclonal antibody, is a recent addition to the treatment of multiple myeloma and is indicated in combination with Rd for the treatment of patients who have received 1 to 3 prior therapies. A number of other classes are also available which include HDAC inhibitors, alkylating agents as well as anthracyclines. However, in addition to these existing therapies, there is still a need for more effective treatments  with  different  mechanisms  of  action  that  provide  alternative  treatment  options  for  these patients.

<div style=\"page-break-after: always\"></div>

Daratumumab is a first-in-class, human IgG1 mAb with a MoA that is novel and completely distinct from other anti-myeloma treatment available.

Following scientific advice from the CHMP (Procedure: EMEA/H/SA/2456/1/FU/1/2014/PA/II) the applicant has  conducted  two  comparative  randomized  Phase  3  studies  of  daratumumab  in  combination  with established  standard  of  care  background  regimens;  either  lenalidomide  and  dexamethasone  (Study MMY3003) or bortezomib and dexamethasone (Study MMY3004). The objective of both studies was to compare the efficacy of daratumumab when combined with these background regimens and to assess if the daratumumab based combination would improve clinical outcomes in subjects with multiple myeloma who have previously been treated with at least one prior therapy when compared to the background regimen alone.

The addition of daratumumab to lenalidomide and dexamethasone (Rd) (MMY3003) or to bortezomib and dexamethasone (Vd)(MMY3004), results in an improvement in PFS, with a 63% reduction in the risk of disease progression or death when daratumumab is added to Rd (DRd) compared to Rd in Study MMY3003 (HR=0.37; 95% CI: 0.27, 0.52; p&lt;0.0001). In the MMY3004 study a 61% reduction in the risk of disease progression  or  death  was  reported,  when  daratumumab  was  added  to  Vd  (DVd)  compared  with  Rd (HR=0.39; 95% CI: 0.28, 053; p&lt;0.0001).  In both studies, the benefit was robust and consistent among all subgroups based on gender, race, age, baseline hepatic and renal impairment and geographical regions.

The positive effect was supported by improvements in key secondary endpoints including time-to-progression (TTP), overall response rate (ORR), depth of response as reflected by the rates of a very good partial response (VGPR) or better and complete response (CR) or better, rate of minimal residual disease (MRD) negativity, and duration of response (DOR).

In Study MMY3003, the ORR is significantly higher in subject receiving DRd, as compared to Rd alone (DRd: 93% vs Rd: 76%; p&lt;0.0001). The responses are robust, with higher VGPR or better rates (DRd: 76% vs Rd: 44%) and rate of CR or better (DRd: 43% vs Rd: 19%). In addition, the MRD negativity rate is significantly higher (DRd: 29% vs Rd: 8%).

In Study MMY3004, the ORR is significantly higher in subjects receiving DVd, as compared to Vd alone (DVd: 83% vs Vd: 63%; p&lt;0.0001). The responses are robust with higher VGPR or better rates (DVd: 59% vs Vd: 29%) and rate of CR or better (DVd: 19% vs Vd: 9%). In addition, the MRD negativity rate is significantly higher (DVd: 14% vs Vd: 3%).

In addition the applicant also conducted two Phase 1/2 studies where daratumumab was administered in combination with either pomalidomide and dexamethasone (Pd) (Study MMY1001), or lenalidomide and dexamethasone (Ld) (study GEN503). The primary objective of these studies was to evaluate safety and tolerability, and for the MMY1001 study, also to evaluate the overall response rate.

Adding daratumumab to another immunomodulatory agent (IMiD), pomalidomide, and dexamethasone (Pd) in heavily pretreated subjects in Study MMY1001, results in ORR (59%; 95% CI: 49; 69) CR or better rate (14%), and a median DOR of 13.6 months. Although these data are interesting, they should be interpreted with caution since no comparator was identified.

## 2.4. Significant clinical benefit based on improved safety

Safety data from a total of 1182 subjects are included in the safety population: 664 subjects received daratumumab in combination with standard background therapy and 518 subjects received background therapies alone.

With the exception of infusion related reactions (IRRs), the safety profiles of daratumumab in combination with Rd, Vd or Pd were similar to those of the background regimens.

Similar to the daratumumab single agent data, IRRs were experienced by approximately half of subjects receiving daratumumab-based regimens (DRd, DVd, DPd). The majority (94%) of IRRs were Grade 1 or 2, with 95% occurring during the first infusion. No Grade 4 or 5 IRRs occurred, and only 5 subjects (0.8%) discontinued treatment due to IRRs.

The incidence of Grade 3 or 4 TEAEs and serious TEAEs was higher in the daratumumab combination groups, the TEAEs could be managed by supportive care and dose modifications, and did not result in an increase in discontinuation of study treatment or deaths.

<div style=\"page-break-after: always\"></div>

Daratumumab may increase cytopenias induced by background therapies, with thrombocytopenia being the most common for subjects receiving bortezomib based regimens and neutropenia the most common for subjects receiving lenalidomide- or pomalidomide-based regimens.

Neutropenia, which is a well known effect of lenalidomide and pomalidomide, was reported more frequently in the daratumumab combination groups than in background therapy alone (DRd: 62%; Rd: 43%; DPd: 79%). Most frequently, neutropenia occurred in the initial cycles, it was managed by dose modifications and growth factor use and rarely led to treatment discontinuation (&lt;1%). The incidence of febrile neutropenia was low (≤7%).

Thrombocytopenia,  a  known  effect  of  bortezomib,  was  reported  by  more  subjects  in  the  DVd  group compared to the Vd group (DVd: 59%; Vd: 44%); however bleeding events were low and the majority were minor (Grade 1 or 2).

Anemia, all grades and Grade 3 or 4, was similar among all treatment groups in the randomized studies (all grades DRd: 31% vs Rd: 35% and DVd: 26% vs Vd: 31%;Grade 3 or 4: DRd: 12% vs Rd: 20% and DVd: 14% vs Vd: 16%).

Although  the  overall  incidence  of  infections  were  reported  by  a  higher  percentage  of  subjects  in  the daratumumab  containing  groups  compared  to  the  respective  background  therapy,  the  majority  of  all infections were mild (Grade 1 or 2) and did not require hospitalization.

The  incidence  of  Grade  3  or  4  infection  was  similar  between  the  daratumumab  combinations  and  the background therapies (DRd: 27%; Rd: 23%; DVd: 21%; Vd: 9%; DPd: 27%), with the most common being pneumonia.

Discontinuations from treatment (2% to 5%) and deaths (0.8% to 2%) due to infection were low and balanced between groups in the randomized studies.

Second primary malignancies (SPM) were reported at a low frequency in the DRd and DVd groups (&lt;4%); no SPMs were reported in the DPd cohort.

Discontinuation of treatment due to TEAEs was low across all treatment groups (DRd: 7%; Rd: 8%, DVd: 7%; Vd: 9%, DPd: 13%), with the most common reason for discontinuation being infections (2% to 5%). Infections were also the most common treatment emergent adverse events (TEAEs) leading to death (1% to 2%), but TEAEs with an outcome of death were low across all treatment groups (DRd: 4%; Rd: 5%, DVd: 5%;  Vd:  6%,  DPd:  7%).  Subgroup  analyses  showed  generally  comparable  safety  profiles  in  various subgroups based on age, gender, race, baseline renal function, baseline hepatic function, and geographic region.

## 2.5. Significant clinical benefit based on major contribution to patient care

Patient-reported outcome concerning functional status and well-being were assessed using 2 PRO measures, the EORTC-QLQ-C30 and the EQ-5D-5L. Compliance was comparable between treatment groups and baseline scores for daratumumab added to the 2 background therapies (DRd and DVd) compared to backbone therapies alone. The PRO results indicated no statistically significant difference between the combination of daratumumab to background therapies (DRd or DVd) and the corresponding background therapies in change from baseline or median time to improvement or worsening in the Global Health Status/QOL subscale of the EORTC-QLQ-C30 or the EQ-5D-5L Utility score or EQ-5D-5L Visual Analog Scale (VAS). When median time to worsening or improvement in the Utility Score or VAS was analysed, no statistically significant differences were observed between DRd and Rd or DVd and Vd.

## 3. Assessment of the MAH's justification of significant clinical benefit

## 3.1. Demonstration of new therapeutic indication

CHMP's position:

Daratumumab was previously approved in May 2016 as monotherapy to treat subjects with advanced stage multiple  myeloma.  The  studies  (GEN501  and  MMY2002)  supporting  the  approved  indication  included

<div style=\"page-break-after: always\"></div>

end-stage refractory subjects who had received 4-5 (median) prior treatments with 69% and 80% of the subjects having &gt; 3 prior therapies in the GEN501 and MMY2002 studies respectively.

The applicant is now extending the indication to include subjects who have less advanced disease and received  at  least  1  prior  treatment,  i.e.  as  second  line  treatment  in  multiple  myeloma.  The  proposed additional  indication  for  daratumumab  in  this  application  is  for  the  treatment  in  combination  with lenalidomide  and  dexamethasone,  or  bortezomib  and  dexamethasone,  of  adult  patients  with  multiple myeloma who have received at least one prior therapy.

The CHMP acknowledges this is a new indication of daratumumab  earlier in the treatment pathway of multiple myeloma.

It is also acknowledged that the two randomized studies, MMY3003 and MMY3004, daratumumab added to 2  standard  of  care  background  regimens,  either  lenalidomide  and  dexamethasone  or  bortezomib  and dexamethasone, show a significant efficacy improvement with an acceptable and manageable safety profile, and that this represents a new indication.

## 3.2. Details of existing therapies

## CHMP's position:

The  applicant  has  satisfactorily  reviewed  and  detailed  the  characteristics  and  limitations  of  existing therapies.

## 3.3. Significant clinical benefit based on improved efficacy

## CHMP's position:

Daratumumab is a novel monoclonal antibody targeting CD38 on multiple myeloma cells inducing tumour cell death through multiple mechanisms of action. The applicant has conducted 2 pivotal comparative phase 3  studies  of  daratumumab  in  combination  with  1  of  2  well  established  standard  of  care  background regimens; either lenalidomide and dexamethasone (Study MMY3003) or bortezomib and dexamethasone (Study  MMY3004).  The  objective  of  both  studies  was  to  compare  the  efficacy  of  daratumumab  when combined with these background regimens and to assess if, through this addition, the daratumumab based combination would improve clinical outcomes in subjects with multiple myeloma who have previously been treated with at least one prior therapy when compared to the background regimen alone.

The clinical trials were well-controlled and had clinically meaningful endpoints. Daratumumab added to Rd (DRd) (study MMY3003) or daratumumab added to Vd (DVd) (Study MMY3004) results in a 63% and 61% reduction in the risk of disease progression or death respectively, when compared with Rd (HR=0.37; 95% CI:  0.27,  0.52;  p&lt;0.0001)  or  Vd  (HR=0.39;  95%  CI:  0.28,  053;  p&lt;0.0001)  in  subjects  with  multiple myeloma who received at least 1 prior therapy. In both studies, the PFS results were consistent among all preplanned  sensitivity  analyses  and  across  different  clinically  relevant  prespecified  subgroups,  such  as number and type of prior lines of therapy, staging, cytogenetic risk group, and whether refractory to last treatment. Further the benefit was robust and consistent among all subgroups based on gender, race, age, baseline hepatic and renal impairment and geographical regions.

The  superiority  in  efficacy  is  supported  by  improvements  in  key  secondary  endpoints  including time-to-progression.

In the Study MMY3003, the ORR is significantly higher in subject receiving DRd, as compared to Rd alone (DRd: 93% vs Rd: 76%; p&lt;0.0001). The responses are deep, with higher VGPR or better rates (DRd: 76% vs Rd: 44%) and in the rate of CR or better (DRd: 43% vs Rd: 19%). In addition, the MRD negativity rate is significantly higher (DRd: 29% vs Rd: 8%). Other phase 3 trials using lenalidomide+dexamethasone (Rd) as background therapy have previously been published. Carfilzomib + Rd vs. Rd alone, elotuzumb + Rd vs. Rd alone and ixazomib + Rd vs. Rd alone (Stewart 2015, Lonial l2015 and Moreau 2016). Although comparison and interpretation with these data should be done with caution, HR for PFS was in the range of 0.69 to 0.74, ie. they showed a reduction in risk of progression or death of 26% to 31%, compared to a 63% reduction in the present MMY3003 study. The ORR results were overall consistent with the PFS results.

<div style=\"page-break-after: always\"></div>

In Study MMY3004, the ORR is significantly higher in subjects receiving DVd, as compared to Vd alone (DVd: 83% vs Vd: 63%; p&lt;0.0001). The responses are deep, with higher VGPR or better rates (DVd: 59% vs Vd: 29%) and a rate of CR or better (DVd: 19% vs Vd: 9%). In addition, the MRD negativity rate is significantly higher  (DVd:  14%  vs  Vd:  3%).  Similarly  phase  3  bortezomib/dexamethasone-controlled  studies  with panobinostat+Vd and carfilzomib + Vd, along with a phase 2 trial with elotuzumab+Vd have been published (San-Miguel 2014, Dimopoulus 2016 and Jakubowiak 2016). HR for PFS in these studies ranged from 0.53 to 0.72, compared with 0.39 in the daratumumab study, i.e. a reduction in risk of progression or death of 28% to 47%, compared with 61% in the MMY3004 study with daratumumab. Although comparison between studies is difficult, these data indicate a clinical meaningful benefit of daratumumab combinations with RD and Vd.

| Existing therapies     | Daratumumab and lenalidomide/dexamethasone                                             | Daratumumab and bortezomib/dexamethasone                                                 |
|------------------------|----------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
| Existing therapies     | Improved efficacy                                                                      | Improved efficacy                                                                        |
| Carfilzomib (Kyprolis) | Yes                                                                                    | Yes                                                                                      |
| Elotuzumab (Empliciti) | Yes                                                                                    | Yes                                                                                      |
| Ixazomib (Ninlaro)     | Yes                                                                                    | Not applicable (Ninlaro is indicated in combination with lenalidomide and dexamethasone) |
| Panobinostat (Farydak) | Not applicable (Farydak is indicated in combination with bortezomib and dexamethasone) | Yes                                                                                      |

Note: Lenalidomide, thalidomide and pomalidomide are not included in the tables in sections 3.3, 3.4, 3.5 and 4. Thalidomide and pomalidomide are not studied with any of the backbones as in the daratumumab studies (MMY3003 and MMY3004) and therefore the comparison is not relevant. In addition the approved indication for thalidomide is 1st line, and for pomalidomide it is 3rd line. Finally, lenalidomide is part of the backbone in study MMY3003.

Having considered the data submitted by the MAH, the CHMP considers that the claimed indication for Darzalex brings a significant clinical benefit over existing therapies based on an improved efficacy compared to Kyprolis, Empliciti, Ninlaro and Farydak.

## 3.4. Significant clinical benefit based on improved safety

## CHMP's position:

Safety data from large comparative studies is included in the application. A total of 664 subjects received daratumumab in combination with standard background therapy and 518 subjects received background therapies alone.

The safety profiles of daratumumab in combination with Rd, Vd or Pd were similar to those of the background regimens, with the exception of infusion related reactions (IRRs),  which were reported by approximately half of subjects receiving daratumumab-based regimens (DRd, DVd, DPd). The majority of IRRs were low grade and occurred mainly during the first infusion, they were manageable and the pre-and post medication as suggested in the product information is endorsed.

The incidence of Grade 3 or 4 TEAEs and serious TEAEs was higher in the daratumumab combination groups, but  were  managed  by  supportive  care  and  dose  modifications,  and  did  not  result  in  an  increase  in discontinuation of study treatment or deaths.

Although daratumumab may increase the cytopenias induced by the background therapies, neutropenia was managed by dose modifications and growth factor use and rarely led to treatment discontinuation (&lt;1%). The incidence of febrile neutropenia was low (≤7%), and bleeding due to thrombocytopenia were low and of minor grade. In the clinical setting, cytopenic adverse effects are well known and manageable.

Although  the  overall  incidence  of  infections  were  reported  by  a  higher  percentage  of  subjects  in  the daratumumab  containing  groups  compared  to  the  respective  background  therapy,  the  majority  of  all

<div style=\"page-break-after: always\"></div>

infections were mild (Grade 1 or 2) and did not require hospitalization. The incidence of Grade 3 or 4 infection was similar between the daratumumab combinations and the background therapies (DRd: 27%; Rd: 23%; DVd: 21%; Vd:9%; DPd: 27%), with the most common being pneumonia.

Discontinuations from treatment (2% to 5%) and deaths (0.8% to 2%) due to infection were low and balanced between groups in the randomized studies.

In  the  previously  published  data  using  the  lenalidomide  or  bortezomib    backbone  treatment,  common toxicities associated with carfilzomib combinations include except from hematologic toxicities, pneumonia hyponatraemia, fatigue, hypophosphatemia, IRR and especially high grade cardiovascular events. Common toxicities with elotuzumab combinations involved mainly infections, incl. opportunistic infections IRR and new primary malignancies except from the hematologic toxicities. Adverse events due to the ixazomib combination include except from hematologic toxicities, fatigue, rash, decreased appetite, diarrhea and vomiting. Toxicity due to panobinostat combination especially includes high rates of gastrointestinal adverse events and discontinuation of the treatment. Based on the above, it is not possible to agree on the claim for 'improved safety' in comparison to existing therapies based on indirect comparisons.

| Existing therapies     | Daratumumab and lenalidomide/dexamethasone Improved safety   | Daratumumab and bortezomib/dexamethasone Improved safety   |
|------------------------|--------------------------------------------------------------|------------------------------------------------------------|
| Carfilzomib (Kyprolis) | Not applicable                                               | Not applicable                                             |
| Elotuzumab (Empliciti) | Not applicable                                               | Not applicable                                             |
| Ixazomib (Ninlaro)     | Not applicable                                               | Not applicable                                             |
| Panobinostat (Farydak) | Not applicable                                               | Not applicable                                             |

## 3.5. Significant clinical benefit based on major contribution to patient care

## CHMP's position:

It is considered a benefit to patient care, that a novel drug as daratumumab with a completely distinct mechanism of action from any other anti-myeloma treatment has become available to a group of patients with a dismal prognosis. Daratumumab offers no new mode of administration, however the treatment schedule is adapted to 2 standard of care treatments, this is considered relevant to subjects compliance.

Besides from the fact that an increase of PFS together with acceptable and manageable safety profile is considered a benefit to patient care, the applicant also evaluated the functional status and well-being of the subjects. No detrimental effect in median time to improvement or worsening in the global health status was demonstrated between the combination of daratumumab and background therapies (DRd or DVd) and the corresponding background therapies.

The applicant has not focused on this issue which is considered acceptable considering the novel mechanism of action, the overwhelming benefit on efficacy, and the acceptable and manageable adverse events. Combining daratumumab with the 2 standard treatments lenalidomide/dexamethasone or bortezomib/dexamethasone doses not add on any concerns related to patient care.

| Existing therapies     | Daratumumab and lenalidomide/dexamethasone   | Daratumumab and bortezomib/dexamethasone   |
|------------------------|----------------------------------------------|--------------------------------------------|
|                        | Major contribution to patient care           | Major contribution to patient care         |
| Carfilzomib (Kyprolis) | Yes                                          | Yes                                        |
| Elotuzumab (Empliciti) | Yes                                          | Yes                                        |

<div style=\"page-break-after: always\"></div>

| Ixazomib (Ninlaro) Panobinostat (Farydak)   | Yes Yes   | Yes Yes   |
|---------------------------------------------|-----------|-----------|

## 4. Conclusion

## CHMP's position:

In conclusion, it is agreed, that addition of daratumumab to standard treatment regimens as lenalidomide and dexamethasone or bortezomib and dexamethasone results in a consistent clinical benefit as compared to standard background therapy alone. The superiority in efficacy is further supported by improvements in key  secondary  endpoints.  When  compared  with  historical,  published  data,  the  daratumumab  based combinations seems to be superior in relation to PFS and ORR, however due to a historical comparison, the results should be interpreted with caution. Concerning the safety profile, the toxicity of daratumumab is consistent  with  the  known  toxicities  of  the  individual  agents  and  clinically  manageable.  Compared  to historical,  published  data,  the  safety  profile  of  daratumumab  combinations  seems  to  be  superior  to carfilzomib  and  panobinostat  containing  regimens,  and  especially  not  to  be  detrimental  to  other combination. Based on the above, it is not possible to agree on the claim for 'improved safety' in comparison to existing therapies based on indirect comparisons. Finally, there is no indication of a detrimental effect on quality of life not in this application or compared to historical data.

| Existing therapies   | Darzalex          | Darzalex        | Darzalex                           |
|----------------------|-------------------|-----------------|------------------------------------|
| Existing therapies   | Improved efficacy | Improved safety | Major contribution to patient care |
| Kyprolis             | Yes               | Not applicable  | Yes                                |
| Empliciti            | Yes               | Not applicable  | Yes                                |
| Ninlaro              | Yes               | Not applicable  | Yes                                |
| Farydak              | Yes               | Not applicable  | Yes                                |

Having considered the data submitted by the MAH, the CHMP by consensus considers that the Darzalex in the claimed indication: ''Darzalex in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone,for the treatment of adult patients with multiple myeloma who have received at least one prior therapy''

-  brings a significant clinical benefit over existing therapies based on an improved efficacy compared to Kyprolis, Empliciti, Ninlaro and Farydak  and major contribution to patient care compared to Kyprolis, Empliciti, Ninlaro and Farydak

## 5. Recommendation

The CHMP reviewed the data submitted by the MAH, taking into account the provisions of Article 14(11) of Regulation (EC) No 726/2004 and the 'Guidance on elements required to support the significant clinical benefit in comparison with existing therapies of a new therapeutic indication in order to benefit from an extended (11-year) marketing protection period', and considers by consensus that the Darzalex in the new therapeutic indication brings a significant clinical benefit in comparison to existing therapies.